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Medullary thyroid carcinoma (MTC) accounts for around 2‐5% of all thyroid malignancies. From 
these, around 25% are inherited forms attributable to germline RET mutations, and 75% are 
sporadic MTCs, with or without somatic mutation in the same RET proto-oncogene. Although the 
genotype-phenotype correlation related to specific germline RET mutations is well established, the 
knowledge of pathways specifically associated with each mutation, as well as to non-RET related 
sporadic MTC still remain largely unknown. Gene expression and microRNA patterns have 
provided a robust tool to identify molecular events related to specific tumor types and to different 
clinical features that could help to identify novel targets for therapy.   
Based on gene expression and microRNA profiling from an outstanding series of tumors, it was 
possible to identify differences between sporadic and familial MTCs. Specifically, PROM1 (also 
called CD133), LOXL2, GFRA1 and DKK4 over-expression were related to RETM918T, while GAL was 
associated with RET634 mutation. Pathway enrichment analysis pointed to Wnt, Notch, NFκB, 
JAK/Stat and MAPkinase signaling as related to MTCM918T group. The immunohistochemical 
assessment of ESM1, GFRA1 and CD133 only revealed a marginal association of the M918T group 
with CD133 protein over-expression. The lack of validation at protein level could be due to other 
underlying mechanism, such as posttranscriptional modifications conducted by microRNAs. 
Based on the in vitro functional studies, we observed that PROM1 or CD133 is significantly 
expressed in MZ-CRC-1 cell lines harboring M918T RET mutation comparing to TT cell line model 
with RET634. On the other hand, silencing CD133 by siRNA induced apoptosis in MZ-CRC-1. CD133 
confers resistance to death by apoptosis, but does not imply a selective advantage on 
proliferation. To our knowledge this is the first time that PROM1 or CD133 overexpression is 
reported among primary tumors. This finding could lead to the identification of novel therapeutic 
targets.   
The miRNome analysis revealed a downregulation of miR-30a, and miR-138 associated with 
MTCM918T group, and miR-124 with MTCC634X. These results were validated in independent series of 
frozen and FFPE series. Furthermore, mRNA-miRNA integration data on the same frozen MTC 
sample series pointed to inversely correlated miR-30a and PROM1 among MTCM918T group.  
In summary, this study has allowed us to identify genes and microRNAs that could be used as 
markers related to specific genetic conditions in MTCs, and that could be taken into account as 
future therapeutic targets.   
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El Carcinoma Medular de Tiroides (CMT) representa el 2-5% de los carcinomas tiroideos. De éstos, 
en torno al 25% son formas familiares y atribuibles a mutaciones germinales en RET, y el 75% 
restante son esporádicos, con o sin mutación somática en el mismo gen. Aunque la correlación 
fenotipo-genotipo asociada a mutaciones germinales específicas de RET está bien establecida, no 
se conoce qué rutas están alteradas ante una mutación concreta en el tumor, ni tampoco aquellas 
implicadas en el desarrollo del tumor en ausencia de mutación somática en RET.  El análisis de 
patrones de expresión génica y de microRNAs ha demostrado ser una herramienta robusta para 
identificar marcadores relacionados con subtipos tumorales o características clínicas, de modo que 
podría ayudar en la identificación de nuevas dianas terapéuticas.    
En este trabajo, basándonos en el perfil transcripcional y de microRNAs de una colección 
sobresaliente de CMTs, fue posible identificar diferencias en los patrones moleculares de CMT 
familiares y esporádicos. En particular, la sobre-expresión de PROM1 (también llamado CD133), 
LOXL2, GFRA1 y DKK4 se asoció a la mutación M918T, y la de GAL a mutaciones que afectaban el 
residuo 634. El análisis de enriquecimiento de rutas apuntaba a que la señalización dirigida por 
Wnt, Notch, NFκB, JAK/Stat y MAP-quinasas se relacionaba con los CMTM918T. La evaluación 
inmunohistoquímica de ESM1, GFRA1 y CD133 reveló únicamente una asociación marginal entre 
sobre-expresión de CD133 y la presencia de la mutación M918T. La falta de validación podría 
deberse a modificaciones postranscripcionales llevadas a cabo por microRNAs.   
Basándonos en estudios funcionales in vitro, se observó que PROM1 estaba significativamente 
expresado en la línea celular MZ-CRC-1, portadora de la mutación RETM918T, en comparación con la 
línea celular TT, portadora de una mutación en RET634.  Por otro lado, se observó que el 
silenciamiento de CD133 con siRNAs inducía apoptosis en la línea MZ-CRC-1. Esto permitía concluir 
que la sobre-expresión de CD133 confiere resistencia a apoptosis, y no implica ventaja selectiva en 
la proliferación. Esta es la primera vez que se describe sobre-expresión de PROM1 en tumores 
primarios. PROM1 podría tenerse en cuenta como una nueva diana terapéutica.  
El análisis del Miroma reveló una baja expresión del miR-30a y miR-138 asociada a CMTM918T, y de 
miR-124 a CMTC634X, y se validó en una serie independiente de CMTs. La integración mRNA-
microRNA de los mismos tumores identificó una relación inversa entre el miR-30a y PROM1 en los 
tumores con RETM918T.  
En resumen, hemos identificado genes y microRNAS que podrían ser utilizados como marcadores 
asociados a mutaciones específicas de RET, a tener en cuenta como futuras dianas terapéuticas.
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1. Thyroid carcinoma 
Among endocrine system malignancies, thyroid tumors are the most common and they account 
for about 1% of all diagnosed cancer cases(Ferlay 2010). The thyroid carcinoma occurs between 
20-50 years of age with incidence rate is from 0.5 to 10 cases per 100.000 individuals (DeLellis 
2004).  The thyroid gland is composed of two different types of cells: the follicular and the 
parafollicular or C-cells. Among the tumors derived from the former cells, the principal histological 
subtypes are papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTP), poorly 
differentiated thyroid carcinoma (PDTC), anaplastic thyroid carcinoma (ATC), and the unique 
benign tumor, the follicular thyroid adenoma (FTA)(DeLellis 2004).  
Medullary thyroid carcinoma (MTC), the subject of the present doctoral thesis, arises from C-cells, 
that  have a neural-crest origin (DeLellis 2004) and produce calcitonin, a hormone that plays an 
important role in calcium blood homeostasis. C-cells producing calcitonin, whose levels are used as 
a diagnostic marker, account for only up to 1% of the thyroid mass, mainly concentrated in the 
posterior upper third of the gland (Khurana, et al. 2004b).  
MTC is an infrequent neoplasia, which accounts for approximately 2-5% of all thyroid 
malignancies(Randolph 2000) and is characterized by a solid mass of polygonal shaped cells with 
frequently observed amyloid deposition. MTC disseminate locally in 50% of cases to cervical and 
mediastinal nodal groups and up to 20% to distant organs such as lungs, bones or liver (DeLellis 
2004). 
Around 75% of cases are sporadic in nature, while the remaining 25% are hereditary and 
associated with the multiple endocrine neoplasia type 2 syndrome (MEN 2, OMIM #171400). The 
major player in MTC development is the RET proto-oncogene, whose germline and somatic 
mutations are responsible for most of familial and sporadic cases respectively (Hofstra, et al. 1994; 
Mulligan, et al. 1993b), although recently there have also been cases reported with BRAF and RAS 
mutations (Goutas 2008; Moura, et al. 2011).    
1.1 Multiple Endocrine Neoplasia type 2 (MEN 2) syndrome and general background 
This disease has a prevalence of 1:30.000(Marsh 2002) and dominant autosomal inheritance, with 
a variable clinical expression pattern, and almost complete penetrance depending on the specific 
RET mutation, as will be further reviewed in this introduction. Inherited MTC cases are 
Introduction   
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characterized mainly by their multifocal and bilateral character. It manifests at  an early age, and 
mostly accompanied by C-cell hyperplasia (CCH) (LiVolsi 1997). Sporadic forms emerge from 
unifocal clonal tumor cell population(Eng 1999), and are generally not associated with 
CCH(Hayashida, et al. 1993). 
Until 1993, when the RET gene (REarranged during Transfection) was found to be specifically 
associated with MEN 2(Mulligan et al. 1993b), management and diagnosis of patients with 
hereditary MTC and their relatives were based on basal and stimulated levels of calcitonin. 
Nowadays genetic analysis is the most sensitive and specific tool in MEN 2 diagnostics and the risk 
of performing a prophylactic thyroidectomy in a normal individual is no longer a concern (Hoff, et 
al. 2010).  
According to clinical presentation, MEN 2 syndrome can be subdivided into three different 
subtypes: multiple endocrine neoplasia type 2A (MEN 2A; OMIM #171400), multiple endocrine 
neoplasia type 2B (MEN 2B; OMIM#162300) and familial medullary thyroid carcinoma (FMTC; 
OMIM#155240). All of them (Table1) are associated with high risk of MTC development (in more 
than 90% of affected individuals). Pheochromocytoma (PCC) manifests in 50% of patients with 
MEN 2A and MEN 2B, while hyperparathyroidism (HPT), due to parathyroid hyperplasia or 
adenoma, occurs in approximately 20-30% in MEN 2A individuals(Eng, et al. 1996a). In addition to 
MTC and PCC, affected MEN 2B patients develop a typical phenotype that includes a marphanoid 
habitus, thickened lips, as well as ganglioneuromas in the mucosa and gastrointestinal 
tract(Skinner, et al. 1996).  
MEN 2A. This subtype constitutes 70%-80% of cases of MEN 2, MTC generally being the first 
manifestation of this subtype. Up to 70% of patients develop cervical lymph node 
metastases(Cohen and Moley 2003). PCC in MEN 2A are diagnosed at an early age and have 
subtler symptoms, while HPT is typically mild with no symptoms(Brandi, et al. 2001). There are 
also some cases with MEN 2A having cutaneous lichen amyloidosis (CLA),  located over the upper 
portion of the back and may appear before the onset of MTC(Seri, et al. 1997).  
FMTC. This subtype constitutes approximately 10%-20% of cases of MEN 2. By definition MTC is 
the only clinical manifestation in this subtype. The age of onset of MTC is later in FMTC and the 
penetrance of the disease is lower than that observed in MEN 2A and MEN 2B (Eng et al. 1996a). 
In fact, after ATA (American Thyroid Association) recommendations in 2009, FMTC is typically 
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considered as a variant of MEN 2A with decreased penetrance of PCC and HPT, rather than an 
isolated subtype(Kloos 2009).  
 
Table 1. Clinical features of MEN2 syndrome. Modified from (Pierotti, et al. 2004). 
MEN 2 syndrome type                                          Characteristic features 
 
MEN 2A                                                                     MTC (95%)            
                                                                                   PCC (50%) 
                                                                                    Parathyroid hyperplasia/adenoma (20-30%) 
 
FMTC                                                                        MTC (100%)                     
MEN 2A with cutaneous lichen amyloidosis     MEN 2A and cutaneous lesions 
MEN 2A/FMTC with Hirschprung´s disease       MEN 2A/FMTC with intestinal ganglionosis 
 
MEN 2B                                                                    MTC (100%)   
                                                                                   PCC  (50%) 
                                                                       Intestinal/mucosal ganglioneuromatosis 
                                                                                   Habitus marfanoid 
  
  
MEN 2B. The MEN 2B subtype constitutes around 5% of cases of MEN 2. It is characterized by the 
early age of the tumor development and shows the highest transforming capacity among all MTC 
forms(Skinner et al. 1996). Individuals with MEN 2B who do not undergo thyroidectomy at an early 
age (less than 1 year) are prone to develop metastatic MTC in childhood. PCC occur in 50% of the 
MEN 2B cases, while HPT is absent or very rare. Pediatric patients with MEN 2B are mostly 
identified in early childhood by the presence of mucosal neuromas on the anterior dorsal surface 
of the tongue, palate, or pharynx and a distinctive facial appearance.  
2. RET proto-oncogene 
RET (REarranged during Transfecion) is a receptor tyrosine kinase (RTK) implicated in nervous 
system development, kidney morphogenesis and spermatogenesis. It was originally identified as 
an oncogene activated by DNA rearrangement in a transformation experiment, were NIH3T3 cells 
were transfected with DNA from human T cell lymphoma(Takahashi 1985).  
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2.1 RET structure and protein 
RET gene in humans is located on chromosome 10q11.2, is about 50 kb and contains 21 exons 
(Pasini, et al. 1995). Due to alternative splicing, there are three different RET isoforms, RET9, 43 
and RET51, that differ at C-terminus. Only two of them are main products in vivo, RET9 and RET51 
(Arighi et al., 2005). RET, being a typical receptor tyrosine kinase (RTK), is a single-pass 
transmembrane protein which comprises extracellular, transmembrane, and cytoplasmic domains 
(Figure 1). More specifically, it consists of two extracellular domains (four cadherin-like regions in 
tandem and a cystein-rich domain), one transmembrane, and two intracellular tyrosine kinase 
domains. RET is a functional receptor for neurotrophic ligands of the gial cell line-derived 
neutrotropic factor (GDNF) family (Figure 1), composed by GDNF, neurturin (NTN), artemin (ARTN) 
and persephin (PSP)(Santoro, et al. 2004a). These ligands require the recruitment of co-receptors 
with high-affinity *GFRα1-4] to be able to bind directly to the RET receptor for full activation and 
the signal transduction (Figure 1). 
2.2 Activation mechanism of RET 
To date, there are two accepted mechanisms for RET dependent pathways activation that involve 
the binding between GFL, GFRα and RET (Figure 1). The first suggests GFL association with the 
GFRα in the first turn to form a complex with one GFL molecule and a GFRα homodimer. This 
complex further recruits two RET molecules into the lipid raft leading to trans-phosphorylation of 
the tyrosine residues in RET and the signaling pathways are being triggered (Airaksinen et al., 
1999). The second is based on the pre-associated complex between GFRα and RET being formed 
first and providing a docking site for the subsequent binding of the GFL (Manie et al., 2001). 
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Figure 1. RET protein structure and mechanism of activation. 
 
2.3 Signaling pathways 
 
RET, similar to the other RTKs, is regulated by phosphorylation at specific tyrosine residues, which 
promotes the signal. Upon ligand stimulation and receptor association, RET undergo dimerization 
and trans-phosphorylation occurs on specific tyrosine residues, which serve as docking sites for 
other signaling proteins. Little is known regarding the specific RET mutation-driven signaling 
pathways and the molecular behavior of non-RET mutated (wild type) cases still remains unclear. 
Basically, wild-type RET, MEN 2A-related RET (RET/MEN 2A), FMTC-related RET (RET/FMTC), and 
MEN 2B-related RET (RET/MEN 2B) display differences in phosphorylation of docking sites and 
isoforms of the RET receptor, triggering specific intracellular signaling cascades (de Groot, et al. 
2006). 
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It is known that RET can activate various well-known RTK pathways including those of 
Ras/extracelluar signal regulated kinase (Erk), phosphatidylinositol 3-kinase (PI3K)/Akt, p38 
mitogen activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK) and PLCγ(Arighi, et al. 
2005a; Ichihara, et al. 2004). Activation of Ras/Erk pathways is important for neuronal survival and 
differentiation(Califano, et al. 2000). PI3K/Akt signaling pathway leads to the transformation 
potential of RET in Rat1 fibroblast cell line and plays role in cell survival and proliferation in 
neurons (Segouffin-Cariou and Billaud 2000). The JNK pathway contributes to the tumorigenic 
activity of RET in neuroblastoma tumor cell lines (Marshall, et al. 1997), while the PLCγ pathway is 
required for full oncogenic activation of RET in the mouse fibroblast cell line, NIH3T3 (Borrello, et 
al. 1996).  
There are several sites recognized by adaptor proteins (Figure 1). Among them, phosphorylated 
Tyr905, 981, 1015, 1062 and 1096 are the most important ones(Encinas, et al. 2004; Ichihara et al. 
2004). Tyr1096 is present only in RET43 and RET51 splicing variants, while Tyr1062 acts as the 
binding motifs of RET51 and RET9. Consequently the signaling cascades mediated by RET51 and 
RET9 will show discrepancy (Kurokawa, et al. 2003).  Moreover, it has been shown that besides the 
tyrosine residues, phosphorylation at the serine 696 residue also plays a role in RET signaling 
(Fukuda, et al. 2002). 
 
2.3.1 Tyrosine 1062 residue 
 
Extensive studies have shown the importance of Tyr1062 in the cellular transformation capacity of 
RET, and as a docking site for the multiple adaptor proteins, including Shc, FRS2, downstream of 
tyrosine kinase 1(Dok1), Dok4/5, insulin receptor substrate-1 (IRS-1), enigma, and Rai, Shank3 and 
PKCα(Arighi et al. 2005a; Kurokawa et al. 2003).  
Phosphorylated Tyr1062 interacting with Shc by recruiting Grb2/Sos (Besset, et al. 2000) or 
Grb2/Gab(Hayashi, et al. 2000) protein complexes underlay its dual function. Association with 
Grb2/Sos activates the Ras/Erk pathway(Besset et al. 2000), while connection of this 
phosphorylated tyrosine with Grb2/Gab triggers PI3K/Akt signaling pathway (Hayashi et al. 2000). 
It was demonstrated that both, Ras/Erk and PI3K/Akt, are important for the activation of the 
transcription factors CREB and NFκB, respectively(Hayashi et al. 2000) and crucial for PC12 cells 
survival(De Vita, et al. 2000). Regarding another protein adaptor, Dok1, it was demonstrated that 
its binding leads to JNK pathway activation and at the same time suppresses the Ras/Erk signaling 
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pathway (Murakami, et al. 2002), while the Dok4/5 enhances it. IRS-1 competes with Shc to the 
Tyr1062 binding and triggers to the activation of PI3K/Akt pathway (Melillo, et al. 2001). A 
member of the Shc-like proteins family, Rai, was found to play an important role in Ras/Erk and 
PI3K/Akt signaling pathways activation (Pelicci, et al. 2002). The enigma protein, which interacts 
with RET9 (Borrello, et al. 2002) is required for the activation of Ras/Erk signaling pathway (Durick, 
et al. 1998). Shank3 mediates sustained Ras/Erk and PI3K/Akt signaling (Schuetz, et al. 2004). 
Finally and interestingly, PKCα is a negative regulator to the RET signaling as reduction in RET 
phosphorylation was demonstrated (Andreozzi, et al. 2003) upon co-expression of this protein. 
 
2.3.2 Other Tyrosine residues: 905, 981, 1015, 1096 and Serine 696 
 
Other well-studied Tyrosine phosphorylation sites of RET are Tyr905, 981, 1015 and 1096, being 
the docking sites for Grb7/10, Src, phospholipase C gamma (PLCγ) and Grb2, respectively (Borrello 
et al. 1996; Encinas et al. 2004). Interestingly, it has been demonstrated that serine 
phosphorylation is also involved in the RET signaling cascade. Phosphorylation at Ser696 of RET, in 
neuronal cells, has been shown to be mediated by GDNF up-regulation of the intracellular cyclic 
AMP (cAMP) level, while the mutation of this serine inhibits lamellipodia formation by GDNF in a 
human neuroblastoma cells(Fukuda et al. 2002).  There is a possible relation between G-proteins 
signaling and RET, as the cAMP is a known key regulator of the G-coupled receptor mediated PKA 
pathways. The complete RET signaling network is detailed and summarized in Figure 2. 
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Figure 2. RET signaling network mediated by docking sites and their direct targets. Modified from 
(de Groot et al. 2006).  
 
2.4 Function of RET 
 
The RET receptor is important for gastrointestinal nervous system differentiation as well as 
sympathetic, neuroendocrine and renal development (Skinner, et al. 2008). The first in vivo study 
to reveal RET functions was based on mouse mutants harboring targeted homozygous mutation of 
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ret. These mice exhibited renal agenesis and severe dysgenesis, lacking enteric neurons 
throughout the digestive tract, and died within first days of their life (Schuchardt, et al. 1994). 
Monoisoformic RET51 mice, lacking the RET9 form, developed kidney hypodysplasia and lacked 
enteric ganglia from the colon(de Graaff, et al. 2001), which point to RET9 as highly important for 
kidney and enteric nervous system (ENS) development. In this regard, it has been demonstrated in 
another in vivo study that mice deficient in RET, GNDF, GFRα1 lacks all neurons in the gut, died 
immediately (for rewiev see(Manie, et al. 2001)). Interestingly, based on expression data, RET is 
expressed at the same moment than the ENS progenitors of neural crest origin entry into foregut 
mesenchyme(Durbec, et al. 1996) suggesting its implication at a very early stage of ENS 
development. One of the RET co-receptors, GFRα1, is expressed in all enteric neuron precursors 
and at an earlier stage compared to GFRα2(Enomoto 2005) which is present in a subpopulation of 
the precursors.  
RET, its ligands, GFLs and co-receptors, GFRαs, are particularly important in sympathetic and 
parasympathetic nervous system development(Airaksinen and Saarma 2002; Sariola and Saarma 
2003). In this regard, it has been observed that the GDNF/GFRα1/RET cascade is essential for the 
migration and proliferation of the cranial parasympathetic neuron precursors, whereas the 
NTN/GFRα2/RET signaling is required for nervous innervation to target organs (e.g. pancreas, 
reproductive organs) in the later developmental stages (Enomoto, et al. 2000; Rossi, et al. 2000). 
 
RET is also implicated in kidney morphogenesis, as the GDNF/RET signaling is essential in nephron 
formation. It was suggested that this particular relation is controlled by negative feedback, where  
GDNF triggers RET signaling, promoting and maintaining high expression levels of Sprouty1 in the 
Wolffian duct, important in nephrogenesis. In response to that, the high level of Sprouty1 
desensitizes RET towards GDNF resulting in Sprouty1 expression decrease(Basson, et al. 2005). 
Sprouty1 has been recently demonstrated, in another in vivo study, to play a role in medullary 
thyroid carcinoma as a tumor-suppressor gene(Macia, et al. 2011).  
Moreover, RET implication has also been demonstrated in spermatogenesis, where GDNF/RET 
signaling has a crucial role in its early event. RET and GFRα1 are expressed in a subset of 
undifferentiated spermatogonia and GDNF is derived from Sertoli cells, implicated in 
spermatogenesis regulation in a paracrine manner, and its overexpression inhibits the 
differentiation process (Sariola and Saarma 2003). 
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Finally, regarding the implication of RET in human disease, basically, the loss-of-function mutations 
result in congenital megacolon or Hirschprung´s disease (HSCR), whereas the gain-of-functions 
give rise to MEN 2 syndrome(Mulligan et al. 1993b). Other RET genetic changes have been 
demonstrated in papillary thyroid carcinoma (PTC), caused by different types of RET 
rearrangements and designated as RET/PTC, although this topic is not the issue of this thesis and it 
will not be further discussed.  
 
3. Relation of RET with MEN2  
 
3.1. Germline RET mutations 
 
As already mentioned, germline RET mutations are related to MEN 2 syndrome development. A 
summary of RET mutations described so far is described in Table 2. Approximately 86%, 97% and 
almost 99% of patients with FMTC, MEN 2A and MEN 2B respectively carry activating mutations in 
RET. Those related to FMTC can be found in both extracellular and the tyrosine kinase domains of 
RET. The former include mainly substitutions of cysteines 609, 618, 620 (exon 10), 630 and 634 
(exon11). The mutations affecting the tyrosine kinase domain include substitutions at residue 768, 
790, 791 (exon 13), 804, 844 (exon 14), or 891 (exon15) (Alberti et al., 2003). Similarly to FMTC, 
the most common alterations related to MEN 2A are missense mutations in the extracellular 
domain. They mainly include changes affecting the cysteines 609, 611, 618, 620 (exon 10), 630 or 
634 (exon 11). Among these mutations, the most common one found in MEN 2A patients is the 
substitution of Cys634, being involved in 80% of the cases (Alberti et al.,2003). RET/MEN 2A 
proteins display constitutive kinase activity due to ligand independent dimerization of the RET 
molecules (Alberti et al., 2003), which is a mechanism similar to that of FMTC. Two variants of 
MEN 2A are defined: MEN 2A associated with cutaneous lichen amyloidosis (CLA) and MEN 2A 
developing together with Hirschsprung’s disease(Decker, et al. 1998). CLA is specifically associated 
with mutations involving codon 634 of exon 11, whereas MEN 2A associated with Hirschsprung’s 
disease is linked to mutations involving codons 609, 611, 618, and 620. Patients with codon 634 
mutation have an increased risk of lymph node metastasis at a young age (Machens, et al. 
2003).The activation mechanism related to non-cysteine RET mutations occurring in the RET 
tyrosine kinase domain are still unknown.   
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MEN 2B is mainly associated with a specific mutation, a substitution of a Methionine to Threonine 
at 918 residue (p.M918T). Only a small portion (<5%) of the MEN2B patients carry another 
mutation (p.A883F). Tumors containing p.M918T often display a more aggressive phenotype 
(Alberti et al., 2003), very likely due to p.M918T causing constitutive activation of RET and 
transforming potential in a ligand-independent manner (Arighi et al., 2005). The p.M918T 
mutation does lead to constitutive dimerization like the cysteine mutations in FMTC and MEN 2A 
do (Alberti et al., 2003).  
 
Information related to which specific mutation is responsible for the disease in a particular patient 
or family is critical due to there is a classification according to the transforming capacity associated 
with each mutation, and thus consequences for the clinical follow up. Hereditary MTCs are divided 
into three different risk categories (Brandi et al. 2001). The cases with highest risk, level 3, (Table 
3) include mutations within the highest transforming capacities that are associated with MEN 2B 
syndrome. As these individuals develop the most severe form of MTC, they should undergo 
surgery during the first 6 months of life, and preferably during the first month. The second 
category within high risk includes mostly cases with 634 RET mutation carriers. For such patients 
total thyroidectomy is offered at the age of 5 years and for the other mutations affecting exon 10 
might be performed later in life. In families with mutations in exons 13-15, which are included in 
an intermediate group risk and level 1 category, MTC clinically usually emerge with an indolent 
course in the second decade of life (de Groot et al. 2006).  
 
 
 
 
 
 
Table 2. Germline RET mutations in MEN2 syndrome and somatic RET mutations in sporadic MTC 
(sMTC). Adapted from (Arighi et al. 2005a).  
Exon Codon number Amino acid change Phenotype 
8 533 Gly  Cys FMTC 
 
 
603 Lys  Gln sMTC 
609 Cys  Ser MEN 2A,  
Cys  Arg MEN 2A, FMTC 
Cys  Tyr MEN 2A 
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10 
611 Cys  Tyr MEN 2A 
Cys  Trp MEN 2A, FMTC 
Cys  Ser MEN 2A,  
Cys  Gly FMTC 
618 Cys  Phe MEN 2A 
Cys  Ser MEN 2A, FMTC 
Cys  Gly MEN 2A 
Cys  Arg MEN 2A, FMTC 
Cys  Tyr MEN 2A, FMTC 
Cys  Stop MEN 2A 
620 Cys  Arg  MEN 2A, FMTC 
Cys  Tyr MEN 2A 
Cys  Phe MEN 2A 
Cys  Ser MEN 2A 
Cys  Gly MEN 2A 
 
 
 
11 
630 Cys  Phe FMTC 
Cys  Arg sMTC 
634 Cys  Tyr MEN 2A, FMTC 
Cys  Arg MEN 2A 
Cys  Phe MEN 2A, FMTC 
Cys  Gly MEN 2A 
Cys  Trp MEN 2A 
Cys  Ser MEN 2A, FMTC 
Cys  Arg sMTC 
634 and 640 Cys  Arg  and  Ala  Gly  De novo MEN 2A 
634 and 641 Cys  Ser  and  Ala  Ser   MEN 2A 
634 and 640 Ala  Gly  and  Ala  Arg  sMTC 
13 768 Glu  Asp FMTC/sMTC 
790 Leu  Phe MEN 2A, FMTC 
791 Tyr  Phe FMTC 
 
14 
804 Val  Leu FMTC 
Val  Met FMTC 
804 and 806 Val  Met  and  Tyr  Cys  De novo MEN 2B 
778 and 804 Val  Ile  and  Val  Met  FMTC 
 
15 
883 Ala  Phe de novo MEN 2B 
  sMTC 
891 Ser  Ala FMTC 
  FMTC and Pheo 
16 918 Met  Thr MEN 2B or sMTC 
922 Ser  Phe sMTC 
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Table 3. Genotype-phenotype correlation. MTC risk levels according to mutated codon of RET 
proto-oncogene. Level 3 is the most severe. From (Brandi et al. 2001). 
 
Mutated codons Risk level Syndrome(s) Recommended actions 
883, 918, 922 3 MEN 2B Thyroidectomy within first 6 months of life 
    
611, 618, 620, 634 2 MEN 2A, MEN 2B,  Thyroidectomy before age 5 years 
  FMTC  
    
609, 768, 790, 
791, 
1 MEN 2A, FMTC Thyroidectomy between age 5 and 10 
years. 
804, 891 1 MEN 2A, FMTC Periodic biochemical testing for MTC if 
thyroidectomy not performed 
 
3.2 Somatic RET mutations 
 
Around 40-50% of sporadic MTC harbor somatic RET mutations (Marsh 2002). The most common 
somatic mutation is the p.M918T change, the same one involved in MEN2B patients. Similarly to 
patients with germline mutations in this residue, the tumors with this mutation are considered to 
have the most aggressive clinical course(Schilling, et al. 2001). Somatic mutations at different 
codons such as 630, 634, 639, 641, 768, 883, 992 as well as deletion in codons 630 and 634 have 
also  been identified(Bugalho 1997). However, the functional role of somatic RET mutations in 
MTC development still requires more investigation. It was shown by Eng and colleagues(Eng, et al. 
1996b) that sporadic MTC cases with p.M918T RET mutations and their metastasis are 
heterogeneous. In this regard, this mutation can arise as a secondary event during progression 
from a metastatic clone or single tumor. A second possibility implies that MTC has polyclonal 
origin.  
 
 
 
4. MTC management, detection and targeted therapies 
 
As already mentioned, MTC disseminate locally in 50% of cases to cervical and mediastinal nodal 
groups and up to 20% to distant organs such as lungs, bones or liver(DeLellis 2004). When the 
disease is outside the thyroid gland, the chances of cure are reduced.  Early diagnosis of tumors 
may affect the therapeutic strategy and chances of cure and may prolong survival. In case of 
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thyroid neoplasias, the fine needle aspiration biopsy is the routine method used to obtain 
prognostic information such as tumor aggressiveness, metastatic potential and response to the 
treatment. 
Every patient with newly diagnosed MTC should be counseled about the possibility of familial 
disease and offered genetic testing. The serum calcitonin measurement, a sensitive marker for 
MTC, becomes useful in screening ¨at-risk¨ individuals and monitoring for disease recurrence in 
previously treated patients. Generally, complete preoperative evaluation of patients with possible 
MTC should consist of measurements of serum calicitonin, carcinogenic embryonic antigen (CEA), 
serum calcium and RET proto-oncogene mutational analysis. MTC in patients with palpable thyroid 
nodule could metastasize locally to the cervical lymph nodes as well as distant metastases to the 
bones, lungs or liver. In case of metastatic MTC diagnostics, imaging techniques such as computed 
tomography (CT) for lymph nodes and lungs (Giraudet, et al. 2007) or contrast-enhanced magnetic 
resonance imaging (MRI) and positron emission tomography (PET) for lung and liver metastases 
detection are widely used (Oudoux, et al. 2007).  Surgery should then be personalized according to 
calcitonin levels, presence of palpable disease, imaging results, RET mutation screening and family 
history. 
For primary MTC patients there are no alternatives except total thyroidectomy, while for 
metastatic advanced disease there is a great need for discovery of new molecular therapies.  
Previous clinical responses rates for chemotherapy in such patients have been disappointing, 
although there are currently some promising observations, as reviewed below. Classifying an 
individual or family by MEN 2 subtype is useful for determining prognosis and management.  
 
4.1 Targeted therapies for MTC 
Taking into account that there are currently several therapeutic approaches based on the use of 
tyrosine kinase inhibitors (TKIs), MTC patients may benefit from development of this particular 
field.  In fact, targeted molecular therapies currently used in metastatic MTC management are 
based on inhibition of RET and other tyrosine kinase receptors that are involved in angiogenesis 
(Table 4). 
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Table 4. Summary of clinical trials in MTC patients with progressive disease. Adapted from 
(Almeida and Hoff 2012). 
Target therapy                     Target                                Clinical phase        Type of MTC patients 
 
Motesanib                             VEGFR, RET                                      II                      advanced MTC                                                                                    
Sorafenib (BAY 43-9006)   VEGFR, RET, BRAF                           II                      advanced MTC 
Sunitinib (SU11248)            VEGFR, RET, BRAF                          II                      metastatic MTC 
Axitinib                                  VEGFR,RET, RET/PTC                     II                                      MTC 
Vandetanib (ZD6474)         VEGFR,RET, EGFR, RET/PTC          II & III           advanced & metastatic MTC 
(100 and 300mg)                                                                                    
Cobazantanib(XL184)          VEGFR, MET, RET                           I                      hereditary & sporadic MTC  
                 
 
Very recently, in 2011, Vandetanib (ZD6474, Zactima), a potent inhibitor of EGFR, VEGFR2-3 and 
RET, was approved by the Food and Drug Administration (FDA) for progressive MTC treatment in 
adults.  After phase II study with treatment of 300mg Vandetanib(Wells, et al. 2011a), and test for 
efficacy in a lower dose (100mg daily) in patients with advanced inherited MTC(Robinson, et al. 
2011), this drug passed to phase III in clinical trials, showing therapeutic efficacy in the patients 
with advanced MTC(Wells, et al. 2011b).  
Cabozantinib (XL184, Exelixis), is another small-molecule inhibitor of VEGFR1 and VEGFR2, 
hepatocyte growth factor receptor (MET) and RET. This drug was implemented in a phase I study 
conducted with 37 MTC patients(Kurzrock, et al. 2011). There is currently an ongoing phase III 
study (http://www.exelixis.com/investors-media/press-releases) performed on metastatic MTC 
comparing XL184 with placebo.  
Sorafenib (BAY 43-9006, Nexavar), is another small-molecule TKI targeting VEGFR2 and VEGFR3, 
RET and BRAF. This drug was approved by the FDA for the treatment of advanced renal cell 
carcinoma and hepatocellular cancer. Sorafenib efficacy in metastatic MTC had been evaluated in 
the phase II study(Lam, et al. 2011).  
Sunitinib (SU11248, Sutent), an inhibitor of the three VEGFRs, RET and RET/PTC subtypes 1 and 3, 
has been mostly associated with stable disease in MTC patients(Carr, et al. 2011) in a phase II 
study. Additionally, other phase II studies targeting VEGFRs are also being tested under 
commercial brands of Motesanib (Schlumberger, et al. 2009) or Axitinib, which did not block RET 
(Cohen, et al. 2008). 
So far, clinical trials have included MTC patients as a minimal part of series of thyroid carcinoma 
patients. Thus, results and conclusions specifically related to MTC patients are scarce. In the next 
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few years, and after International Consortiums´ joint efforts to recruit metastatic and advanced 
MTC patients to be analyzed as a whole, we can probably expect robust conclusions with regards 
to the molecular features related to the success of their treatment. 
 
5. Genomics 
 
5.1 Transcriptomics 
 
Although there is a well-established genotype-phenotype correlation for MEN2 patients, the 
mechanisms by which RET-mutations cause tumors, the development of sporadic MTC in the 
absence of RET mutations, and the specific oncogenic pathways involved, require further study. 
There is an urgent need to identify signaling pathways specifically related to familial and sporadic 
MTC using transcriptional profiling to gain new information about specific markers that could be 
used as potential therapeutic targets.  
Transcriptional profiling has emerged as a robust tool to identify biomarkers related to the tumor 
differentiation stage and malignant behavior, among other features. Limitations related to this 
approach often arise from high quality RNA material requirements. Moreover, expression 
microarrays are based on freshly prepared mRNA extracts and show many difficulties with 
formalin fixed paraffin embedded (FFPE) tissue samples frequently containing degraded or low 
quality RNA material. Another pitfall is genomic data analysis, being mostly very time-consuming 
and often very complex in order to integrate all underlying information relevant to the biology of 
the specific disease. Despite many difficulties, these transcriptomic techniques compensate by 
retrieving a lot of information from a single experiment, including therapeutic targets and 
prognostic marker discoveries as well as many others such as sensitivity to specific treatments etc.  
In fact, there are several studies focused on MTCs using this strategy (Ameur, et al. 2009; Jain, et 
al. 2004a; Lacroix, et al. 2005; Musholt, et al. 2005b; Watanabe, et al. 2002b) showing differences 
in gene expression according to specific RET mutation, although we are far from understanding the 
secondary processes involved in MTC pathogenesis.  
5.2. microRNAs 
 
MicroRNAs are small, around 20 nucleotide long, non-coding single-stranded RNA molecules 
regulating the expression of target genes by imperfect (in animals) binding to the 3´-UTR 
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(untranslated region) and possibly 5´-UTR of mRNA(Lytle, et al. 2007). To become mature form, 
miRNAs are processed by enzymatic complexes Dorsha and Dicer(Wiemer 2007), and they repress 
translation or lead to mRNA degradation of their target genes (Figure 3). Currently there are 
around 2000 human miRNA sequences annotated in the miRBase database version 18.0 
(http://www.mirbase.org/) and this number is still growing. Regardless of the relatively small 
number of miRNAs, as each single miRNA targets several hundred genes and a single target gene 
can bind to multiple miRNAs(Lewis, et al. 2003) making the whole network very complex, it is 
believed that around 30% of all human genes are a target for miRNA regulation (Lewis, et al. 
2005). There is also evidence that these small molecules are expressed in a tissue-/cell-specific 
manner, being restrictively reserved to specific cell type or ubiquitously associated within different 
human body compartments (Landgraf, et al. 2007).  
It was previously demonstrated that dysfunctional expression of microRNAs is a frequent attribute 
of malignant behavior(Calin and Croce 2006). Nowadays, aberrant expression of specific 
microRNAs is associated with all cancer types. Germline and somatic mutations as well as 
polymorphisms in the mRNAs targeted by miRNAs can also lead to cancer predisposition and 
progression (Calin and Croce 2007). Growing evidence points to miRNA, being implicated in 
oncogenic processes, suggesting that miRNA expression profiling can distinguish tumors according 
to diagnosis and developmental cancer stages for  more accurate studies than usually provided by 
traditional gene expression analyses(Lu, et al. 2005). Small non-coding RNAs can play a dual role in 
tumorigenesis, acting as oncogenes (e.g. miR-155 of miR-17-92 cluster family members), or tumor 
suppressors (e.g. miR-15a and miR-16). To date, there are three proposed mechanisms implicating 
miRNA deregulation in cancer. These processes involve chromosomal lesions at regions encoding 
miRNAs, failure in the their biosynthetic pathway machinery and finally epigenetic 
regulation(Lawrie 2008). 
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Figure 3. Biogenesis and microRNA function. miRNAs are transcribed in the nucleus by RNA polymerase II to 
form pri-miRNA which has to be processed to become functional mature form. This is possible due to 
RNAsas Dorsha and Dicer. The first processing is made in the nucleus by Dorsha and pre-miRNA is generated, 
which is transported to the cytoplasm and then Dicer processes the second part to obtain mature miRNA 
form. Then miRNA acts together with RISC complex which proceed the target gene silencing via two 
mechanisms: degradation of mRNA or inhibition of mRNA translation. Modified from (Bartel 2009). 
 
Little is known regarding the studies based on the direct role of microRNAs implicated in MTC 
development. There are only two studies on miRNAs of MTC. The first one  pointed to the miR-183 
and miR-375 overexpression as lymph node metastasis prediction, although based on a small 
cohort of patients and not taking into account specific RET mutations in MTC development 
(Abraham, et al. 2011).  The second one compares miRNA profiles of 2MTCs with unknown genetic 
background comparing them versus follicular-cell type origin thyroid carcinomas(Nikiforova, et al. 
2008). Mian and colleagues have very recently could not validate  the results of these mentioned 
studies (Mian, et al. 2012). 
So far, apart from those above mentioned, there are no other miRNA profiling studies been 
performed on these rare tumors, offering a field to increase our understanding of this disease. The 
combination of both transcriptome and mirnome data can be a powerful tool to retrieve more 
relevant information underlying development and biology of the disease.  
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El Carcinoma Medular de tiroides (CMT) representa el 2-5% de los carcinomas tiroideos, y deriva 
de las células parafoliculares o células C, que secretan calcitonina, la hormona que regula los 
niveles de calcio en sangre. El CMT se disemina localmente a nódulos cervicales y mediastínicos en 
el 50% de los casos, y hasta en un 20% a órganos distantes como pulmón, huesos o hígado 
(DeLellis 2004). 
La mayor parte son esporádicos (75%), desarrollándose el 25% restante en el contexto de una 
Neoplasia Endocrina Múltiple tipo (MEN2, OMIM #171400). De acuerdo a la presentación clínica, 
el síndrome MEN2 está subdividido en Neoplasia Endocrina Múltiple tipo 2A (MEN 2A; OMIM 
#171400), Neoplasia Endocrina Múltiple tipo 2B (MEN 2B; OMIM#162300) y Carcinoma Medular 
de Tiroides familiar (FMTC; OMIM#155240). Esta enfermedad presenta una prevalencia de 
1:30.000(Marsh 2002), con una herencia autosómica domiante, expresión clínica variable, y una 
penetrancia casi completa dependiente de la mutación específica de RET responsable de la 
enfermedad en cada caso. 
El gen responsable del desarrollo del CMT es el proto-oncogen RET, que codifica para un receptor 
tirosina-quinasa (RTK). Mutaciones activantes, tanto germinales como esporádicas, son 
responsables de la mayoría de los casos familiares o esporádicos respectivamente (Hofstra et al. 
1994; Mulligan et al. 1993b), aunque recientemente han sido también descritas mutaciones en 
BRAF y RAS (Goutas 2008; Moura et al. 2011). 
El gen RET está localizado en la banda cromosómica 10q11.2, está distribuido en 50kb y contiene 
21 exones (Pasini et al. 1995). Existen tres isoformas diferentes, RET9, RET43 y RET51, como 
consecuencia de un proceso de splicing alternativo, que difieren en el extremo C-terminal. RET 
contiene dos dominios extracelulares (cuatro regiones “cadherin-like” en tandem, y un dominio 
rico en cisteínas), un dominio transmembrana, y dos dominios tirosina quinasa intracelulares. RET 
es el receptor para ligandos de la familia del factor derivado de las células de la glía (GDNF), 
compuesta por GDNF, neurturina (NTN), artemina (ARTN) y persephina (PSP)(Santoro et al. 
2004a). Estos ligandos necesitan reclutar co-receptores para conseguir que se active la 
transducción de señales. Hasta la fecha hay dos mecanismos de activación dependiente de RET 
aceptados, que implican la unión entre GFL, GFRα y RET (Figura 1). El primero propone que se 
forma un complejo entre una molécula de GFL y una de GFRα, y el segundo plantea que se forma 
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un complejo entre GFRα y RET, que desencadena la aparición de un sitio de unión para GFL (Manie 
et al., 2001). 
RET, al igual que otros RTKs, está regulado por fosforilación de residuos específicos de tirosina, lo 
que promueve la señal. Tras la estimulación del ligando y la asociación al receptor, RET se dimeriza 
y la trans-fosforilación ocurre en residuos intracelulares de tirosina concretos, que sirven como 
sitios de unión para otras proteínas que participan en la señalización. Se sabe muy poco sobre qué 
rutas de señalización se ven activadas ante mutaciones en RET particulares, así como de las 
implicadas cuando el tumor aparentemente no se desarrolla como consecuencia de una mutación 
en RET (de ahora en adelante RET wild-type).  
Se sabe que RET puede activar varias rutas dependientes de RTKs bien conocidas, como la Erk, 
PI3K/Akt, MAPK, JNK y PLCγ(Arighi et al. 2005a; Ichihara et al. 2004). Hay varios sitios reconocidos 
como adaptadores de proteínas (Figure 1). Entre ellos, los más importantes son las tirosinas 
fosforiladas de las posiciones 905, 981, 1015, 1062 y 1096 (Encinas et al. 2004; Ichihara et al. 
2004). Básicamente, lo que ocurre es que la proteína RET normal, las relacionadas con MEN2A, 
con MEN2B y con CMTf muestran diferencias en su fosforilación y por tanto en los sitios de unión 
a otras proteínas, que conducen a activar cascadas de señalización intercelular específicas en cada 
caso (de Groot et al. 2006). 
En cuanto a la función de RET, se sabe que este receptor es importante en el desarrollo del 
sistema nervioso gastrointestinal, así como del simpático, neuroendocrino y renal (Skinner et al., 
2008). Su implicación también ha sido demostrada en espermatogénesis, proceso para el cual la 
señalización dependiente de GDNF/RET tiene un papel crucial.  
Con respecto al papel de RET en enfermedades humanas, es destacable que las mutaciones de 
pérdida de función conducen al desarrollo de la enfermedad de Hirschprung (HSCR), y las de 
ganancia de función a un MEN2 (Mulligan et al. 1993b). En carcinoma papilar de tiroides se ha 
demostrado la importancia de otro tipo de alteraciones genéticas que afectan a RET, 
caracterizadas por translocaciones cromosómicas con otros segmentos del genoma. 
En relación con las mutaciones asociadas a MEN2, hay una correlación fenotipo-genotipo que 
estratifica dichas mutaciones en tres niveles de riesgo. Las clasificadas como nivel 1 de riesgo 
afectan a los residuos 609, 768, 790, 791, 804, y 891, y se asocian con desarrollo de CMT. 
Pacientes con mutaciones de nivel 2 (afectan a los residuos 611, 618, 620, y 634) tienen un mayor 
   Introducción 
 
  65 | P a g e  
riesgo, y se asocian a una mayor probabilidad de desarrollar metástasis del CMT. Mutaciones de 
nivel 3 (resíduos 883 y 918) tienen la capacidad transformante más elevada de todas, y conducen 
al desarrollo de CMTs con riesgo de metástasis a edades tempranas (Frank-Raue and Raue 2009). 
En torno al 40-50% de los CMT esporádicos presentan una mutación somática en RET (Marsh, et 
al. 1996). La más frecuente es la mutación p.M918T, que es la misma que está implicada en la 
mayor parte de los pacientes MEN2B, y se asocia a los cursos clínicos más agresivos (Schilling et al. 
2001). La información relativa a qué mutación específica es la responsable de la enfermedad en un 
paciente o en una familia es crítica de cara a tener en cuenta el riesgo que tiene asociado, y por 
tanto con consecuencias para el seguimiento clínico.  
El manejo de CMTs primarios pasa por una tiroidectomía realizada por expertos, mientras que 
para la enfermedad avanzada existe una necesidad real de descubrir nuevas dianas terapéuticas. 
Teniendo en cuenta que actualmente hay en marcha varios ensayos clínicos basados en el uso de 
inhibidores de tirosina quinasa, los pacientes con CMT podrían beneficiarse de este campo en 
particular. De hecho, las terapias moleculares dirigidas utilizadas en CMT metastásico están 
basadas en la inhibición de RET y de otros receptores tirosina quinasa implicados en angiogénesis. 
Hay una necesidad urgente de identificar rutas de señalización específicamente relacionadas con 
el carácter hereditario o esporádico de los tumores.  
El análisis de perfiles de expresión génica ha sido utilizado como herramienta para identificar 
eventos moleculares asociados a subtipos tumorales, o procesos asociados concretos, como 
metástasis proliferación y angiogénesis(Glinsky 2006). Hay numerosos estudios que también han 
demostrado su potencial para identificar firmas moleculares asociadas a características 
clínicas(van de Vijver, et al. 2002) lo que podría ayudar a la identificación de nuevas dianas 
terapéuticas. De hecho, ya hay varios estudios enfocados en CMTs que han utilizado esta 
estrategia (Ameur et al. 2009; Jain, et al. 2004b; Lacroix et al. 2005; Musholt, et al. 2005a; 
Watanabe, et al. 2002a) y que muestran diferencias en el perfil de expresión génica de acuerdo a 
la mutación específica en RET, si bien estamos aún lejos de entender los procesos secundarios 
implicados en el desarrollo de un CMT.  
Por otra parte, apenas se conoce el papel que los microRNAs puedan tener en el desarrollo de 
CMTs. Hasta la fecha hay solo dos estudios sobre el tema. El primero describe la sobre-expresión 
del miR-183 y del miR-375 asociada a la aparición de metastasis, aunque está basado en una 
cohorte de pacientes pequeña y no se tiene en cuenta qué mutaciones en RET caracterizaban cada 
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tumor (Abraham et al. 2011).  El segundo estudio comparaba el perfil de microRNAs de dos CMTs 
con background genetic desconocido, con el mostrado por tumores tiroideos derivados de célula 
folicular (Nikiforova et al. 2008). Estos resultados no pudieron ser validados en un estudio reciente 
(Mian et al. 2012). 
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The final goal of this work was to characterize the transcriptional and microRNA profiles 
specifically related to hereditary and sporadic MTC according to specific RET mutation, by using 
the same cohort of tumors. Due to there is a long list of unanswered questions regarding the 
signaling pathways associated with MTC development according to specific genetic condition, 
integration of these two OMIC approaches (gene expression and miRNA) might reveal an 
important input in deeper understanding of MTC biology. Therefore, the specific aims of this work 
were: 
 
1) To define the transcriptome and mirnome of MTC cases according to the different 
individual genetic background. For that purpose it was consider the presence of the 
M918T RET mutation in sporadic MTC, sporadic MTC WT (no RET mutation) and 
hereditary MTC with germline RET mutation. 
 
2) To identify biomarkers related to each genetic class included in the study, as well as 
pathways specifically altered, that could be the target of future therapeutic options.  
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El objetivo final de este trabajo fue caracterizar el perfil transcripcional y de microRNAs 
relacionados con el carácter esporádico y hereditario de los CMT, y relativos a mutaciones 
específicas en RET, utilizando para ello la misma coleción de tumores. Dado que hay una larga lista 
de preguntas sin respuesta relacionada con las rutas de señalización asociadas al desarrollo de 
CMTs bajo condiciones genéticas concretas, la integración de los resultados procedentes de estas 
dos plataformas (expresión génica y microRNAs) podría profundizar en el conocimiento de la 
biología del tumor. Los objetivos específicos de este trabajo fueron: 
1) Definir el transcriptoma y el mirnoma del CMT, de acuerdo con el backgroung genetico 
individual del paciente. Para ello se consideraron 3 grupos de análisis: tumores 
esporádicos con la mutación M918T en RET, tumores esporádicos sin mutación 
detectable or Wild Type, y CMTs hereditarios pertenecientes a pacientes con mutaciones 
germinales en RET.   
 
2) Identificar biomarcadores relacionados con cada una de las clases genéticas incluidas en 
el estudio, así como rutas específicamente alteradas, que pudiesen ser consideradas 
como futuras dianas terapéuticas.  
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1.1 Medullary Thyroid Carcinoma patients 
Extracted DNA from peripheral blood samples of patients diagnosed with at least MTC was 
collected from 1996 to 2010 from Spanish hospitals. After obtaining consent from each patient, 
clinical information was collected through a questionnaire (supplementary annex 1), and when 
possible, the corresponding tumors used for further analysis. The genetic and general 
characteristics of the available tumors (frozen or FFPE) are detailed in Supplementary annex Table 
1. Specific data such as gender, age at the diagnosis, the presence of metastasis (at the time of 
diagnosis or follow-up) and the existence of personal or family history of the disease were 
retrieved. Tumors were classified according to the molecular screening for RET proto-oncogene, 
and then this information was considered for further analyses.  
 
1.2 Frozen MTC tissue samples  
Sixty-nine frozen tumors from unrelated patients diagnosed with MTC were collected at the time 
of surgery from Spanish hospitals through the Spanish National Tumor Bank Network and from the 
Surgical Pathology Department of Medical and Surgical Sciences, Padova, Italy. Each frozen tissue 
sample was included in a matrix of polyvinyl (Tissue - Tek ® OCTTM, Sakura, NL) and stored at -80 ° 
C until use for DNA or RNA extraction and hybridization onto arrays, or for RET mutational 
screening (in case that previous genetic information on the patient was not available). Staining 
with haematoxylin-eosin (H&E) was carried out for each of the tissues in order to assess the 
presence and abundance of tumor cells. All tissues were evaluated by two pathologists by 
hematoxylin and eosin staining; only samples with a high percentage (>80%) of tumor cells were 
included in the study. The protocol for staining with H&E of the frozen and paraffin tumor sections 
is detailed below: 
1. Hydrate with absolute ethanol (2 minutes) and later with ethanol 95% (2 minutes). 
2. Wash with distilled water (B. Braun Medical SA, Barcelona, Spain) for 2 minutes. 
3. Stain with Mayer haematoxylin for 15 minutes. 
4. Wash with distilled water for 2 minutes. 
5. Stain with eosin for 2 minutes. 
6. Remove the eosin remains, using 70% ethanol. 
7. Dehydrate through successive washing with 96% ethanol (30 seconds), absolute ethanol (2 
minutes) and xylol (2 washes, 2 minutes each). 
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8. Mount a cover objects in preparation with Eukitt (Electron Microscopy Sciences, Fort 
Washington, PA, USA). 
Note: Staining of the frozen tissue sections did not require any previous step as the OCTTM does 
not interfere in the staining part nor in the nucleic acids (RNA and DNA) extraction.  
 
1.3 Formalin fixed paraffin embedded (FFPE) samples and tissue microarray (TMA) 
To validate results derived from gene expression and miRNA profiling study, an independent series 
of formalin fixed paraffin embedded tumors was available, composed of 38 MTC samples 
Supplementary annexes table 1 and 2, that  were assessed by H&E staining (with a pre-step of de-
paraffination with xylol).  
Moreover, two 2 tissue microarrays (TMAs) constructed from 67 MTCs (molecularly characterized) 
were used for validation step with immunohistochemistry (IHC). For this purpose, representative 
tumor areas were selected and cylinders of 1mm in diameter included in a new block of paraffin 
with a 0,8mm separation between each tissue sample. MTC tumors included in the TMAs are 
detailed in Supplementary annexes table 3A and Table 3B, representing different mutations in the 
RET proto-oncogene as well as cases without detectable RET mutation. The first TMA (TMA-1), 
Supplementary annex Table 3A, contained 54 independent MTC tissues; of these, 12 carried a 
germline RET mutation in codon 634, 9 had a somatic M918T mutation, and 22 were classified as 
wild type (WT). This TMA also contained 4 other thyroid cancer types and 2 normal tissues used as 
controls, as well as the normal thyroid tissue of 13 MTC cases included in the TMA. TMA-2 
(Supplementary annex Table 3B) was constructed with cores from matched FFPE material from 13 
frozen samples used for profiling [6 MTCs from RET634 carriers, 4 with a RET918 somatic mutation, 
and 3 WT MTCs], as well as 2 MTCs not hybridized, 2 thyroid cancers of a different subtype and 12 
normal thyroid tissues from the corresponding MTCs included in this TMA.  
 
1.4 MTC cell line models 
MZ-CRC-1 cells, derived from a metastatic MTC and harbor the M918T RET mutation (Cooley 1995; 
Santoro, et al. 1995), and TT cell line, harboring a mutation at residue 634 of RET were available.  
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2. DNA extraction 
 
2.1 DNA extraction from peripheral blood 
DNA extraction from the peripheral blood was performed following an automated method 
(MagNa Pure LC; Roche Diagnostics GmbH, Mannheim, Germany): 
1. Starting from 1ml of peripheral blood, the system adds:  
 0,115ml of proteinase K solution,  
 0,84ml of lysis-union buffer to promote cell lysis and generate saline conditions suitable for the 
subsequent retention of DNA,  
 0,54ml of the MGP reagent, which retains the DNA through magnetic crystalline particles.  
2. Washing with 2,42ml of Washing Solution I to discard components not joined to the magnetic 
particles (proteins, cell membranes and inhibitors of amplification such as heparin). 
3. Washing with 1,28ml of Washing Solution II to remove cell remains and to reduce the saline 
concentration. 
4. Washing with 0,84ml of Washing Solution III to remove the remains of ethanol. 
5. Finally, re-suspending purified DNA in 200μl of solution buffer previously pre-heated. 
 
2.2 DNA extraction from frozen tumour material 
DNA extraction from frozen tumour samples was carried out from 15-20 slide sections of 20μm 
thickness each cut using cryostat (Leica Microsystems, Barcelona, Spain). DNA Extraction was 
carried out with Dneasy Tissue Kit (Qiagen, Chatsworth, CA, USA) according to the manufacturer´s 
instructions with some modifications detailed below:  
1. Immerse obtained cuts in O.C.T. (Tissue-Tek® O.C.T.TM, Sakura, NL) material in 200μl of ATL 
solution. 
2. Add 20μl proteinase K and mix vigorously, then incubate in a thermo cycler with agitation at 
55°C until the material is completely digested. The incubation time can vary between 3 hours and 
overnight. 
3. Stir again and add 200μl of AL solution. Mix and incubate at 70°C for 10 minutes. 
4. Add 200μl of absolute ethanol and homogenize. 
5. Pass the mixture to the column, supplied in the kit, and place in a collector tube. Centrifuge at 
8,000 rpm for 1 minute. Discard the collector tube with the supernatant. 
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6. Place the column in a new collector tube and add 500μl of the AW1 solution. Centrifuge at 8000 
rpm for 1 minute. Discard the collector tube with the supernatant. 
7. Place the column in a third collector tube and add 500μl of the AW2 solution. Centrifuge at 
13,000 rpm for 3 minutes to dry the membrane of the column completely. Discard the collector 
tube with the supernatant. 
8. Place the column in a new clean tube and mark appropriately. Add 200μl of distilled water 
directly on the membrane and incubate at 15-20°C for 1 minute. Centrifuge for 1 minute to elute 
the DNA. Optionally, the elution can be performed using a lesser volume of water if expected to 
obtain little amounts of DNA. 
9. Quantify 1μl DNA using NanoDrop ™ ND-1000 (NanoDrop Technologies, Wilmington, DE, USA) 
spectrophotometer. In those cases in which the concentration exceeding 1μg/μl, prepare a 1/10 
dilution and use 1μl of this material to quantification, avoiding a possible saturation of the 
measurement. Freeze the remaining volume at -20°C until use. 
  
2.3 DNA extraction from formalin fixed paraffin embedded (FFPE) material 
Using a microtome (Leica Microsystems, Barcelona, Spain), 4 sections, each of 30μm thickness 
were obtained from each sample, and were introduced in 1.5ml tubes.  
The extraction protocol used was similar to extraction from frozen tissue material but including 
the following previous steps for the deparaffination of the sample: 
1. Place the paraffin cuts in a 1.5 or 2ml tube. 
2. Add 600μl of xylol and mix vigorously. 
3. Centrifuge at room temperature at 13,000 rpm for 5 minutes. 
4. Remove the supernatant with a pipette without dragging the pellet. 
5. Repeat the washing with xylol (steps 2 to 4). 
6. Add 1000μl of absolute ethanol to the pellet to eliminate the residues of xylol and mix 
vigorously. 
7. Centrifuging at room temperature at 13,000 rpm for 5 minutes. 
8. Remove the ethanol with a pipette without dragging the pellet. 
9. Repeat washing with ethanol (steps 6 to 8). 
10. Incubate the pellet with the tube open at 37°C for 10-15 minutes (till the ethanol is 
evaporated). 
11. Continue with Protocol DNA extraction of frozen material from step 1. 
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3. RNA extraction and analysis 
 
3.1 RNA extraction from frozen material 
Total RNA extraction from frozen tumour samples was carried out from 15-20 slide sections of 
20μm thickness each cut using cryostat (Leica Microsystems, Barcelona, Spain). Extraction was 
followed by the TRI Reagent® Protocol (Molecular Research Centre, Cincinnati, OH, USA): 
1. Homogenize tissue sections (50-100mg approximately) in 1ml of solution TRI Reagent. Leave at 
room temperature for 5-15 minutes. 
2. Add 0,2ml of chloroform. Mix vigorously. 
3. Centrifuge at 4°C and at 13,500 rpm for 15 minutes. 
4. Recover the aqueous phase and add 0,5ml of isopropanol. Mix and leave overnight at -20ºC. 
Centrifuge at 4°C and at 13,500 rpm for 20 minutes. 
5. Discard the supernatant and wash with 1ml of 75% aqueous ethanol. Centrifuge at 4°C and at 
13,500 rpm for 5 minutes. 
6. Dry pellets at 65°C for 3-5 minutes. 
7. Re-suspend dried pellet in 12-15μl of RNAase free water. 
8. Stir gently in a thermo cycler at 37°C for 20 minutes. 
9. Use 1μl of the RNA obtained for its quantification using Nanodrop ND‐1000 (Wilmington, DE, 
USA).  
Simultaneously, 1μl of the RNA mixed with 4μl RNAase free water and 5μl of formamide (Applied 
Biosystems, Foster City, CA, US) in 1,5% agarose gel was  tested. The remaining volume at -80°C 
was frozen until use.  
Total RNA samples which presented degraded profile in an agarose gel electrophoresis (<500 
mRNA bp), were extracted again in order to obtain good quality biological material. 
 
3.2 RNA extraction from formalin fixed paraffin embedded (FFPE) material 
Total RNA extraction from FFPE tissue was carried out using the miRNeasy FFPE (Qiagen, 
Chatsworth, CA, USA) kit following the Protocol according to the manufacturer´s instructions as 
specified below: 
1. Cut4 sections of 30μm thickness each using microtome and deposit them in a 1,5ml tube. 
2. Add 1ml of xylol and shake for 10 seconds at the room temperature. 
3. Centrifuge at 13,000 rpm at 20-25°C for 2 minutes. Discard the supernatant, avoid touching the 
pellet. 
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4. Add 1ml of absolute ethanol and mix it vigorously. 
5. Centrifuge again at 13,000 rpm at 20-25°C for 2 minutes. Remove the supernatant, avoid 
touching the pellet. 
6. Incubate at 37°C with open tube for 10 minutes or until the residual ethanol has evaporated. 
7. Re-suspend the pellet in 240μl of PDK solution and add 10μl of proteinase K and mix vigorously. 
8.  Incubate at 55°C for 15 minutes and then at 80°C for 15 minutes. 
9. Add 500μl of RBC solution and mix vigorously. 
10. Transfer the mixture to a column gDNA Eliminator spin (provided by the kit) and place it in a 
tube collector of 2ml. Centrifuge at 10,000 rpm for 30 seconds. Discard the column and keep the 
collected volume. 
11. Add 1,750μl of absolute ethanol to the collected volume and mix with the pipette. Perform the 
next step immediately. 
12. Transfer 700μl of the volume to the RNeasy MiniElute column, spin and place it in a tube 
collector of 2ml. Close the lid gently and centrifuge at 10,000 rpm for 15 seconds. Discard the 
supernatant. Repeat until the entire volume of the sample has gone through the column. 
13. Add 500μl of RPE solution to the column. Close the lid gently and centrifuge at 10,000 rpm for 
15 seconds to wash the membrane of the column. Discard the liquid elute. 
14. Add 500μl of RPE solution to the column again. Close the lid gently and centrifuge at 10,000 
rpm for 2 minutes. 
15. Place the column in a tube collector of 2ml. Open the lid of the column and centrifuge at 
13,000 rpm for 5 minutes. Discard the tube collector. 
16. Place the column in a tube collector of 1,5ml. Add 14-30μl RNase-free water directly on the 
membrane of the column. Close the lid gently and centrifuge at 13,000 rpm for 1 minute. Keep the 
RNA obtained at -80°C until use. 
 
3.3 RNA extraction from cell lines 
Total RNA from MZ-CRC-1 and TT cells was extracted using the RNAeasy kit (QIAGEN, Alameda, CA) 
following the manufacturer´s instructions.  
 
3.4 Analysis of RNA integrity and quality  
For RNA samples obtained from frozen tissues that showed an optimal profile on the agarose gel, 
an evaluation of their integrity was carried out. Agilent 2100 Bioanalyzer (Agilent Technologies, 
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Palo Alto, CA, USA) was used for that purpose. This method estimates the integrity of RNA 
according to an algorithm called RNA Integrity Number (RIN), which corresponds to the quantified 
value of integrity by Agilent software. The RIN varies from 0 to 10, where 10 corresponds to the 
highest quality of RNA material. Only those samples with a value equal to or greater than 7 RIN 
(recommendation of the manufacturer) were selected for the gene expression and miRNA 
profiling study. In case of miRNAs, small RNA protocol was assessed to check RNA quality and 
miRNA content in a total RNA.  
 
4. RET genetic screening 
 
DNA extracted from peripheral blood as well as from frozen tumour material, when only available, 
was used for the genetic characterization of the MTC tumors. Point mutation screening included 
the specific coding regions (exons) of RET proto-gene (8, 10, 11, 13-16) associated with MTC 
development.  The PCR conditions and primers used are described in table 5. A standard PCR 
procedure was used in a final volume of 25μl, which contained 100 ng of genomic DNA, 10% of the 
final volume of the 10XPCR solution (50mM KCl, 10mM Tris and 1,5mM MgCl2), 200mM dNTPs 
(deoxyribonucleotide triphosphate) mix (dATP, aGTP, dCTP and dTTP; Fermentas-Life Sciences, 
Ontario, Canada), 20pmol of each specific primer and 1 unit of Taq polymerase. The reactions 
were carried out using Eppendorf thermocyclers (Eppedorf AG, Hamburg, Germany). Samples, 
once amplified, were tested by agarose gel electrophoresis at 2% dyed with ethidium bromide 
(0,5μg/ml) (Sigma-Alrdich, Alcobendas, Spain). The amplified products were purified and 
sequenced afterwards.   
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Table 5. Primers, amplicon length (bp) and melting temperature (Tm) of the RET mutational 
screening applied in the study.  
RET gene primer pair  Primer pair sequence Amplicon length (bp) & Tm (ºC) 
RET-EXON 8-FORWARD GTGCTCCTGGCACTGTCTTT Amplicon length : 438 bp             
Tm: 60ºC RET-EXON 8-REVERSE GCTATGCTGGCATCGAGAG 
RET-EXON 10-FORWARD TATGCTTGCGACACCAGTTG Amplicon length : 294 bp             
Tm: 62ºC RET-EXON 10-REVERSE CAGCAATTTCCTCCCTTGTT 
RET-EXON 11-FORWARD CAGAGCATACGCAGCCTGTA Amplicon length : 448 bp             
Tm: 62ºC RET-EXON 11-REVERSE CACAGACTGTCCCCACACAG 
RET-EXON 13-FORWARD TGACCTGGTATGGTCATGGA Amplicon length : 239 bp             
Tm: 58ºC RET-EXON 13-REVERSE GGAGAACAGGGCTGTATGGA 
RET-EXON 14-FORWARD AAGACCCAAGCTGCCTGAC Amplicon length : 328 bp             
Tm: 60ºC RET-EXON 14-REVERSE GCTGGGTGCAGAGCCATA 
RET-EXON 15-FORWARD GTCTCACCAGGCCGCTAC Amplicon length : 375 bp             
Tm: 62ºC RET-EXON 15-REVERSE TATCTTTCCTAGGCTTCCCAA 
RET-EXON 16-FORWARD GCCTGGCCTTCTCCTTTAC Amplicon length : 192 bp             
Tm: 60ºC RET-EXON 16-REVERSE TAACCTCCACCCCAAGAGAG 
Highlighted in blue: tumoral DNA screening for somatic RET mutations. 
 
5. Gene expression characterization by using microarrays 
 
The study of the expression profiles of MTC frozen tumors was carried out through a competitive 
hybridization between the tumor RNA (marked with a green fluorophore) and a universal 
reference RNA (marked with a red fluorophore) (Agilent Technologies, Palo Alto, CA, USA) on a 
commercially available platform of complementary DNA (cDNA) (Whole Human Genome 
Microarray format 4x44k). This platform contains 45,015 features with approximately 41,000 
unique probes representing 22,000 genes that make up the complete human genome. Using this 
method, and starting from the total RNA, a fluorescent complementary RNA (cRNA) is generated 
which is further used for a competitive hybridization in which genes, that are over-expressed (red) 
or under-expressed (green), in the corresponding sample are detected. cRNA preparations, 
hybridizations, washes and detection were done as recommended by the supplier and generally 
following procedure is shown at Figure 4.  
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Figure 4 Schematic representation of Agilent data analysis procedure. 
 
5.1 cDNA synthesis and cRNA labeling 
Universal Human Reference RNA (Stratagene, La Jolla, CA, USA) was used as a control for all 
samples. Total RNA was amplified and labeled with cyanine 5 (Cy5)-conjugated dUTP for tumor 
samples, whereas cRNA from Universal Human Reference RNA was labeled with cyanine 3 (Cy3)-
conjugated dUTP using Agilent’s Low RNA Input Linear Amplification Kit (Agilent Technologies, 
Palo Alto, CA) following the manufacturer´s instructions.  
Briefly, 500ng of total RNA was reversed transcribed to double-strand cDNA using a poly dT-T7 
promoter primer. Firstly, template RNA and quality-control transcripts of known concentration 
and quality were first denatured at 650C for 10 min and incubated for 2 hours at 400C with 5x first 
strand Buffer, 0.1 M DTT, 10 mM dNTP, MMLV RT, and RNase-out. The MMLV RT enzyme was 
inactivated at 650C for 15 min. cDNA products were then used as templates for in vitro 
transcription to generate fluorescent cRNA. cDNA products were mixed with a transcription 
master mix in the presence of T7 RNA  polymerase and Cy5 or Cy3 labeled-CTP and incubated at 
400C for 2 hours. Labeled cRNAs were purified using QIAGEN’s RNeasy mini spin columns and 
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eluted in 40ul of nuclease-free water. After amplification and labeling, cRNA quantity and cyanine 
incorporation were determined using a NanoDrop™ ND-1000 (NanoDrop Technologies, 
Wilmington, DE, USA). The following values were recorded: Cy3 or Cy5 dye concentration 
(pmol/μL), RNA absorbance ratio (260 nm/280 nm), cRNA concentration (ng/μL). To determine the 
cRNA yield and specific activity of each reaction we used the following equations: Concentration of 
cRNA * 40 μL (elution volume) / 1000 = μg of cRNA; (Concentration of Cy3/Cy5) / (Concentration 
of cRNA)*1000 = pmol Cy3 per μg cRNA.  If the specific activity was <7.0 pmol Cy3 or Cy5 per μg 
cRNA I did not proceed to the hybridization step and repeated the cRNA preparation. 
 
5.2 Hybridization 
For each hybridization, 1μg of Cy3 labeled cRNA (reference) and 1μg of Cy5 labeled cRNA (tumor 
sample) were mixed, fragmented and hybridized onto Agilent Whole Human Genome (4x44K) 
Oligo Microarray. Briefly, 1μg of Cy3 labeled cRNA (reference) and 1μg of Cy5 labeled cRNA sample 
of interest were mixed along with 10x Blocking Agent and 25x Fragmentation buffer to a final 
volume of 45μl. After 30-minute incubation at 600C, the cRNA fragmentation step was stopped by 
adding 2x GE Hybridization buffer HI-RPM.  Following the microarray handling tips from Agilent the 
hybridization assembly was prepared and the sample was placed in a hybridization oven set to 
650C for 17 hours with rotation at 10 rpm.  
 
5.3 Washing and scanning 
The two-channel hybridized microarrays were disassembled at room temperature in Agilent Gene 
Expression Wash Buffer 1 and washed in this solution for one minute. Then the microarray slides 
were moved into pre-heated (37°C) solution of Gene Expression Wash Buffer 2 and were washed 
for one minute. Finally, moved into 100% acetonitrile at room temperature and incubated for one 
minute. After washing, microarrays were scanned using a fluorescent Agilent Microarray Scanner 
G2565 (Agilent Technologies, Palo Alto, CA, USA) in a special chamber free of ozone to omit 
possibility of Cy5 fluorophore degradation.  
 
5.4 Data analysis - extraction, normalization and preprocessing 
Two-channel arrays were hybridized and quantified using Agilent Feature Extraction software 
(version 9.5.3) and run on all array datasets using the GE2-v5_95_Feb07 protocol recommended 
for this platform. Reproducibility and reliability of each single microarray was assessed using 
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Quality Control report data. Microarray Background subtraction was done using the normexp 
(Ritchie, et al. 2007) method. The data set was normalized using loess within-array normalization 
and quantile between-array normalization. Normalization was performed using limma (Smyth, et 
al. 2005) package, publicly available in R (version 2.11.1, Bioconductor; www.bioconductor.org). 
Expression ratios were calculated (Cy5 processed signal was divided by Cy3 processed signal) and 
log2 transformed. Normalized data were preprocessed using GEPAS server (Montaner 2006). 
Inconsistent replicates (SD>1) were discarded, and consistent replicates were averaged. Finally, 
genes that exhibited flat patterns (SD>0.8) across the set of samples were filtered and omitted in 
further comparisons. Microarray dataset from the set of tumors analyzed in this study is publicly 
available at GEO database (GEO accession number, GSE32662). 
 
6. MicroRNA expression microarrays 
 
For identifying the microRNA profiling 300 ng of total RNA was amplified, then labeled with Hy3 
fluorescent dye and hybridized onto 1-color miRNA microarray (Exiqon, v.11.0 -hsa, mmu & rho) 
according to the manufacturer’s instructions using miRCURY LNATM microRNA Array kit (Exiqon). 
This array contains capture probes targeting 1084 human miRNAs annotated in the miRBASE 
database (www.mirbase.org).   
 
 6.1 Labeling and hybridization: miRCURY LNA™ microRNA Array 
Prior to performing the labeling, the fluorescent dye (Hy3) and the spike-in miRNAs were dissolved 
by adding 29μL and 30μL of nuclease-free water, respectively, and incubated in ice for 30 min. The 
spike-in miRNAs were aliquoted to avoid repeated freeze/thawing. 
The purified total RNA with preserved small RNAs and RIN above 7 was dissolved in RNAse-free 
water to a final amount of 300ng of RNA.  
The labeling procedure was follow according manufacturer instructions: 
1. Place all miRCURY LNA™ microRNA Array Power Labeling kit components on ice and thaw them 
for 15-20 minutes. Mix all components vigorously excluding the enzymes. 
2. Add 1μL of Spike-in miRNA kit, 0,5μL of CIP buffer and 0,5μL of CIP enzyme to a 2μL of total RNA. 
Pipette all the reagents up and down and mix vigorously. 
3. Incubate the mixture at 370C for 30 minutes using a PCR cycler with heated lid. 
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4. Stop the enzyme reaction and denature the RNA by incubation at 950C for 5 minutes followed 
by snap cooling on ice. Leave on ice between 2, to up to 15 minutes and then centrifuge the 
reaction after the incubation on ice briefly. 
5. To avoid direct light exposure while performing this step, add 3μL of Labeling buffer, 1,5μL of 
Fluorescent label (Hy3TM), 2μL of DMSO, 2μL of Labeling enzyme to a final volume of 4μL of the 
mixture from step 4. 
6. Mix and centrifuge the reagents briefly and incubate them at 160C for 1h using a PCR cycler with 
heated lid. Protect reaction from light. 
7. Incubate at 650C for 15 minutes and after stopping the labeling reaction, centrifuge and leave 
on ice. The labeled samples are ready for the hybridization part, on the array. Hybridization should 
preferably occur within next 1-2h. 
 
The hybridization protocol was followed according to manufacturer´s instructions: 
1. Adjust the volume of the sample from the Hy3 labeling reaction to 200μL by adding nuclease-
free water. 
2. Add 200μL of Hybridization buffer and denature the sample at 950C for 2 minutes.  Leave on ice 
from 2 up to 15 minutes and then add 400μL to reservoir. 
3. Incubate at 560C for 16h in a hybridization chamber with rotation.   
   
6.2 Washing and scanning: miRCURY LNA™ microRNA Array 
Further on the slides were washed during repetitively procedure as followed: 
1. Wash in buffer A at 560C for 2 minutes. 
2. Wash in buffer B at 230C for 2 minutes. 
3. Wash in buffer C at 230C for 2 minutes. 
4. Dry the slides in absolute ethanol by immersing for 1 minute. 
After washing, microarrays were scanned using a fluorescent Agilent Microarray Scanner G2565 
(Agilent Technologies, Palo Alto, CA, USA). 
6.3 miRNA normalization and preprocessing 
Fluorescence intensities on scanned one-color images were quantified using Feature Extraction 
v9.5 software (Agilent Technologies) using the modified Exiqon protocol. Background correction 
was carried out, and raw data were normalized by quantiles.  Normalized data were preprocessed 
using GEPAS server(Montaner, et al. 2006). Differentially expressed miRNAs were identified by 
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applying linear models using the Bioconductor limma R package (Smyth 2005) 
(http://www.bioconductor.org). Microarray dataset is publicly available at GEO database.  
 
7. Bioinformatic analysis of gene expression and miRNA data 
 
7.1 Unsupervised clustering 
MTC tumor samples were grouped according to their expression profiles by average linkage 
hierarchical clustering (Pearson correlation, uncentered metrics) using  Gene Cluster 2.0 (Reich 
2004) and Treeview (http://rana.stanford.edu/software) algorithms were used to obtain clustering 
of the data sets. Unsupervised clustering was implemented by a SOM algorithm. The level of 
expression of each gene in each sample, relative to the median level of expression of that gene 
across all the samples is represented using a green-black-red color scale. Green corresponds to 
expression value below median, black, to median and red above median. Only tumors exhibiting 
the 634 or the M918T RET mutation, and tumors classified as WT were used in further analysis.  
 
7.2 Supervised clustering 
To determine if there were genes and miRNAs differentially expressed between particular groups 
associated with specific RET mutations, supervised classification was performed with T-test with 
200.000 permutations or with linear models (limma), implemented in the POMELO II tool 
(Morrissey and Diaz-Uriarte 2009), freely available in Asterias web server 
(http://asterias.bioinfo.cnio.es). T-test was also carried out using a T-Rex application from the 
GEPAS package and for differential expression analysis(Montaner et al. 2006). To account for 
multiple hypothesis testing, the estimated significance level (p-value) was adjusted using 
Benjamini’s False Discovery Rate (FDR) correction (Benjamini, et al. 2001). Those genes with FDR 
<0.05 and miRNAs with FDR<0.15 and both with a fold-change>2 were considered as significantly 
differentially expressed and selected for the validation step. Moreover, alternatively, Significance 
Analysis of Microarrays (SAM) (Tusher, et al. 2001), was performed for analysis of miRNA/genes 
significantly different between two classes, comparing groups with specific genetic conditions, 
where T-test statistics was applied. SAM calculates a score for each miRNA/gene on the basis of 
the change in expression relative to the standard deviation (SD) of all measurements. A threshold 
of q-value of 0.01 (transcriptional profiling) and 0.15 (miRNA profiling) were used and 3000 
permutations were applied. The missing values were excluded.   
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7.3 Functional profiling and pathways analysis 
 
7.3.1. Gene Ontology analysis 
Functional enrichment of gene ontologies (GOs) for differentially expressed genes (DEGs) was 
performed using the FatiGO tool (Al-Shahrour, et al. 2004) implemented in Babelomics software. 
Fisher’s exact test was performed to obtain significant over-representation of GO terms in the 
DEGs list versus the rest of the genome. GO terms showing an FDR<0.05 were considered 
significant.  
 
7.3.2. Gene Set Enrichment Analysis (GSEA) 
Gene Set Enrichment Analysis (GSEA) (Subramanian, et al. 2005) was performed to gain insight 
into global molecular networks and canonical pathways related to MTC specific genetic condition-
driven signature and translating differentially expressed genes into pathways between specific 
genetic groups. GSEA outcome is based on the study of the distribution of gene sets sharing 
functional annotations across a list of genes ranked according to differential expression. GSEA 
gene sets are defined based on prior biological knowledge, e.g., published information about 
biochemical pathways or co-expression in previous experiments. In our data analysis we have 
included the Biocarta (www.biocarta.com) and KEGG (www.genome.jp/kegg/) datasets as a source 
of pathway annotations. The ranking of all genes in the sets were determined and an enrichment 
score (ES) was calculated for each pathway as a measure of its relevance. This enrichment score 
value was further normalized in order to calculate the normalized enrichment score (NES) used for 
pathway evaluation. The ranking of genes was performed with T-test, with an absolute mode for 
gene list sorting. 1000 gene set permutations were done on the gene expression profiles to assess 
the statistical significance of the pathways. FDR (q value) is computed by GSEA program. Pathways 
within FDR <0.25, were considered significantly enriched between classes under comparison.  
 
7.3.3. Ingenuity Pathway Analysis (IPA) 9.0 
Once a list of significantly differentially expressed genes is obtained, interesting targets of miRNAs 
or molecular signatures originating from different MTC subtypes were explored by applying 
different tools for functional analysis. Their function is to analyze between/inter interaction of 
different genes implicated in the study. One of them, the Ingenuity Pathways Analysis (IPA ‐ 
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Ingenuity Systems, Mountain View, California) is a network application, which allows us to analyze 
the biology of different list of genes at different levels, integrating data from various experimental 
platforms, allowing further in depth study of the molecular and chemical interactions, cellular 
phenotypes and related diseases.  IPA was used to assess the enrichment of groups of genes 
associated with specific genetic conditions such as RET634, RET918 and RETWT, together with their 
implicated biological functions and signaling pathways. This computer-based programme was also 
used to identify the direct physical and functional interactions between proteins. 
 
7.4. mRNA-miRNA expression integration and functional enrichment analysis 
 
As miRNA and mRNA profiling data were available from the same tumor set, we performed an 
integration of both profiles assuming that increased or decreased expression of specific miRNA 
results in at least partially decreased or increased expression of corresponding target mRNAs 
respectively. Significantly differentially expressed miRNAs and mRNA from comparisons MTC634 vs 
MTC918 and MTC918 vs MTCWT were used in the analysis.  
Those significant miRNAs according to the Fisher’s exact test (FDR<0.1) were selected on the basis 
of their non-random association with the gene expression signature of interest (FDR <0.05). The 
microRNA predicted targets were identified using miRBase Targets Release v5.0 and Target Scan. 
Then we researched the inverse correlation between upregulated expression of a microRNA and 
its predicted targets using MAGIA(Sales, et al. 2010) web tool applying the parametric linear 
Pearson correlation for all analyses. IPA 9.0 (www.ingenuity.com) was used to assess potential 
biological pathways, functions and networks for significant putative targets (FDR<0.25) of miRNAs 
revealed previously from miRNA-mRNA integration analysis.  
 
8. Validation by quantitative RT-PCR 
 
For the validation of microarray data, genes and significantly differentially expressed miRNAs 
among profiling results were selected to be assessed by RT qPCR. PCRs were done on an ABI Prism 
7000 sequence detection system (Applied Biosystems, Foster City, CA, USA).  
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8.1. Validation of the results from gene expression profiling by quantitative RT-PCR  
For gene expression results validation, the independent FFPE and frozen samples series were used.  
As endogenous references we used β-glucoronidase (GUS), 60S acidic ribosomal protein P0 
(RPLP0) and peptidylprolyl isomerase A (PPIA); GUS was used to normalize the quantification of 
mRNA expression. Reverse transcription was performed using 1μg total RNA and random 
hexamers (FFPE samples), or 0,5μg total RNA and oligoDT (frozen specimens), and M-MLV Reverse 
Transcriptase (Promega Corporation, Madison, WI, USA). PCRs were done on an ABI Prism 7600 
sequence detection system (Applied Biosystems, Foster City, CA, USA) using the Universal Probe 
Library set (https://www.roche-applied-science.com) as described  by the manufacturer. All 
analyses were performed in triplicate. The Kruskal-Wallis test (nonparametric ANOVA) for multiple 
class comparisons and the nonparametric Mann-Whitney test for two class comparisons were 
used to compare the genetic classes. Quantification data were calculated by the 2-ΔΔCT method.  
 
8.2. Validation of the results from miRNA expression profiling by quantitative RT-PCR  
Significantly differentially expressed miRNAs among profiling results were selected according to 
the mentioned criteria to be assessed by RT qPCR. Frozen and FFPE independent MTC series were 
used for validation. As endogenous references we used RNU-5G, SNORD48 and SNORA66 to 
normalize the quantification of miRNA expression. Reverse transcription was performed with 
miRCURY LNATM Universal RT microRNA PCR system (Exiqon) using 20ng total RNA according to the 
manufacturer´s instructions. Samples (cDNAs) were diluted 1:80 and stored at -20°C until used for 
real-time PCR.  PCRs were done on an ABI Prism 7900HT sequence detection system (Applied 
Biosystems, Foster City, CA, USA) using the LNATM microRNA PCR primer/SYBR® Green mix (Exiqon) 
as described by the manufacturer. PCR reactions were performed in triplicates and negative 
controls were included. The Kruskal-Wallis test (nonparametric ANOVA) for multiple class 
comparison was assessed (P value<0.05) and was carried out using SPSS software package version 
17.0 (SPSS, Inc., Chicago, IL). Quantification data were calculated by the 2-ΔΔCT method and qBase 
(Biogazelle) software was used(Hellemans, et al. 2007).  
 
9. Immunohistochemistry (IHC) 
 
Immunohistochemical staining was performed on both MTC tissue microarrays available. TMA 
blocks were sectioned at a thickness of 3μm and dried for 1h at 60ºC.  Deparaffinization, 
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rehydration and epitope retrieval were achieved by heat treatment in a PT Link (Dako, Glostrup, 
Denmark) at pH 9. Before staining the sections, endogenous peroxidase was blocked. Primary 
antibodies used were anti-CD133 (1:500, ab19898 Abcam, Cambridge, MA, USA), anti-GFRα1 
(1:500, C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-ESM1, (1:500, clone 6D4 
Santa Cruz Biotechnology, Santa Cruz, CA, USA); incubations with primary antibodies were 
according to the manufacturers' instructions. After incubation with anti-CD133, the reaction was 
visualized with EnVision™ FLEX (Dako, Glostrup, Denmark) using diaminobenzidine chromogen as a 
substrate; anti-GFRα1 binding was visualized with the LSAB+ Kit (Dako, Glostrup, Denmark) using 
diaminobenzidine chromogen as a substrate; anti-ESM1 binding was visualized with DAKO 
EnVision TM FLEX Mouse kit (Linker)(DAKO, Carpinteria, CA, USA), the sections were 
deparafinated, and made the recovery of the antibody to PH9 PT link (DAKO, Carpinteria, CA, USA) 
and AB incubation for 30 min. Sections were counterstained with hematoxylin. Appropriate 
positive and negative controls were also tested.  
Immunoexpression was graded semi-quantitatively by considering the percentage and intensity of 
the staining. A histological score was obtained for each sample, which ranged from 0 (no 
immunoreaction) to 300 (maximum immunoreactivity). Interpretation was done as previously 
described (Gallel 2008). Since each TMA included two cores from each case, immunohistochemical 
evaluation was done after examining all samples.  
 
10.  MTC cell lines and in vitro functional studies on MTC cell lines (MZ-CRC-1 and TT) 
MZ-CRC-1 cells, derived from a metastatic MTC and harbor the M918T RET mutation (Cooley 1995; 
Santoro et al. 1995), and TT cell line, harboring a mutation at residue 634 of RET were available.  
 
10.1 Cell culture and nucleofection 
MZ-CRC-1 cells were a generous gift from Dr. Robert F. Gagel (M.D. Anderson Cancer Center, 
University of Texas). TT cells were from the American True Type Culture Collection (ATCC). Both 
cell lines were maintained in DMEM medium supplemented with 10% inactivated fetal bovine 
serum, 1% pyruvate, 1% non essential amino acids, 100U/ml penicillin and streptomycin at 37ºC in 
5% of CO2 in air. For nucleofection of MZ-CRC-1 cells, two million cells per condition were 
incubated with 2μM synthetic siRNAs (Sigma) directed against human CD133 in a buffer containing 
150mM phosphate buffer, 100mM KCl and 10mM MgCl2. Cells were nucleofected using the A30 
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program of an Amaxa Nucleofector II device (Lonza). Rapidly after nucleofection, the cells were re-
suspended in medium and seeded onto 6-well plates. 
10.2 Lentivirus construction and infection 
An expression cassette consisting of the cytomegalovirus (CMV) promoter followed by the human 
Pprominin1 open reading frame was cloned into a modified pDSL_hpUG vector (ATCC, cat # 
10326371) lacking the Ubiquitin c-GFP cassette. Briefly, the Prominin1 open reading frame was 
first cloned into pcDNA3 (Invitrogen) by standard techniques. Using a construct such as a 
template, a PCR product consisting of the CMV promoter followed by the Prominin1 ORF and 
flanked by attB sites was generated. Finally, this product was sequentially cloned into pDONR221 
entry vector (Invitrogen) and then moved to the final destination vector (FUSPA) via gateway 
recombination technology.  
Lentiviral particles were produced essentially as described (Encinas, et al. 2008). Briefly, 293T cells 
were co-transfected by the calcium phosphate method with the above plasmid plus plasmids 
coding for the envelope and the packaging systems (VSV-G and Δ8.9, respectively). The day after, 
the transfection culture medium was replaced with fresh medium and left for additional 2-3 days 
to allow lentiviruses to be produced and released. Supernatants were then harvested, filtered 
through a 0.45 μm filter, and directly applied to TT cells. Typically, cells were infected overnight 
and experiments were conducted 4 to 5 days after infection.  
10.3 Apoptosis assays 
Three days after transfection, we analyzed the number of apoptotic nuclei by Hoechst staining. 
Cell-permeant Hoechst 33342 dye was directly added to cells at a final concentration of 0,5mg/ml, 
and incubated 15 minutes at 37ºC. Cells were then photographed under a fluorescence 
microscope (Olympus IX70). The percentage of apoptotic nuclei was scored in triplicate by a naïve 
observer. Five hundred to one thousand cells per condition were counted.   
10.4 Real time quantitative PCR (RT-qPCR) 
Total RNA from MZ-CRC-1 cells was extracted with the RNAeasy kit (QIAGEN, Alameda, CA) and 
reverse transcribed using the TaqMan® Reverse Transcription kit from Applied Biosystems (Foster 
City. CA). The relative mRNA levels of CD133 and GFRα1 were measured by real-time PCR using 
TaqMan® probes from Applied Biosystems (Hs01009250_m1 (CD133) and Hs00237133_m1 
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(GFRα1)). Probe Hs99999905_m1 (GAPDH) was used for data normalization. Results were 
calculated by the 2-ΔΔCT method. 
 
11. Statistical analysis 
Immunoexpression was analyzed in two different ways, as a continuous variable, and as a binary 
variable using the median as the cut-off. For the first analysis, Mann-Whitney U test was used, and 
for the second, difference in expression was tested with a Chi-squared or Fisher's exact test when 
appropriate. Statistical analyses were carried out using SPSS software package version 17.0 (SPSS, 
Inc., Chicago, IL). Nominal two-sided P-values less than 0.05 were considered statistically 
significant. 
In order to identify statistically significant associations between differentially expressed 
microRNAs (FDR < 0.1) and gene expression signatures (FDR <0.05), the analysis of consistency of 
predicted microRNA-mRNA targeting pairs with the pair components inversely correlated. Those 
miRNAs and genes with significant FDR values were subjected to Fisher´s exact test and selected 
on the basis of their non-random association with their expression signature of interest. For 
multiclass comparisons with non-parametric ANOVA, the U-Kruskal-Wallis test was applied 
comparing three groups of MTC: MTC634, MTCM918T, MTCWT.  
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Results I. Gene expression profiling project.  
 
1. Molecular genetic characteristics of the MTC tumors 
 
Medullary thyroid carcinomas were classified according to their specific RET mutation. Forty-nine 
MTCs out of the 69 available passed the selection criteria (good RNA quality and high tumor 
percentage in the tissue, >80%) and were hybridized onto Agilent microarray platform. Among the 
49 tumors used for profiling, 7 carried a germline RET mutation in codon 634, 14 carried the 
M918T RET mutation, and 20 were classified as WT. The remaining eight MTCs had 6 different 
germline mutations and 2 different somatic mutations in RET (supplementary appendix Table 1). 
These latter 8 tumors were not considered in clustering analysis. Twenty-tree out of the 38 
additional independent formalin-fixed paraffin embedded (FFPE) MTCs (supplemental annex 
Tables 1 and 2) as well as those frozen tumors not considered for hybridization purposes were 
used for validation by RT-qPCR. 
 
2. Data reveal differential expression profiles in inherited and sporadic MTC 
 
Unsupervised hierarchical clustering, performed using standard correlation as a measure of 
similarity across all hybridized samples, showed a relatively low heterogeneity distributed over 
two principal branches (Figure 5).  
An enrichment with familial MTC cases with germline RET mutations was observed in the second 
branch of the cluster, whereas the first one was enriched with sporadic MTC with somatic M918T 
RET mutations and WT cases. This observation led to us to do a supervised analysis based on the 
known mutations of each available tumor. Differential expression analysis was performed 
comparing MTCsM918T vs MTCsWT, and MTCsM918T vs MTCs634 (Figures 6A and 6B), obtaining a list of 
360, and 18 significant genes (GEO accession number GSE32662) respectively. 
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Figure 5. Unsupervised clustering of hybridized frozen MTC series. Partial heat map showing two principal 
branches after applying unsupervised clustering to the 49 MTCs. The first branch was enriched with 
MTC
M918T
 cases and the second with familial MTC cases, mostly with RET
634 
mutation. Color bar, green and 
red, represents relative under- and over expression levels respectively. MTC cases were named using ID case 
and extensions as: S_918 (sporadic MTC with somatic M918T RET mutation), F_634 (familial MTC with 634 
RET mutation) and S_WT (sporadic MTC with no RET mutation), S_UN_WT (sporadic MTC with no data 
regarding somatic RET mutation). 
 
 
 
 
 
 
 
 
  Results   
   
  103 | P a g e   
 
 
 
Figure 6A. Differential expression analysis of MTCs
M918T
 vs MTCs
WT
 using the GEPAS package. The first 100 
genes with a false discovery rate (FDR) <0.05 are shown, including information about t statistic. 
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Figure 6B. Differential expression analysis of MTCs
M918T
 vs MTCs
634 
using the GEPAS package. The first 100 
genes with a false discovery rate (FDR) <0.05 are shown, including information about t statistic. 
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Based on threshold-free methodology using GSEA, signaling pathways were identified as 
significantly differently expressed (FDR<25%) when comparing MTCsM918T vs MTCs634 and 
MTCsM918T vs MTCsWT (Supplemental annex Tables 4A and 4B, respectively). The M918T cluster was 
correlated with several pathways related to malignant tumor behavior, such as the p53, caspase, 
cytokine, Wnt, NFκB, MAPK, IL1R, JAK/Stat, and Notch pathways. 
 
Analyses of Gene Ontologies (GO) revealed significant biological processes in the M918T group 
associated as well with malignant behavior (shown in bold in supplementary annex Table 5). They 
were mainly associated with cell-cycle, cell adhesion and proliferation and anti-apoptotic activity 
pointing to aggressive course of this specific MTC group. 
Further one, hierarchical clustering analysis of the most relevant FatiGO outputs for biological 
processes, revealed a long list of significant results associated specifically with MTCM918Tgroup. 
They again, pointed to the importance of cell adhesion, migration and proliferation ontologies 
(Supplementary annex Table 6). 
FatiGO analysis (supplementary appendix Table 5) and GSEA analysis (supplementary appendix 
Tables 4A and 4B) revealed similar significant pathways associated with the M918T group.  
 
3. Markers identified as specific of genetic condition 
After applying the filtering criteria (FDR <0.05 and fold change greater than 2), five genes (PROM1, 
GFRA1, LOXL2, GAL, and DKK4) appeared to be markers of different genetic conditions and were 
selected for further validation at the mRNA level.  
GAL was the only gene statistically significant found to be a specific marker for the germline RET 
mutation in codon 634. The expression of the other four genes was validated by quantitative RT-
PCR as up-regulated markers among MTCsM918T. Due to limited availability of RNA, it was only 
possible to validate PROM1 and LOXL2 in FFPE MTC samples. Figures 7A and 7B summarize these 
results in the independent frozen and FFPE series, respectively.
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Figure 7A. Result from validation in frozen independent MTC series.
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Although not selected for further validation, other genes differentially expressed among the three 
different genetic conditions considered herein had been reported to be involved in cancer of 
tissues derived from neural crest, and also in the RTK signaling pathway. Therefore, these previous 
findings were considered as a cross-validation of our results. Among these markers, the up-
regulated genes associated with the M918T mutation were ESM1, NPR1, PITX2, RTN1, and SHC1. 
ESM1 (endothelial cell-specific molecule 1) is associated with cell migration and proliferation, and 
its over-expression has been previously described in sporadic RETM918T MTC cases (Ameur et al. 
2009). NPR1 (natriuretic peptide receptor A/guanylate cyclase A) regulates the activation of 
ERK1/2(Deng 2010), as well as Ras/Raf/ERK and Wnt/β-cathenin pathways. PITX2 (paired-like 
homeodomain 2) is involved in tumorigenesis and Wnt/β-cathenin signaling, and is expressed in 
neural crest cells (Zacharias 2010). RTN1 (reticulon 1), overexpression of which leads to apoptosis 
of neuroblastoma cell lines, is involved in secretion or membrane trafficking in neuroendocrine 
cells as well as in tumorigenesis, and is expressed in neurons and neuroendocrine cells (Steiner 
2004). Fibroblasts transformed by RETC634R display constitutive RET-mediated phosphorylation of 
SHC which activates the RAS/MAPK signaling pathway (Ohiwa, et al. 1997).  
 
 
Figure 7B.  RT-qPCR with Taqman probes of LOXL2 and PROM1 expression in an independent FFPE 
MTC validation series.  
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4. Immunohistochemical characterization 
 
We performed immunohistochemistry (Figure 8) for GFRA1, ESM1 and CD133 (PROM1). 
Differences at the mRNA level were not validated at the protein level. GFRA1 and ESM1 protein 
levels were not significantly different among the groups. CD133 showed higher staining in 
MTCsM918T than in MTCs634 (P=0.059), in agreement with mRNA detection (Table 6). 
 
 
 
Figure 8. Representative microscopic images of immunohistochemical staining for PROM1 (CD133) 
(I), ESM1 (II) and GFRα1 (III) in medullary thyroid carcinoma. 
 
 
 
 
Table 6. Statistical analysis of 3 different IHC markers: (A) PROM1 (CD133), (B) ESM1 and (C) 
GFRA1, respectively. Statistical analyses from three different comparisons: MTC634 vs MTCWT, 
MTC634 vs MTC918 and MTCWT vs MTC918. 
( A ) 
 
PROM1 (CD133) 
  
            number of cases   
    WT 634 M918T Total 
staining low 13 8 6 27 
  moderate 11 10 2 23 
  high 11 2 5 18 
Total   35 20 13 68 
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P value 
    634 vs WT 0.161 
    634 vs 918 0.059 
    WT vs 918 0.539 
    
      
      ( B ) 
 
ESM1 
   
            number of cases   
    WT 634 M918T Total 
staining low 11 7 7 25 
  moderate 13 4 3 20 
  high 10 9 3 22 
Total   34 20 13 67 
      
 
P value 
    634 vs WT 0.329 
    634 vs 918 0.420 
    WT vs 918 0.380 
    
      
      ( C ) 
 
GFRA1 
   
            number of cases   
    WT 634 M918T Total 
staining low 9 6 3 18 
  moderate 8 4 4 16 
  high 11 4 2 17 
Total   28 14 9 51 
      
 
P value 
    634 vs WT 0.741 
    634 vs 918 0.723 
    WT vs 918 0.578 
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5. Silencing CD133 by siRNA induces apoptosis 
We used the MZ-CRC-1 cell line nucleofected with two different synthetic siRNAs against human 
CD133 for in vitro validation. Knockdown efficiency was assessed in parallel dishes by RT-qPCR, 
and the number of apoptotic nuclei was scored as percentage of total nuclei. As shown in Figure 9 
both siRNAs caused an increase in the number of apoptotic nuclei, suggesting that CD133 is 
necessary for the survival of these cells.  
 
 
Figure 9. Top panel: Knockdown efficacy of two different siRNAs against human CD133. MZ-CRC-1 
cells were nucleofected with either buffer or the indicated siRNAs against CD133 (CD133.1 and 
CD133.2). Three days later CD133 expression was assessed by real time RT-PCR. Bottom panel: 
Silencing of CD133 causes apoptotic death of MZ-CRC-1 cells. Cells were nucleofected as above 
and three days later the number of nuclei showing apoptotic morphology was scored.   
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6. PROM1 overexpression assay based on lentiviral approach and PROM1 clone 
formation. 
6.1 CD133 overexpression in MZ-CRC-1 and TT cell lines. 
We checked the CD133 mRNA levels using the quantitative RT-PCR experiment. PROM1 levels 
were higher in MZ-CRC-1 cell line comparing to TTs. The higher incorporation of BrdU in MZ-CRC-1 
vs TT cells indicated a higher rate of cellular proliferation (Figure 10). 
 
 
Figure 10. PROM1 (CD133) levels in MZ-CRC-1 and TT cell lines.  
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According to these results, PROM1 over-expression does not affect the proliferation of both, TT 
and MZ-CRC-1 cell lines. PROM1 over-expression seemed to be associated with the resistance to 
death by RPI-1 (well know RET inhibitor) in TT cell lines, although also it was observed in MZ-CRC-
1. This was observed after 48h treatment conducted by reduction with MTT assay (Figure 11A), 
while there were not differences after 24h of treatment (Figure 11B).  
 
 
Figure 11A. 48h treatment with RPI-1 RET inhibitor in TT and MZ-CRC-1 cell lines. 
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Figure 11B. 24h treatment with RPI-1 RET inhibitor in TT and MZ-CRC-1 cell lines. 
 
7. Data reveal differential miRNA expression profiles in inherited and sporadic MTC 
Unsupervised hierarchical clustering, performed using standard correlation as a measure of 
similarity across all hybridized samples, showed a relatively low heterogeneity distributed over 
two principal branches (Figure 12). An enrichment of MTC918 cases was observed in the second 
branch of the cluster, whereas the first branch was enriched with WT and MTC634 cases. The 
supervised analysis was performed comparing MTCs918 vs MTCsWT, and MTCs918 vs MTCs634 (Figure 
13), obtaining a long lists of 602, and 276 significant miRs (GEO publicly available data) 
respectively.    
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Figure 12. Unsupervised clustering of hybridized frozen MTC series. Partial heat map showing two principal 
branches after applying unsupervised clustering to the 49 MTCs. The first branch was enriched with 
MTC
M918T
 cases and the second with familial MTC cases, mostly with RET
634 
mutation. Color bar, green and 
red, represents relative under- and over expression levels respectively. MTC cases were named using ID case 
and extensions as: S_918 (sporadic MTC with somatic M918T RET mutation), F_634 (familial MTC with 634 
RET mutation) and S_WT (sporadic MTC with no RET mutation). 
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Figure 13. A. MiRNA differential expression analysis of MTCs
M918T
 vs MTCs
WT
 and B. MiRNA differential 
expression analysis of MTCs
M918T
 vs MTCs
634 
using the GEPAS package. The first 100 miRs with a false 
discovery rate (FDR) <0.05 are shown, including information about t statistic.  
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8. Biomarkers of specific genetic condition 
Seven miRs common for two comparisons (hsa-miR-124, hsa-miR-1249, hsa-miR-129*, hsa-miR-
129-3p, hsa-miR-205, hsa-miR-30a, hsa-miR-7) fit filtering criteria and hsa-miR-138 had significant 
FDR and almost reach fold change of 2. Five of them (hsa-miR-124, hsa-miR-129-3p, hsa-miR-138, 
hsa-miR-30a and hsa-miR-7) were selected for validation by RT-qPCR. Hsa-miR-30a and hsa-miR-
138 were over-expressed and specific for the germline RET634 mutation, being down-regulated in 
MTC918 group. The expression of the hsa-miR-124 was validated by quantitative RT-PCR as up-
regulated markers among MTCs918. Due to limited availability of RNA from FFPE tumors; it was 
only possible to validate hsa-miR-138 in this material. Figure 14 summarizes these results in the 
independent frozen and FFPE series, respectively. 
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Figure 14. RT-qPCR with LNA
TM
 microRNA PCR primer/SYBR® Green mix (Exiqon) of miR-124, miR-30a and miR-138 expression in an independent frozen and 
FFPE (in frame) MTC validation series.
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9. mRNA-miRNA integration 
 
In total 36 mRNA gene targets were deregulated and being co-regulated by the 26 miRNAs from 
comparison MTC918 vs MTC634,and 247 of genes 90 miRs negatively correlated from comparison 
MTC918 vs MTCWT, respectively. The functions of identified mRNAs and the molecular pathways 
they potentially target were assessed by IPA and MAGIA softwares. IPA analysis was performed on 
the selected differentially expressed predicted mRNAs targets, retrieved from the MAGIA analysis. 
We obtained a list of the biological functions of putative miRNA target genes from MAGIA analysis 
performed by IPA analysis (Table 7). They point to cancer and cell death categories and functions 
related to malignant cell transformation. 
NF-κB pathway revealed to be one of the most interesting one identified among the different 
genetic MTC groups., From the both comparisons MTCM918T vs MTC634 and MTCM918T vs MTCWT, the 
most interesting findings were that the biological functions associated with MTCM918T group were 
related to malignant behavior, metastatic potential and cell adhesion process, often implicated in 
tumorgenesis (Supplementary annex Table 7).  IPA network analysis of the miRNA mRNA targets 
that were differentially expressed among MTC groups, highlighted “Cellular Growth and 
Proliferation”, “Cellular Development”,  and “Tissue Morphology network” (Figure 15) as the most 
significant ones, involving 17 putative miRNA targets.
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Table 7. IPA analysis of biological functions of putative miRNA target genes from MAGIA analysis. 
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Figure 15. IPA network analysis based on putative miRNA targets from MAGIA analysis. Cellular 
Growth and Proliferation, Cellular Development, Tissue Morphology network. 
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1. The power of high-throughput technologies  
 
Approximately one third of the patients with MTC have recurrence after surgery. Metastasis 
development occurs more frequently in sporadic than in hereditary MTC. Thus, it is critical to 
perform the somatic RET mutations analysis in apparently sporadic cases, and to find out the 
biological effect that somatic mutations can have on the patients’ health. Furthermore, since the 
biological effect of the different mutations is different in terms of signaling pathway activation, we 
should expect to find differences in the ages of MTC development or prognosis. For example, 
patients with mutations in codons 918 and 634 should expierience more aggressive evolution of 
the tumor than patients with genetic variants associated with mild/moderate transforming 
capacity in which clinical courses would be expected to be more indolent.  
Treating MTC patients is not a trivial issue. Medullary thyroid carcinoma metastasizes during 
follow-up with low chances of survival. For the primary MTCs, total thyroidectomy is the only 
current approach and there are no other alternatives for the metastatic stages(Schlumberger 
2008). Thus, there is a huge need to identify potential therapeutic targets. While a genotype-
phenotype correlation has been well established for MEN2 cases, little is known about signaling 
pathways and biomarkers for specific germline and somatic RET mutations related to the MTC 
development.  
High –throughput microarray techniques has become an effective tool to identify gene/miRNA 
sets with similar patterns of differential expression according to histological subtype, existence of 
metastatic disease, biomarker discovery etc. Although it is an efficient technique, it presents a 
series of difficulties, such as the need of following optimized protocols and applying careful data 
analysis of the complex underlying biological processes. After identifying specific biomarkers 
related to a concrete condition, their final application to the clinical setting has to include at least 
an immunostaining validation. The post-transcriptional modifications add complexity to the overall 
understanding of the process. Consequently it is difficult to translmit the obtained results to the 
clinic immediately. In recent years, several studies have been published on different types of solid 
tumors where the correlation between the expression profiles and the presence of the specific 
mutations have allowed identification of  transcriptional changes associated with each genotype in 
breast cancer(Bertucci, et al. 2004), in melanoma(Pavey, et al. 2004), and in 
pheochromocytoma(Lopez-Jimenez, et al. 2010), among others. While there are numerous studies 
based on transcriptome characterization focused on follicular cell-derived thyroid cancer, those 
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related to MTC are scarce. In the case of the former thyroid tumors, a clear relation between the 
genotype and the specific changes in gene regulation has been identified (DeLellis 2004). In the 
case of MTC tumors, there are several difficulties which have contributed to the lack of studies. 
Firstly, comparisons of primary tumors versus normal C-cells are not possible due to the very low 
parafollicular cell representation (about 1%) in the thyroid cell mass (Khurana, et al. 2004a). 
Furthermore, it is challenging to obtain a sufficiently large series of frozen MTC tissues for genomic 
study due to the rarity of the tumor itself. This explains why only few studies on MTC profiling 
have been reported (Ameur et al. 2009; Jain et al. 2004b; Lacroix et al. 2005; Musholt et al. 2005a; 
Watanabe et al. 2002a). The work of this doctoral thesis was focused on identifying more accurate 
and additional information related to specific RET mutation through gene expression and 
microRNA profiling. Our interest pointed to the identification of specific genetic biomarkers, 
biological processes and network interactions associated with concrete germline and somatic RET 
mutations. The power of this study was the outstanding series of molecularly characterized series 
of tumors available. The unsupervised clustering demonstrated that this approach was able to 
cluster cases according to the specific RET mutation considered. Basically, we found that familial 
and sporadic cases were grouped in separated branches of the cluster as shown in figure 5. This 
finding is especially interesting due to the fact that some of the RET mutations are associated with 
higher transforming capacities, but knowledge about the underlying biological mechanisms is still 
lacking. After applying supervised analysis to MTC918, MTC634 and MTCWT groups, it was possible to 
select a list of genes as potential biomarkers to validate. 
 
2. Biomarkers and pathways specifically related to each genetic class  
Our study revealed concrete biomarkers associated to specific RET mutations, such as PROM1 or 
CD133, GFRA1, LOXL2, GAL, and DKK4 over-expression related to MTCsM918T group, or GAL over-
expression related to mutations affecting the 634 residue. In agreement with the GAL over-
expression associated with MTCs634 described herein, GAL over-expression was previously 
observed in PC12 rat pheocromocytoma cell lines (Tofighi, et al. 2008). GAL is involved in 
neuropeptide signaling, tumorigenesis, nervous system development and the regulation of cell 
proliferation; it is expressed in neuroblastoma and pheochromocytoma cancer cell lines, and it 
activates MAPK and ERK signaling (Berger, et al. 2005; Hawes 2006; Sugimoto, et al. 2009; Tofighi 
et al. 2008). These findings suggest that GAL over-expression may be involved in the development 
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of the phenotype exhibited by MEN2A patients carrying a 634 germline RET mutation. These 
patients develop pheochromocytoma in at least 50% of cases (Eng 1996; Machens, et al. 2005).  
GFRA1 (GDNF family receptor alpha 1), associated with MTCsM918T, is a known co-receptor of RET 
which mediates its activation through the binding of RET ligands. These include ligands that are 
widely expressed and promote the survival of neurons during development. GFRA1 has been 
previously reported as a genetic risk factor associated with susceptibility to developing sporadic 
MTC in a case-control study (Gimm 2001), and our results support its role in MTC development.  
DKK4 (Dickkopf-4), another gene overexpressed in MTCsM918T, was demonstrated to be 
significantly upregulated in colorectal cancer reflecting activation of the Wnt canonical pathway 
(Matsui 2009). Furthermore, KREMEN2 (kringle containing transmembrane protein 2) co-operates 
with DKK4 to regulate Wnt signaling (Mao and Niehrs 2003). KREMEN2 was upregulated similarly 
to DKK4 in M918T tumors included in our study. Deregulation of the Wnt pathway results in the 
development of cancer and other diseases, and Wnt/β-catenin signaling and JNK noncanonical 
pathways are implicated in RET signaling, which is activated in MTC. Deregulation of the Wnt 
pathway specifically associated with RETM918T MTC could open new perspectives for treatment.   
The most interesting results among the M918T group were the over-expression of LOXL2 and 
PROM1 (CD133), which could partially explain the high rate of metastasis related to MTCs that 
carry this mutation. LOXL2 (lysyl oxidase-like 2) activates Snail/E-cadherin and Src kinase/Focal 
adhesion kinase (Src/FAK) pathways, and is associated with tumor cell invasion. LOXL2 is linked to 
epithelial-mesenchymal transition (EMT), which leads to metastasis and lower survival rates in 
epithelial and neuroendocrine tumors (Peinado 2005, 2008; Peng, et al. 2009; Ruckert, et al. 
2010). Our results are in agreement with the increased expression of genes associated with EMT 
previously observed in MEN2B MTCs(Jain et al. 2004b).  
PROM1 was the gene most significantly over-expressed among the MTCsM918T included in our 
series of primary tumors. PROM1 was recently reported by Zhu et al. (Zhu 2010) to be a cancer 
stem cell marker in MZ-CRC-1 cell lines harboring a M918T RET mutation. MTCs bearing the 
M918T RET mutation are resistant to treatment, and a high PROM1 (or CD133) expression might 
be related to such resistance. In this regard, high expression of CD133 is associated with neural 
crest-derived stem cells, and slowly differentiating cancer stem cells have proved resistant to 
irradiation and cytotoxic drugs (Zhu 2010). To our knowledge, ours is the first study based on 
primary tumors pointing to a PROM1 over-expression associated with the M918T mutation. 
Another study recently showed an association of poor prognosis with a high expression of CD133 
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in medulloblastoma tumors, suggesting that it might be a more general prognostic marker (Raso, 
et al. 2011).  
Immunohistochemical assessment of ESM1, GFRA1 and CD133 in the 71 FFPE MTCs only revealed 
a tendency towards association of the M918T group with PROM1 or CD133 protein over-
expression. The lack of validation at protein level could be due to another underlying mechanism, 
such as posttranscriptional modifications conducted to microRNAs. Furthermore, after silencing 
CD133 with two different siRNAs, we observed decreased levels of CD133 mRNA which led to an 
increased number of apoptotic nuclei. This significant correlation between silencing of CD133 and 
apoptosis led us to conclude that CD133 is not only a specific biomarker for the M918T RET 
mutation, but its targeting seems feasible and might lead to apoptotic cell death. As already 
mentioned, usually the MTCM918T is associated with greater aggressiveness and with the acquisition 
of resistance for variety of chemotherapeutics. Bearing this in mind, MTC patients could be 
stratified according to their genetic condition, since those with high CD133 protein expression 
could benefit from a targeted treatment. 
Based on the significantly differentiated gene/miRNA target lists we performed further analyses in 
order to identify underlying signaling pathways and biological processes associated with the 
specific MTC groups. In this regard, GO biological function analyses using FatiGO/Babelomics 
revealed that important processes such as anti-apoptotic functions, proliferation, migration, cell 
cycle and adhesion were highly associated with the M918T group. To search for the genes related 
to each specific RET mutation, we used the whole gene expression profile in order to perform a 
pathway analysis. In that context, the GSEA tool was applied with Biocarta and KEGG as a source of 
pathway annotations and the IPA 9.0 software was used to find the top Biocarta/KEGG pathways 
significantly (FDR<25%) differentially expressed between different groups. Pathway enrichment 
analysis of the M918T group pointed to signaling cascades mainly involved in tumor invasion and 
metastasis (NFκB, interleukin, cytokine, p38MAPK, Wnt, JAK/Stat, Notch, MAPK or cell adhesion), 
which corresponds to what would be expected on the grounds of the clinical behavior of M918T-
related MTCs. Among these pathways, the Notch pathway is known to play an important role in 
the normal development of neuroendocrine cells, including the calcitonin producing C-cells of the 
thyroid (Cook 2010).  
The most recurrent terms were NfκB, TGF-β, focal adhesion and others related to remodeling of 
the cytoskeleton, which generally facilitate the EMT process allowing the tumors cells to spread to 
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distant organs causing metastasis. The TGF-β signaling pathway is a well known linker to the EMT 
process in the advanced stages of cancer development (Siegel and Massague 2003).In our series it 
was enriched in MTCM918T, which exhibits the worst prognosis among all MTCs. EMT is a well-
known process allowing dissemination of tumor cells that involves cell-cell interactions, tight 
junctions, matrix remodeling and cytoskeleton reorganizations together with cell polarity changes 
(loss in epithelial cells) (Grunert, et al. 2003).  
TGF-β leads to fibrosis and, together with NF-kB, controls the inflammation processes. Snail, 
another main player in EMT, is related to decreased proliferation and has been found to be a main 
inducer of EGFR signaling. Important genes in EMT processes such as cadherins, chemokines, 
collagens and laminins were significantly differentially expressed among our MTC tumor series, 
suggesting these carcinomas had mesenchymal cell properties that were linked to tumor invasion.  
In addition to NF-κB, MAPK/JNK pathways were also significantly activated. JNKs are a group of 
mitogen-activated protein kinases (MAPKs) being stimulated by multiple factors including 
cytokines, DNA-damaging agents and environmental stresses, and play a crucial role in 
programmed cell death or apoptosis control. The inhibition of JNKs has been shown to enhance 
chemotherapy-induced inhibition of tumor cell growth (Vasilevskaya and O'Dwyer 2003). These 
results required further functional validation in order to confirm discovery of specific pathways.  
In summary, we identified specific biomarkers related to different genetic conditions by means of 
expression analysis. The over-expression of LOXL2 and DKK4, involved in the cell adhesion 
pathway and the EMT process, or the Wnt pathway respectively, as well as the fact that a 
decrease in PROM1/CD133 expression was associated with an increased number of apoptotic 
nuclei, opening new therapeutic possibilities to improve MTC management. Prospective studies 
based on larger cohorts of MTC tumors with lower TNM stages would be necessary to assess the 
prognostic role of the genes which are responsible for the metastatic potential of such 
carcinomas.  
3. The contribution of microRNAs to MTC development 
 
Aberrant microRNA expression patterns have been described in various hematological and solid 
cancers, finding high correlation with progression and prognosis. Additionally, microRNA 
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expression profiles have been linked to the clinical features of several cancers, suggesting their 
usefulness as potential diagnostic and prognostic markers.  
The biological significance as well as the oncogenic potential of miRNAs in MTC development has 
been poorly investigated. So far there are only two studies on miRNA data. The first one was based 
on a very small datasets of 2 MTC cases with unknown genetic background, which were compared 
with follicular cell-derived thyroid tumors (Nikiforova et al. 2008). The second one compared 
sporadic and hereditary MTC cases, not taking into account specific RET mutations associated with 
different transforming capacities(Abraham et al. 2011). Very recently, an Italian group from 
Padova was unable to validate the proposed biomarkers in these two previous reports (Mian et al. 
2012). To our knowledge, there are no studies based on the specific RET mutational status as well 
as no studies assessing possible miRNA-regulated gene networks. 
As previously discussed for mRNA profiling, our findings suggested that the miRNA expression 
profile was able to cluster MTCs according to underlying genetic conditions. In this regard, it was 
possible to obtain long lists of microRNAs related to each specific MTC mutational group, 
comparing the differentially expressed miRs between MTC918 vs MTC634 and MTC918 vs MTCWT with 
a significant FDR value <0.15. Once again, this approach, applied on one of the largest series of 
primary MTCs described so far, pointed to differences in MTC biology associated with familial and 
sporadic nature of such tumors. In fact, three miRNA biomarkers were identified by microRNA 
profiling for sporadic and hereditary MTC with specific RET mutations, which were validated by RT-
qPCR in an independent frozen and FFPE MTC series.  
4. miRNAs specific to each genetic class. PROM1 and miR-30a relation 
 
According to our data, miR-124 was over-expressed in MTCs918 and down-regulated in MTC634 
cases, suggesting that the miR-124 could be acting as an oncomir in sporadic MTC tumorogenesis. 
In other words, acting on tumor suppressor genes and stimulating cancer development.  This miR 
is involved in nervous system development and neuronal differentiation(Yu, et al. 2008), and it 
correlates with the neural-crest origin of MTCs. Interestingly, there have been previous reports the 
overexpression of miR-124 in a sub-population of gliobliastoma multiforme cells expressing neural 
crest stem cell marker CD133(Silber, et al. 2008), as well as its deregulation in meduloblastoma 
and glioblastoma multiforme (Li, et al. 2009; Pierson, et al. 2008). Up-regulation of miR-124 
induces neuronal differentiation of mouse neuroblastoma cell lines CAD and Neuro2a and the 
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mouse embryonal tumor cell line P19(Makeyev, et al. 2007), suggesting miRNAs could be valuable 
therapeutic targets if they would act similarly in promoting differentiation of human tumor cells 
and tumor stem cells (TSCs). Taking into account that MTCs with M918T RET mutation also had 
high expression of CD133 or PROM1, the miR-124 might be useful as a potential therapeutic target 
in MTC treatment.  
MiR-30a and miR-138, downregulated in MTC918 group, are expressed in neurons and 
neuroendocrine cells (Steiner 2004), and associated with cell migration and proliferation. Their 
over-expression has been described as leading to apoptosis of neuroblastoma cell lines, and 
involved in secretion or membrane trafficking in neuroendocrine cells as well as in tumorigenesis.  
MiR-138 is one of the most frequently down-regulated microRNA in tumors, and seems to be 
important in cancer progression in human metastatic tumors (Baffa, et al. 2009). Its 
downregulation is linked to EMT in squamous cell carcinoma cell lines (Jiang, et al. 2010; Liu, et al. 
2011), which leads to metastasis. Its deregulation was also observed in thyroid carcinomas 
(Mitomo, et al. 2008; Yip, et al. 2011) associated with poor prognosis. 
MiR-30a, which suppresses EMT by targeting Snai1, was found to be downregulated in non-small 
cell lung cancer(Kumarswamy, et al. 2011). In this regard, it is worth noting the increased 
expression of genes associated with EMT observed in MTCs918 (Jain et al. 2004b). PROM1, a miR-
30a putative target, was the gene most significantly over-expressed among the MTCs918, observing 
a significant negative-inverse correlation between miR-30a and PROM1.  
Among other miRNAs derived from our study, miR-885-5p was down-regulated in hereditary cases 
with the 634 RET mutation. In this regard, miR-885-5p has been previously demonstrated as being 
up-regulated in RET related-pheocromocytomas (Tombol, et al. 2010), and also found in 
neuroblastoma. Furthermore, the overexpression of miR-885-5p has been previously reported to 
be associated with malignant mesothelioma tissues(Guled, et al. 2009). Another marker, miR-154, 
already validated in Nikiforova study(Nikiforova et al. 2008), was up-regulated in MTCM918T cases, 
pointing to another potential miRNA for functional validation. 
5. MicroRNA-mRNA interactions: a way of understanding underlying biological 
mechanisms involved in MTC development 
It is known that biological processes are not only regulated at a transcriptional level, but that 
posttranscriptional modifications of proteins also take place. Thus, microRNAs are key pieces for 
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the comprehensive understanding of the process. To highlight the role of significantly differentially 
expressed miRNAs associated with specific RET status and to discover processes modified by post-
transcriptional regulation, in silico predicted miRNA-mRNA interactions were identified and 
pathway analysis of the targets was performed. To our knowledge, there have been no studies 
based on integration miRNA and gene expression data in MTC. This was possible in this study due 
in part to the microRNA profiling data and transcriptional data that were derived from the same 
MTC sample sets. 
After identifying the entire list of interactions by MAGIA (supplementary annex Table 7), IPA 
analysis pointed out the NF-κB pathway as significantly activated in the MTC918 group. This result 
was in agreement with data obtained from gene expression data, where the GSEA retrieved it also 
among the top significant canonical pathways. 
NF-κB is a ubiquitously expressed transcription factor involved in a wide spectrum of cellular 
functions including cell cycle control, stress adaptation, inflammation and control of apoptosis. Its 
activation has been found to be involved in the development of human malignancies, and it 
appears to be important for a cancer cell´s survival. It is also associated with more aggressive 
tumor phenotypes and resistance to drug therapies (Arlt, et al. 2003; Arlt, et al. 2001; Biswas, et al. 
2003; Dong, et al. 1999). The fact of finding NF-kB pathways activated among MTC918 could 
partially explain the treatment resistance observed in these patients.  
In summary, we identified specific biomarkers related to different genetic conditions by means of 
microRNA expression analysis. The over-expression of miR-124 and down-regulation of miR-138 
and miR-30a in MTC918 were associated with the EMT process and malignant behavior, or the Nf-
κB pathway respectively, opening new therapeutic possibilities to improve MTC management.  
6. Clinical implications and molecular targeted therapies 
One fundamental issue to consider when a new pharmaceutical/compound is intended to be 
introduced in a clinical trial is the selection of biomarkers. The OMIC technologies have become 
widely used to retrieve not only relevant information regarding complex cancer biology, but also 
to identify specific biomarkers associated with treatment resistance.  
Regarding the available alternative solutions for MTC patients, it has been previously shown that 
different RET mutants show different affinities to specific tyrosine kinase inhibitors (TKIs). For 
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instance, resistance to inhibitors such as PP1-2 and vandetanib was observed for V804M RET 
mutant in contrast to RETC634R (Santoro, et al. 2004b) , whilst sorafenib was effective in both RET 
mutants(Carlomagno, et al. 2006; Plaza-Menacho, et al. 2007). Despite the progress and effort 
made recently in the field, alternative treatments to the conventional therapies have failed to 
provide significant improvements in the prognosis of the patients with MTCs. Therefore, more 
focussed analyses taking into account the genetic background are required.  With respect to this, 
little is known about additional mechanisms that can modify the treatment response, such as 
miRNA regulation dependent on RET mutational status. Taking advantage of the same cohort of 
patients, the integration of gene expression and miRNA data could facilitate the identification of 
molecular pathways and miRNA biomarkers which underlie the biology of MTC development, and 
thereby facilitate the design of new and effective therapeutic solutions. It was especially 
interesting that a PROM1 (CD133) over-expression was found among MTC harboring M918T RET 
mutation. Such a result could explain the tumor recurrence frequently associated with this specific 
mutation, as this gene is a neural crest stem cell marker. Cancer stem cells have the capacity of 
self-renewal; an over-expression of the PROM1 gene could indicate the existence of a higher 
proportion of neural crest stem cell, and explain the association between the presence of this 
mutation and recurrence. Furthermore, according to predictions available, PROM1 is a predicted 
target of miR-30a. This result could point to new targets, such as miRs for a future MTC 
therapeutic option, based on specific RET mutation status.  
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1) Both transcriptome and mirnome characterization of MTCs revealed specific molecular 
signatures according to the primary RET mutation.   
 
2) Over-expression of PROM1, LOXL2, DKK4 and GFRA1 was related to the M918T RET mutation, 
and over-expression of GAL to mutation affecting 634 residue in RET.  
 
3) Pathway enrichment analysis of gene expression profile linked to the M918T group pointed to 
signaling cascades mainly involved in tumor invasion and metastasis (NFκB, interleukin, 
cytokine, p38MAPK, Wnt, JAK/Stat, Notch, MAPK or cell adhesion). 
 
4) Silencing CD133 by siRNA led to an increased number of apoptotic nuclei. CD133 confers 
resistance to death by apoptosis. It is not only a specific biomarker for the M918T RET 
mutation, but also a good candidate for future therapeutic options. 
 
5) The downregulation of miR-30a, and miR-138 was associated with MTCM918T group, and miR-
124 with MTCC634X, and could be considered as potential specific biomarkers. 
 
6) The integration of miRNA and mRNA profiles revealed an over-expression of PROM1 (CD133) 
and a down-regulation of has-miR-30a as inversely correlated in MTCM918T group. According to 
the relation from the former to neural crest stem cell, these findings suggest this correlation 
could be linked with the clinical resistance to chemotherapy observed in this specific group of 
patients. 
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1. Los perfiles de expression génica y los de microRNAs identificados en CMT difieren de 
acuerdo a la mutación de RET presente en estos tumores.  
 
2. La sobre-expresión de PROM1, LOXL2, DKK4 y GFRA1 se asocial a la presencia de la 
mutación M918T en RET, y la sobre-expresión de GAL a mutaciones en el residuo 634. 
 
3. El análisis de enriquecimiento de rutas a partir de resultados de perfiles de expression 
permitió identificar una asociación significativa entre la mutación M918T y cascadas de 
señalización relacionadas con invasión y metástasis. Entre ellas destacaron NFκB, 
interleuquinas, citoquinas, p38MAPK, Wnt, JAK/Stat, Notch, MAPK or adhesión celular. 
 
4. La ablación de CD133 mediante el uso de ARN de interferencia conduce a un incremento 
en el número de núcleos apoptóticos. CD133 no solo es un marcador de la mutación 
M918T en RET, sino que podría ser considerado como diana terapéutica en un futuro.  
 
5. La baja expression del miR-30a y del miR-138 se asoció con la presencia de la mutación 
M918T en RET, y la del miR-124 con el grupo caracterizado por mutaciones en 634. Al 
menos estos microRNAs podrían considerarse biomarcadores específicos de mutación.  
 
6. El análisis integrado de los resultados derivados de ambas plataformas, perfiles de 
expression génica y de microRNAs, reveló que PROM1 (CD133) y el has-miR-30a estaban 
inversamente correlacionados en los CMT con la mutación M918T en RET. De acuerdo con 
la relación del primero con la existencia de células progenitoras de cresta neural, estos 
hallazgos sugieren que esta relación podría explicar la resistencia a quimioterapia 
observada en este grupo de pacientes. 
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Supplementary annex Table 1. Clinical and genetic information of the frozen and FFPE MTC series.   
Nº ID 
miRN
A 
Array
*
 
cDNA 
Array 
Frozen
a,b
/ 
FFPE MTC
† 
 Gender 
Year 
of 
birth 
Antec. 
Germline 
mutation 
Somatic 
mutation 
Classification 
1 MTC20 yes yes Frozen
a,b
 Fam F 1936 no C634R - ¨634¨ 
2 MTC23 yes yes Frozen
a,b
 Fam F 1986 yes C634R - ¨634¨ 
3 MTC26 yes yes Frozen
a,b
 Fam M 1966 yes C634R - ¨634¨ 
4 MTC28 yes yes Frozen
a,b
 Fam M 1957 yes C634R - ¨634¨ 
5 MTC1 yes yes Frozen
a,b
 Fam F 1988 yes C634S - ¨634¨ 
6 MTC2 yes yes Frozen
a,b
 Fam M 1943 yes C634S - ¨634¨ 
7 MTC22 yes yes Frozen
a,b
 Fam M 1973 yes C634Y - ¨634¨ 
8 MTC71 yes yes Frozen
a,b
 Fam F 1955 yes C620G - - 
9 MTC76 yes yes Frozen
a,b
 Fam F 1965 yes C620G - - 
10 MTC29 yes yes Frozen
a,b
 Fam M 1968 yes C618S - - 
11 MTC27 yes yes Frozen
a,b
 Fam M 1944 yes NA NA - 
12 MTC62 yes yes Frozen
a,b
 Fam M 1967 yes NA - - 
13 MTC44 yes yes Frozen
a,b
 S M 1944 no Neg M918T ¨918¨ 
14 MTC38 yes yes Frozen
a,b
 S M 1924 no Neg M918T ¨918¨ 
15 MTC39 yes yes Frozen
a,b
 S F 1979 no Neg M918T ¨918¨ 
16 MTC46 yes yes Frozen
a,b
 S M 1949 no Neg M918T ¨918¨ 
17 MTC19 yes yes Frozen
a,b
 S M 1949 no Neg M918T ¨918¨ 
18 MTC16 yes yes Frozen
a,b
 S F 1948 no Neg M918T ¨918¨ 
19 MTC64 yes no Frozen
b
 S M 1947 no Neg M918T ¨918¨ 
20 MTC37 yes yes Frozen
a,b
 S M 1954 no Neg M918T ¨918¨ 
21 MTC74 yes yes Frozen
a,b
 S M 1941 no Neg M918T ¨918¨ 
22 MTC31 yes yes Frozen
a,b
 S F 1944 no Neg Neg ¨WT¨ 
23 MTC41 yes yes Frozen
a,b
 S M 1926 no Neg Neg ¨WT¨ 
24 MTC48 yes yes Frozen
a,b
 S M 1968 no Neg Neg ¨WT¨ 
25 MTC49 yes yes Frozen
a,b
 S M 1958 no Neg Neg ¨WT¨ 
26 MTC51 yes yes Frozen
a,b
 S M 1939 no Neg Neg ¨WT¨ 
27 MTC4 yes yes Frozen
a,b
 S F 1953 no Neg Neg ¨WT¨ 
28 MTC53 yes yes Frozen
a,b
 S M 1955 no Neg Neg ¨WT¨ 
29 MTC17 yes yes Frozen
a,b
 S F 1951 no Neg Neg ¨WT¨ 
30 MTC30 yes yes Frozen
a,b
 S F 1963 no Neg Neg ¨WT¨ 
31 MTC70 yes yes Frozen
a,b
 S F 2001 no Neg E-16 Neg ¨WT¨ 
32 MTC72 yes yes Frozen
a,b
 S F 1946 no Neg E-16 Neg ¨WT¨ 
33 MTC73 yes yes Frozen
a,b
 S M 1920 no Neg E-16 Neg ¨WT¨ 
34 MTC77 yes yes Frozen
a,b
 S M 1937 no Neg E-16 Neg ¨WT¨ 
35 MTC78 yes yes Frozen
a,b
 S F 1959 no Neg E-16 Neg ¨WT¨ 
36 MTC35 yes yes Frozen
a,b
 S F 1922 no Neg unkown ¨WT¨ 
37 MTC36 yes yes Frozen
a,b
 S M 1937 no Neg unkown ¨WT¨ 
38 MTC33 yes yes Frozen
a,b
 S F 1936 no Neg unkown ¨WT¨ 
39 MTC52 yes yes Frozen
a,b
 S M 1944 no Neg C634R ¨634¨ 
40 MTC47 yes yes Frozen
a,b
 S M 1963 no Neg C630G - 
41 MTC34 no yes Frozen
a
 S F 1942 no Neg unknown ¨WT¨ 
42 MTC15 no yes Frozen
a
  S F 1948 no Neg M918T ¨918¨ 
43 MTC18 no yes Frozen
a
 S M 1968 no Neg M918T ¨918¨ 
44 MTC50 no yes Frozen
a
  S F 1949 no Neg M918T ¨918¨ 
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45 MTC54 no yes Frozen
a
 S M 1961 no Neg M918T ¨918¨ 
46 MTC57 no yes Frozen
a
  S M 1938 no Neg M918T ¨918¨ 
47 MTC68 no yes Frozen
a
 S M 1979 no Neg M918T ¨918¨ 
48 MTC3 no yes Frozen
a
  S F 1929 no Neg M918T ¨918¨ 
49 MTC32 no yes Frozen
a
 Fam F 1976 no M918T - ¨918¨ 
50 MTC21 no yes 
Frozen
a
  Fam 
F 1936 yes 
E 11, 10 
Neg - - 
51 MTC81 no no 
Frozen Fam 
F 1947 
unkno
wn C634Y - ¨634¨ 
52 MTC82 no no Frozen Fam F 1966 yes C634Y - ¨634¨ 
53 MTC83 no no Frozen Fam F 1979 yes C634Y - ¨634¨ 
54 MTC7 no no Frozen Fam F 1970 yes C634Y - ¨634¨ 
55 MTC9 no no Frozen Fam M 1963 yes C634Y - ¨634¨ 
56 MTC13 no no Frozen Fam M 1972 yes C634Y - ¨634¨ 
57 MTC10 no no Frozen Fam M 1971 yes C634Y - ¨634¨ 
58 MTC87 no no Frozen Fam F 1970 yes C634S - ¨634¨ 
59 MTC88 no no Frozen Fam F 1969 yes C634R - ¨634¨ 
60 MTC89 no no Frozen Fam F 1993 yes C634R - ¨634¨ 
61 MTC56 no no Frozen S M 1958 no Neg M918T ¨918¨ 
62 MTC11 no no Frozen S M 1962 no Neg M918T ¨918¨ 
63 MTC90 no no Frozen S M 1981 no Neg M918T ¨918¨ 
64 MTC43 no no 
Frozen S 
F 1938 no 
E 11, 10 
Neg Neg ¨WT¨ 
65 MTC40 no no Frozen S M 1933 no Neg - ¨WT¨ 
66 MTC66 no no Frozen S F 1971 no Neg E-16 Neg ¨WT¨ 
67 MTC67 no no Frozen S M 1942 no Neg E-16 Neg ¨WT¨ 
68 MTC79 no no 
Frozen S 
F 1958 
unkno
wn 
E 11, 10 
Neg Neg ¨WT¨ 
69 MTC80 no no 
Frozen S 
F 1944 no 
E 11, 10 
Neg Neg ¨WT¨ 
70 MTC91 no no FFPE Fam M 1978 yes C634W - ¨634¨ 
71 MTC92 no no FFPE Fam F 1944 yes C634Y - ¨634¨ 
 72 MTC93 no no FFPE Fam F 1973 yes C634Y - ¨634¨ 
73 MTC94 no no FFPE Fam M 1982 yes C634Y - ¨634¨ 
74 MTC95 no no FFPE Fam F 1952 yes C634W - ¨634¨ 
75 MTC96 no no FFPE Fam M 1948 yes C634Y - ¨634¨ 
76 MTC97 no no FFPE Fam F 1917 yes C634R - ¨634¨ 
77 MTC98 no no FFPE Fam M 1958 yes C634Y - ¨634¨ 
78 MTC99 no no FFPE Fam M 1948 yes C634R - ¨634¨ 
79 MTC100 no no FFPE Fam M 1960 yes C634Y - ¨634¨ 
80 MTC101 no no FFPE Fam F 1965 yes C634Y - ¨634¨ 
81 MTC102 no no FFPE Fam F 1959 yes C634R - ¨634¨ 
82 MTC128 no no FFPE Fam F 1969 yes C634R - ¨634¨ 
83 MTC129 no no FFPE Fam F 1993 yes C634R - ¨634¨ 
84 MTC127 no no FFPE Fam F 1970 yes C634S - ¨634¨ 
85 MTC104 no no FFPE S F 1954 no - M918T ¨918¨ 
86 MTC105 no no FFPE S F 1937 no - M918T ¨918¨ 
87 MTC106 no no FFPE S F 1949 no - M918T ¨918¨ 
88 MTC107 no no FFPE S M 1928 no - M918T ¨918¨ 
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89 MTC108 no no FFPE S F 1931 no - M918T ¨918¨ 
90 MTC109 no no FFPE S M 1948 no - M918T ¨918¨ 
91 MTC110 no no FFPE S M 1949 no - M918T ¨918¨ 
92 MTC111 no no FFPE S F 1961 no - M918T ¨918¨ 
93 MTC124 no no FFPE S F 1932 no - M918T ¨918¨ 
94 MTC126 no no FFPE S M 1952 no - M918T ¨918¨ 
95 MTC114 no no FFPE S M NA no Neg Neg ¨WT¨ 
96 MTC115 no no FFPE S F 1936 no Neg Neg ¨WT¨ 
97 MTC112 no no FFPE S M 1951 no Neg Neg ¨WT¨ 
98 MTC116 no no FFPE S M 1926 no Neg Neg ¨WT¨ 
99 MTC113 no no FFPE S M 1952 no Neg Neg ¨WT¨ 
100 MTC117 no no FFPE S M 1967 no Neg Neg ¨WT¨ 
101 MTC118 no no FFPE S F 1929 no Neg Neg ¨WT¨ 
102 MTC119 no no FFPE S M 1961 no Neg Neg ¨WT¨ 
103 MTC120 no no FFPE S F NA no Neg Neg ¨WT¨ 
104 MTC121 no no FFPE S M 1951 no Neg Neg ¨WT¨ 
105 MTC122 no no FFPE S F 1976 no Neg Neg ¨WT¨ 
106 MTC123 no no FFPE S M 1952 no Neg Neg ¨WT¨ 
107 MTC125 no no FFPE S M 1974 no Neg Neg ¨WT¨ 
* Indicate if the sample was or not hybridized onto miRCURY LNATM microRNA Array. Those not used for hybridization purposes, were used for independent 
validation through RT-qPCR using LNATM microRNA PCR primer/SYBR® Green mix (Exiqon).† Indicate the familial or the sporadic nature of the tumor, 
according to germline or somatic RET mutation status, as well as the existence of personal or familiar antecedents. a Frozen MTC tumor hybridized onto 
Agilent 4X44K Whole Human Genome Array.b  Frozen MTC tumor hybridized onto miRCURY LNATM microRNA Array. 
Abbreviations: Gender: F, female; M, male; Antec- antecedents (personal or familiar); NA- not available; Neg – negative; E-10, E-11, E-16 : exon 10, exon 16 
and exon 11, respectively. Fam- Familial, S- Sporadic. 
 
Supplementary annex Table 2. FFPE MTC series for independent validation.  
 
Nº ID case Gender 
Year of 
birth 
MTC
*
 RET mutation Classification  
1 MTC91 M 1978 Familial C634W ¨634¨ 
2 MTC92 F 1944 Familial C634Y ¨634¨ 
3 MTC93 F 1973 Familial C634Y ¨634¨ 
4 MTC94 M 1982 Familial C634Y ¨634¨ 
5 MTC95 F 1952 Familial C634W ¨634¨ 
6 MTC96 M 1948 Familial C634Y ¨634¨ 
7 MTC97 F 1917 Familial C634R ¨634¨ 
8 MTC98 M 1958 Familial C634Y ¨634¨ 
9 MTC99 M 1948 Familial C634R ¨634¨ 
10 MTC100 M 1960 Familial C634Y ¨634¨ 
11 MTC101 F 1965 Familial C634Y ¨634¨ 
12 MTC102 F 1959 Familial C634R ¨634¨ 
13 MTC145 F 1962 Sporadic M918T ¨918¨ 
14 MTC104 F 1954 Sporadic M918T ¨918¨ 
15 MTC105 F 1937 Sporadic M918T ¨918¨ 
16 MTC106 F 1949 Sporadic M918T ¨918¨ 
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17 MTC107 M 1928 Sporadic M918T ¨918¨ 
18 MTC108 F 1931 Sporadic M918T ¨918¨ 
19 MTC109 M 1948 Sporadic M918T ¨918¨ 
20 MTC110 M 1949 Sporadic M918T ¨918¨ 
21 MTC111 F 1961 Sporadic M918T ¨918¨ 
22 MTC112 M 1951 Sporadic Negative WT 
23 MTC113 M 1952 Sporadic Negative WT 
* Indicate the familial or the sporadic nature of the tumor, according to germline or somatic RET 
mutation status, as well as the existence of personal or familiar antecedents.  Abbreviations. Gender: F, 
female; M, male; 
 
Supplementary annex Table 3A. Genetic information of the TMA-1. 
 
Nº ID Tumor/tissue Somatic mutation 
Germinal 
mutation 
Normal 
thyroid 
Classification 
1 MTC134 MTC - C618F   not used 
2 MTC150 MTC - C618F   not used 
3 MTC154 MTC - C618F   not used 
4 MTC99 MTC - C634R   ¨634¨ 
5 MTC98 MTC - C634R yes ¨634¨ 
6 MTC102 MTC - C634R   ¨634¨ 
7 MTC97 MTC - C634R   ¨634¨ 
8 MTC94 MTC - C634W yes ¨634¨ 
9 MTC91 MTC - C634W yes ¨634¨ 
10 MTC95 MTC - C634W   ¨634¨ 
11 MTC93 MTC - C634Y   ¨634¨ 
12 MTC151 MTC - C634Y   ¨634¨ 
13 MTC92 MTC - C634Y   ¨634¨ 
14 MTC100 MTC - C634Y   ¨634¨ 
15 MTC101 MTC - C634Y yes ¨634¨ 
16 MTC137 MTC - S891A yes not used 
17 MTC106 MTC M918T Neg yes ¨918¨ 
18 MTC107 MTC M918T Neg   ¨918¨ 
19 MTC145 MTC M918T Neg   ¨918¨ 
20 MTC108 MTC M918T Neg   ¨918¨ 
21 MTC136 MTC M918T Neg   ¨918¨ 
22 MTC109 MTC M918T Neg   ¨918¨ 
23 MTC105 MTC M918T Neg   ¨918¨ 
24 MTC110 MTC M918T Neg   ¨918¨ 
25 MTC104 MTC M918T Neg yes ¨918¨ 
26 MTC135 MTC C618R Neg   not used 
27 MTC156 MTC C620F Neg   not used 
28 MTC149 MTC C634R Neg   not used 
29 MTC155 MTC C634S Neg   not used 
30 MTC159 MTC A883F Neg   not used 
31 MTC113 MTC  E 10, 11, 15, 16 neg Neg   ¨WT¨ 
32 MTC112 MTC  E 10, 11, 15, 16 neg Neg   ¨WT¨ 
33 MTC117 MTC  E 10, 11, 15, 16 neg Neg yes ¨WT¨ 
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34 MTC132 MTC  E 10, 16 neg Neg   ¨WT¨ 
35 MTC152 MTC  E 15, 16 neg Neg   ¨WT¨ 
36 MTC146 MTC  E 11, 16 neg Neg   ¨WT¨ 
37 MTC147 MTC  E 11, 16 neg Neg   ¨WT¨ 
38 MTC148 MTC  E 11, 16 neg Neg   ¨WT¨ 
39 MTC143 MTC  E 11, 16 neg Neg   ¨WT¨ 
40 MTC140 MTC  E 11, 16 neg Neg yes ¨WT¨ 
41 MTC138 MTC  E 16 neg Neg   ¨WT¨ 
42 MTC139 MTC  E 16 neg Neg   ¨WT¨ 
43 MTC142 MTC  E 16 neg Neg yes ¨WT¨ 
44 MTC131 MTC  E 16 neg Neg yes ¨WT¨ 
45 MTC141 MTC  E 16 neg Neg yes ¨WT¨ 
46 MTC144 MTC  E 16 neg Neg   ¨WT¨ 
47 MTC133 MTC  E 16 neg NA yes ¨WT¨ 
48 MTC115 MTC Neg Neg   ¨WT¨ 
50 MTC157 MTC Neg Neg   ¨WT¨ 
51 MTC116 MTC Neg Neg   ¨WT¨ 
52 MTC114 MTC Neg Neg   ¨WT¨ 
53 MTC130 MTC Neg Neg   ¨WT¨ 
54 MTC153 MTC NA Neg   not used 
55 MTC158 MTC NA Neg   not used 
57 PDTC1 PDTC       control 
58 PTC1 PTC       control 
59 PTC2 PTC       control 
60 PTC3 PTC       control 
61 MC medulla cortex       control 
62 PL placenta       control 
Abbreviations: NA- not available; Neg – negative; E-10, E-11, E-15, E-16 : exon 10, exon 11, exon 15 and exon 
16, respectively.  
 
 
 
Supplementary annex Table 3B. Genetic information of the TMA-2 .  
 
Nº ID  Tumor 
Somatic 
mutation 
Germline 
mutation 
Normal 
thyroid 
Classification 
1 MTC20_P MTC - C634R Yes ¨634¨ 
2 MTC23_P MTC - C634R Yes ¨634¨ 
3 MTC28_P MTC - C634R Yes ¨634¨ 
4 MTC22_P MTC - C634Y Yes ¨634¨ 
5 MTC24_P* MTC - C634Y Yes ¨634¨ 
6 MTC25_P* MTC - C634R Yes ¨634¨ 
7 MTC18_P MTC M918T Neg Yes ¨918¨ 
8 MTC19_P MTC M918T Neg No ¨918¨ 
9 MTC46_P MTC M918T Neg No ¨918¨ 
10 MTC16_P MTC M918T Neg No ¨918¨ 
11 MTC17_P MTC WT E 10, 11 Neg Yes ¨WT¨ 
12 MTC31_P MTC WT E 10, 11 Neg Yes ¨WT¨ 
13 MTC21_P MTC Unkown E 10, 11 Neg Yes ¨WT¨ 
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14 MTC27_P MTC Unkown Unkown Yes not used 
15 MTC29_P MTC - C618S Yes  Not used 
16 HCN1 
Hürthle cell 
neoplasm       control 
17 FTC1  FTC       control  
*tumors not hybridized due to lack of RNA. 
Abbreviations: FTC- Follicular Thyroid Carcinoma; Neg – negative. P:FFPE sample code associated to MTC 
frozen samples code. 
 
 
Supplementary  annex Table 4A.  GSEA analysis of MTCM918T vs MTC634. Enriched pathways  
in M918T group. 
 
BIOCARTA PATHWAY NAME NES NOM p-val* FDR q-val† 
TCRPATHWAY 1,766 0,002 0,053 
NKTPATHWAY 1,830 0,000 0,055 
HIVNEFPATHWAY 1,784 0,002 0,056 
INFLAMPATHWAY 1,768 0,005 0,058 
ATRBRCAPATHWAY 1,788 0,005 0,060 
STEMPATHWAY 1,833 0,004 0,066 
DEATHPATHWAY 1,732 0,005 0,066 
NO2IL12PATHWAY 1,793 0,006 0,068 
NTHIPATHWAY 1,709 0,011 0,077 
NFKBPATHWAY 1,845 0,000 0,079 
BCRPATHWAY 1,678 0,011 0,086 
IL1RPATHWAY 1,688 0,009 0,086 
RELAPATHWAY 1,667 0,017 0,087 
LAIRPATHWAY 1,640 0,013 0,103 
CASPASEPATHWAY 1,849 0,004 0,110 
DCPATHWAY 1,906 0,000 0,115 
TH1TH2PATHWAY 1,605 0,024 0,127 
TNFR1PATHWAY 1,576 0,030 0,151 
CTLA4PATHWAY 1,556 0,041 0,155 
IL12PATHWAY 1,562 0,038 0,155 
NKCELLSPATHWAY 1,531 0,032 0,175 
FMLPPATHWAY 1,513 0,033 0,189 
AMIPATHWAY 1,484 0,057 0,212 
TNFR2PATHWAY 1,476 0,063 0,212 
ERYTHPATHWAY 1,489 0,054 0,215 
ETSPATHWAY 1,443 0,070 0,234 
P38MAPKPATHWAY 1,414 0,052 0,237 
CSKPATHWAY 1,446 0,071 0,239 
WNTPATHWAY 1,422 0,069 0,240 
CCR5PATHWAY 1,415 0,068 0,243 
IL2PATHWAY 1,405 0,078 0,243 
CYTOKINEPATHWAY 1,425 0,068 0,244 
MAPKPATHWAY 1,447 0,021 0,246 
KEGG PATHWAY NAME NES NOM p-val* FDR q-val† 
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NATURAL KILLER CELL MEDIATED CYTOTOXICITY 2,276 0,000 0,001 
P53 SIGNALING PATHWAY 2,142 0,000 0,002 
TYPE I DIABETES MELLITUS 2,067 0,000 0,002 
ASTHMA 1,917 0,000 0,010 
CYTOKINE-CYTOKINE RECEPTOR INTERACTION 1,880 0,000 0,012 
APOPTOSIS 1,837 0,000 0,016 
NATURAL KILLER CELL MEDIATED CYTOTOXICITY 1,802 0,000 0,022 
HEMATOPOIETIC CELL LINEAGE 1,801 0,000 0,019 
CELL CYCLE 1,794 0,000 0,018 
ONE CARBON POOL BY FOLATE 1,777 0,004 0,019 
DNA REPLICATION 1,765 0,005 0,020 
TOLL-LIKE RECEPTOR SIGNALING PATHWAY 1,732 0,005 0,027 
T CELL RECEPTOR SIGNALING PATHWAY 1,629 0,009 0,063 
JAK-STAT SIGNALING PATHWAY 1,520 0,042 0,105 
B CELL RECEPTOR SIGNALING PATHWAY 1,519 0,021 0,140 
LEUKOCYTE TRANSENDOTHELIAL MIGRATION 1,506 0,014 0,145 
NOTCH SIGNALING PATHWAY 1,505 0,030 0,135 
PATHOGENIC ESCHERICHIA COLI INFECTION-EHEC 1,485 0,021 0,148 
PYRIMIDINE METABOLISM 1,461 0,009 0,166 
COMPLEMENT AND COAGULATION CASCADES 1,458 0,029 0,159 
* NOM p-value is the significance of the normalized enrichment score (NES); †FDR q-val is the false discovery rate (FDR), the  
estimated probability that a gene set with a given NES represents a false positive finding; The GSEA  analysis report highlights  
enriched gene sets with an FDR of less than 25%. 
 
Supplementary annex Table 4B.  GSEA analysis of MTCM918T vs MTCWT. Enriched pathways in 
M918T group. 
 
BIOCARTA PATHWAY NAME NES NOM p-val* FDR q-val† 
CYTOKINEPATHWAY 2,153 0,000 0,000 
COMPPATHWAY 2,139 0,000 0,001 
DCPATHWAY 2,090 0,000 0,005 
LAIRPATHWAY 2,020 0,000 0,008 
INFLAMPATHWAY 1,998 0,000 0,007 
NKTPATHWAY 1,990 0,000 0,006 
ERYTHPATHWAY 1,931 0,002 0,014 
STEMPATHWAY 1,797 0,004 0,053 
NKCELLSPATHWAY 1,715 0,015 0,100 
GCRPATHWAY 1,697 0,013 0,105 
FMLPPATHWAY 1,651 0,008 0,132 
RAC1PATHWAY 1,611 0,025 0,164 
CXCR4PATHWAY 1,593 0,019 0,172 
TH1TH2PATHWAY 1,590 0,024 0,164 
IL1RPATHWAY 1,527 0,030 0,233 
SPPAPATHWAY 1,517 0,037 0,233 
KEGG PATHWAY NAME NES NOM p-val* FDR q-val† 
COMPLEMENT AND COAGULATION CASCADES 2,430 0,000 0,000 
ASTHMA 2,160 0,000 0,001 
TYPE I DIABETES MELLITUS 2,118 0,000 0,001 
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PROTEASOME 1,923 0,000 0,013 
HEMATOPOIETIC CELL LINEAGE 1,772 0,000 0,045 
PORPHYRIN AND CHLOROPHYLL METABOLISM 1,771 0,002 0,037 
CYTOKINE-CYTOKINE RECEPTOR INTERACTION 1,732 0,000 0,047 
PATHOGENIC ESCHERICHIA COLI INFECTION 1,728 0,000 0,042 
PYRIMIDINE METABOLISM 1,698 0,000 0,047 
P53 SIGNALING PATHWAY 1,680 0,002 0,049 
ANDROGEN AND ESTROGEN METABOLISM 1,673 0,002 0,047 
PENTOSE AND GLUCURONATE INTERCONVERSIONS 1,664 0,013 0,047 
NICOTINATE AND NICOTINAMIDE METABOLISM 1,607 0,018 0,071 
CELL CYCLE 1,603 0,004 0,068 
MAPK SIGNALING PATHWAY 1,614 0,012 0,092 
TOLL-LIKE RECEPTOR SIGNALING PATHWAY 1,550 0,004 0,098 
APOPTOSIS 1,500 0,007 0,132 
DNA REPLICATION 1,498 0,030 0,126 
ARGININE AND PROLINE METABOLISM 1,493 0,039 0,124 
CELL ADHESION MOLECULES (CAMS) 1,445 0,041 0,153 
RENIN-ANGIOTENSIN SYSTEM 1,433 0,074 0,174 
PARKINSON'S DISEASE 1,398 0,080 0,210 
GAP JUNCTION 1,389 0,031 0,212 
LONG-TERM DEPRESSION  1,360 0,031 0,244 
CITRATE CYCLE (TCA CYCLE) 1,355 0,095 0,242 
*NOM p-value is the significance of the normalized enrichment score (NES); †FDR q-val is the false discovery rate (FDR), the  
estimated probability that a gene set with a given NES represents a false positive finding. The GSEA analysis report highlights  
enriched gene sets with an FDR of less than 25%. Pathways are ranked by the FRD q-value. 
 
Supplementary annex Table 5.  FatiGo/Babelomics analysis of GO biological processes.  
Nº Term (GO) M918T gene list 
odds_ratio 
_log 
pvalue adj_pvalue 
1 
muscle organ 
development 
(GO:0007517) 
FAM65B,TNNI3,SPIB,MEOX2,EZH2,PAX7 1,92 3,85E-04 2,88E-02 
2 
organ morphogenesis 
(GO:0009887) 
TNNI3,SPIB,CDH13,HOXC8,TNF,PDGFRA,CHST11, 
MEOX2,ONECUT2,RUNX2,PITX2,SHC1 
1,78 3,23E-06 1,50E-03 
3 
tissue development 
(GO:0009888) 
TNNI3,SPIB,IKZF1,TNF,CHST11,NRTN,MEOX2, 
ONECUT2,RUNX2,EZH2,PAX7 
1,67 2,08E-05 4,36E-03 
4 
negative regulation of 
cytokine production 
(GO:0001818) 
SPIB,TNF,CIDEA 3,08 4,68E-04 3,26E-02 
5 
chondrocyte 
differentiation 
(GO:0002062) 
SPIB,CHST11,RUNX2 3,04 5,24E-04 3,33E-02 
6 
myeloid leukocyte 
differentiation 
(GO:0002573) 
SPIB,IKZF1,TNF,RELB,IFI16 3,01 8,59E-06 2,10E-03 
7 
DNA metabolic process 
(GO:0006259) 
SPIB,FANCI,PDGFRA,ESCO2,CIDEA,TYMS,SHC1,TERT 1,55 5,13E-04 3,33E-02 
8 
DNA replication 
(GO:0006260) 
SPIB,PDGFRA,TYMS,SHC1,TERT 1,95 1,01E-03 4,83E-02 
9 
protein amino acid 
phosphorylation 
(GO:0006468) 
SPIB,NEK2,GSG2,TNF,PIM2,TRIB2,ADRA2A,STK17B, 
PDGFRA,SHC1 
1,43 3,05E-04 2,70E-02 
10 
anti-apoptosis 
(GO:0006916) 
SPIB,CDH13,TNF,IL2RB,PIM2,PAX7,TERT 2,31 1,24E-05 2,79E-03 
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11 
induction of apoptosis 
(GO:0006917) 
SPIB,TNF,CASP4,STK17B,BID,CIDEA,IFI16 2,15 3,18E-05 5,82E-03 
12 
cellular component 
movement 
(GO:0006928) 
SPIB,CDH13,TNF,ADRA2A,PDGFRA,NRTN,ONECUT2 
,MTSS1 
1,44 1,07E-03 4,94E-02 
13 
cytoskeleton 
organization 
(GO:0007010) 
SPIB,NEK2,CXCL1,ADRA2A,ARHGAP4,MTSS1,SHC1 1,61 8,24E-04 4,26E-02 
14 cell cycle (GO:0007049) 
SPIB,NEK2,GSG2,TNF,PIM2,FANCI,GAS2L1,ESCO2, 
HMGA2 
1,34 1,04E-03 4,92E-02 
15 
cell adhesion 
(GO:0007155) 
SPIB,SIRPG,CDH13,SDK1,TNF,ONECUT2,CLEC4M, 
MTSS1,SHC1,LOXL2 
1,41 3,68E-04 2,83E-02 
16 
leukocyte adhesion 
(GO:0007159) 
SPIB,TNF,CLEC4M 3,14 3,93E-04 2,88E-02 
17 
enzyme linked receptor 
protein signaling 
pathway (GO:0007167) 
SPIB,CDH13,STAP1,PDGFRA,CHST11,CIDEA,NRTN 
,ONECUT2,RUNX2,MTSS1,SHC1 
2,19 1,64E-07 1,60E-04 
18 
transmembrane 
receptor protein 
tyrosine kinase signaling 
pathway (GO:0007169) 
SPIB,CDH13,STAP1,PDGFRA,NRTN,RUNX2,MTSS1, 
SHC1 
2,25 4,62E-06 1,50E-03 
19 
transforming growth 
factor beta receptor 
signaling pathway 
(GO:0007179) 
SPIB,CHST11,CIDEA,ONECUT2 2,56 3,56E-04 2,83E-02 
20 
protein kinase cascade 
(GO:0007243) 
SPIB,GSG2,TNF,ADRA2A,STK17B,NRTN,HMGA2,SHC
1 
1,67 2,41E-04 2,28E-02 
21 
Rho protein signal 
transduction 
(GO:0007266) 
SPIB,CDH13,ADRA2A,ARHGAP4 2,24 1,12E-03 4,95E-02 
22 
pattern specification 
process (GO:0007389) 
SPIB,MFNG,RAX,HOXC8,MEOX2,PAX7,PITX2 2,16 2,99E-05 5,82E-03 
23 aging (GO:0007568) SPIB,SHC1,TERT,LOXL2 2,33 8,30E-04 4,26E-02 
24 
positive regulation of cell 
proliferation 
(GO:0008284) 
SPIB,SIRPG,CDH13,TNF,ADRA2A,PDGFRA,RUNX2,SH
C1 
1,91 5,07E-05 7,81E-03 
25 
negative regulation of 
cell proliferation 
(GO:0008285) 
SPIB,SIRPG,CDH13,CXCL1,TNF,RERG 1,73 1,00E-03 4,83E-02 
26 
apoptotic mitochondrial 
changes (GO:0008637) 
SPIB,PIM2,BID 3,21 3,26E-04 2,73E-02 
27 
negative regulation of 
metabolic process 
(GO:0009892) 
SPIB,IKZF1,HOXC8,TNF,IGF2BP2,CIDEA,RUNX2,HMG
A2 
1,43 1,09E-03 4,94E-02 
28 
positive regulation of 
metabolic process 
(GO:0009893) 
SPIB,IKZF1,CDH13,TNF,IL2RB,PDGFRA,ONECUT2,RU
NX2,SHC1 
1,38 7,97E-04 4,24E-02 
29 
regulation of signal 
transduction 
(GO:0009966) 
SPIB,CDH13,TNF,DKK4,TRIB2,ADRA2A,CHST11,CIDEA
,ONECUT2, 
RUNX2,HMGA2,SHC1 
1,68 8,33E-06 2,10E-03 
30 
negative regulation of 
signal transduction 
(GO:0009968) 
SPIB,DKK4,CHST11,CIDEA,ONECUT2,RUNX2,HMGA2 2,42 6,16E-06 1,80E-03 
31 
positive regulation of cell 
death (GO:0010942) 
SPIB,TNF,CASP4,STK17B,BID,CIDEA,IFI16 1,83 2,27E-04 2,28E-02 
32 
peptide transport 
(GO:0015833) 
SPIB,CPLX3,TNF,TAP1,CLEC4M 2,67 4,07E-05 6,61E-03 
33 
cell-cell adhesion 
(GO:0016337) 
SPIB,SIRPG,CDH13,TNF,CLEC4M,SHC1 1,93 3,66E-04 2,83E-02 
34 
regulation of cell-cell 
adhesion (GO:0022407) 
SPIB,SIRPG,TNF 3,26 2,85E-04 2,61E-02 
35 
positive regulation of 
cell-cell adhesion 
(GO:0022409) 
SPIB,SIRPG,TNF 3,75 7,30E-05 1,02E-02 
36 cell projection assembly SPIB,CDH13,ONECUT2,MTSS1 2,39 6,52E-04 3,74E-02 
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(GO:0030031) 
37 
myeloid cell 
differentiation 
(GO:0030099) 
SPIB,IKZF1,TNF,RELB,IFI16 2,28 2,40E-04 2,28E-02 
38 
regulation of cell 
adhesion (GO:0030155) 
SPIB,SIRPG,CDH13,TNF,ONECUT2 2,45 1,08E-04 1,27E-02 
39 
positive regulation of 
cell migration 
(GO:0030335) 
SPIB,CDH13,PDGFRA,ONECUT2 2,51 4,32E-04 3,08E-02 
40 
cellular response to DNA 
damage stimulus 
(GO:0034984) 
SPIB,FANCI,ESCO2,CIDEA,IFI16,TYMS 1,73 9,90E-04 4,83E-02 
41 
regulation of growth 
(GO:0040008) 
SPIB,IKZF1,CDH13,ESM1,HMGA2,RERG,SHC1 1,99 8,81E-05 1,17E-02 
42 
regulation of cell 
proliferation 
(GO:0042127) 
SPIB,SIRPG,CDH13,CXCL1,TNF,ADRA2A,PDGFRA,CH
ST11,RUNX2,RERG,PTGER2,SHC1 
1,76 3,91E-06 1,50E-03 
43 
vitamin D biosynthetic 
process (GO:0042368) 
SPIB,TNF 4,07 7,38E-04 4,06E-02 
44 
odontogenesis of 
dentine-containing tooth 
(GO:0042475) 
SPIB,PDGFRA,RUNX2 2,83 9,42E-04 4,75E-02 
45 
regulation of apoptosis 
(GO:0042981) 
SPIB,CDH13,TNF,IL2RB,PIM2,CASP5,CASP4,STK17B,C
HST11,BID,CIDEA,PAX7,IFI16,TERT 
1,94 8,91E-08 1,45E-04 
46 
positive regulation of 
apoptosis (GO:0043065) 
SPIB,TNF,CASP4,STK17B,BID,CIDEA,IFI16 1,84 2,08E-04 2,25E-02 
47 
negative regulation of 
apoptosis (GO:0043066) 
SPIB,CDH13,TNF,IL2RB,PIM2,CHST11,CIDEA,PAX7,T
ERT 
2,13 3,18E-06 1,50E-03 
48 
regulation of 
programmed cell death 
(GO:0043067) 
SPIB,CDH13,TNF,IL2RB,PIM2,CASP5,CASP4,STK17B,C
HST11,BID,CIDEA,PAX7,IFI16,TERT 
1,93 9,90E-08 1,45E-04 
49 
positive regulation of 
programmed cell death 
(GO:0043068) 
SPIB,TNF,CASP4,STK17B,BID,CIDEA,IFI16 1,84 2,17E-04 2,27E-02 
50 
negative regulation of 
programmed cell death 
(GO:0043069) 
SPIB,CDH13,TNF,IL2RB,PIM2,CHST11,CIDEA,PAX7,TE
RT 
2,12 3,44E-06 1,50E-03 
51 
positive regulation of 
DNA replication 
(GO:0045740) 
SPIB,PDGFRA,SHC1 3,06 4,96E-04 3,30E-02 
52 
positive regulation of cell 
adhesion (GO:0045785) 
SPIB,SIRPG,CDH13,TNF 2,84 1,27E-04 1,43E-02 
53 
smooth muscle cell 
proliferation 
(GO:0048659) 
SPIB,CDH13,TNF,SHC1 2,89 1,06E-04 1,27E-02 
54 
regulation of smooth 
muscle cell proliferation 
(GO:0048660) 
SPIB,CDH13,TNF,SHC1 2,93 9,23E-05 1,17E-02 
55 
positive regulation of 
smooth muscle cell 
proliferation 
(GO:0048661) 
SPIB,CDH13,TNF,SHC1 3,19 3,44E-05 5,92E-03 
56 
skeletal system 
morphogenesis 
(GO:0048705) 
SPIB,HOXC8,PDGFRA,CHST11,RUNX2 2,58 5,97E-05 8,74E-03 
57 
cytokine secretion 
(GO:0050663) 
SPIB,TNF,CIDEA 3,02 5,53E-04 3,37E-02 
58 
regulation of 
developmental process 
(GO:0050793) 
SPIB,IKZF1,CDC42SE1,CDH13,TNF,IL2RB,PIM2,CHST1
1,CIDEA,RUNX2,EZH2,PAX7,TERT 
1,67 4,49E-06 1,50E-03 
59 
cartilage development 
(GO:0051216) 
SPIB,CHST11,RUNX2,PAX7 2,59 3,22E-04 2,73E-02 
60 
negative regulation of 
protein transport 
(GO:0051224) 
SPIB,TNF,CIDEA 2,91 7,49E-04 4,06E-02 
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61 
positive regulation of 
cellular component 
movement 
(GO:0051272) 
SPIB,CDH13,PDGFRA,ONECUT2 2,44 5,50E-04 3,37E-02 
62 
centrosome separation 
(GO:0051299) 
SPIB,NEK2 4,16 6,34E-04 3,71E-02 
63 
negative regulation of 
amino acid transport 
(GO:0051956) 
SPIB,TNF 3,85 1,10E-03 4,94E-02 
64 
palate development 
(GO:0060021) 
SPIB,PDGFRA,MEOX2 3,06 4,96E-04 3,30E-02 
65 
limb development 
(GO:0060173) 
SPIB,RAX,CHST11,MEOX2 2,39 6,70E-04 3,77E-02 
66 
positive regulation of 
calcidiol 1- (GO:0060559) 
SPIB,TNF 4,16 6,34E-04 3,71E-02 
 
Supplementary annex Table 6.  Biocarta pathways in M918T group compared to Agilent Whole 
Genome: Biocarta significant terms (pvalue<0.05) from FatiGo analysis. 
Nº Term (Biocarta Pathway) M918T gene list odds_ratio_log pvalue adj_pvalue 
1 
Angiotensin II mediated activation of JNK Pathway via 
Pyk2 dependent signaling(h_At1rPathway) SPIB,SHC1 3,302 3,07E-03 2,57E-02 
2 BCR Signaling Pathway (h_bcrPathway) SPIB,SHC1 3,028 5,06E-03 3,28E-02 
3 
Bioactive Peptide Induced Signaling Pathway 
(h_biopeptidesPathway) SPIB,SHC1 3,202 3,68E-03 2,57E-02 
4 
CBL mediated ligand-induced downregulation of EGF 
receptors (h_cblPathway) SPIB,PDGFRA 4,168 6,78E-04 2,11E-02 
5 
Cadmium induces DNA synthesis and proliferation in 
macrophages (h_cdMacPathway) SPIB,TNF 3,945 9,89E-04 2,11E-02 
6 
Apoptotic Signaling in Response to DNA Damage 
(h_chemicalPathway) SPIB,BID 3,682 1,56E-03 2,12E-02 
7 Cytokine Network (h_cytokinePathway) SPIB,TNF 3,762 1,36E-03 2,12E-02 
8 
Induction of apoptosis through DR3 and DR4/5 Death 
Receptors (h_deathPathway) SPIB,BID 3,156 4,01E-03 2,66E-02 
9 
Phospholipids as signalling intermediaries 
(h_edg1Pathway) SPIB,PDGFRA 3,302 3,07E-03 2,57E-02 
10 EGF Signaling Pathway (h_egfPathway) SPIB,SHC1 3,414 2,52E-03 2,57E-02 
11 EPO Signaling Pathway (h_epoPathway) SPIB,SHC1 3,682 1,56E-03 2,12E-02 
12 Role of Erk5 in Neuronal Survival (h_erk5Pathway) SPIB,SHC1 3,849 1,17E-03 2,11E-02 
13 
Fc Epsilon Receptor I Signaling in Mast Cells 
(h_fcer1Pathway) SPIB,SHC1 2,845 7,06E-03 4,17E-02 
14 Growth Hormone Signaling Pathway (h_ghPathway) SPIB,SHC1 3,202 3,68E-03 2,57E-02 
15 
Adhesion and Diapedesis of Granulocytes 
(h_granulocytesPathway) SPIB,TNF 3,945 9,89E-04 2,11E-02 
16 
Calcium Signaling by HBx of Hepatitis B virus 
(h_HBxPathway) SPIB,SHC1 5,149 1,53E-04 1,04E-02 
17 
Role of ERBB2 in Signal Transduction and Oncology 
(h_her2Pathway) SPIB,SHC1 3,251 3,37E-03 2,57E-02 
18 HIV-I Nef (h_HivnefPathway) SPIB,TNF,BID 2,949 6,98E-04 2,11E-02 
19 Stress Induction of HSP Regulation (h_hsp27Pathway) SPIB,TNF 3,945 9,89E-04 2,11E-02 
20 IGF-1 Signaling Pathway (h_igf1Pathway) SPIB,SHC1 3,539 2,01E-03 2,38E-02 
21 
Multiple antiapoptotic pathways from IGF-1R signaling 
lead to BAD phosphorylation (h_igf1rPathway) SPIB,SHC1 3,302 3,07E-03 2,57E-02 
22 Signal transduction through IL1R (h_il1rPathway) SPIB,TNF 3,202 3,68E-03 2,57E-02 
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23 IL 2 signaling pathway (h_il2Pathway) SPIB,IL2RB,SHC1 4,025 3,87E-05 1,02E-02 
24 
Cytokines and Inflammatory Response 
(h_inflamPathway) SPIB,TNF 3,302 3,07E-03 2,57E-02 
25 Insulin Signaling Pathway (h_insulinPathway) SPIB,SHC1 3,539 2,01E-03 2,38E-02 
26 Integrin Signaling Pathway (h_integrinPathway) SPIB,SHC1 3,156 4,01E-03 2,66E-02 
27 Keratinocyte Differentiation (h_keratinocytePathway) SPIB,TNF 2,879 6,63E-03 4,01E-02 
28 NF-kB Signaling Pathway (h_nfkbPathway) SPIB,TNF 3,682 1,56E-03 2,12E-02 
29 Nerve growth factor pathway (NGF) (h_ngfPathway) SPIB,SHC1 3,357 2,79E-03 2,57E-02 
30 p38 MAPK Signaling Pathway (h_p38mapkPathway) SPIB,SHC1 3,202 3,68E-03 2,57E-02 
31 PDGF Signaling Pathway (h_pdgfPathway) SPIB,PDGFRA,SHC1 3,773 7,48E-05 1,02E-02 
32 
Regulation of transcriptional activity by PML 
(h_pmlPathway) SPIB,TNF 3,849 1,17E-03 2,11E-02 
33 Links between Pyk2 and Map Kinases (h_pyk2Pathway) SPIB,SHC1 3,302 3,07E-03 2,57E-02 
34 
Acetylation and Deacetylation of RelA in The Nucleus 
(h_RELAPathway) SPIB,TNF 4,168 6,78E-04 2,11E-02 
35 SODD/TNFR1 Signaling Pathway (h_soddPathway) SPIB,TNF 4,301 5,43E-04 2,11E-02 
36 
Sprouty regulation of tyrosine kinase signals 
(h_spryPathway) SPIB,SHC1 3,762 1,36E-03 2,12E-02 
37 TNF/Stress Related Signaling (h_stressPathway) SPIB,TNF 3,608 1,78E-03 2,30E-02 
38 T Cell Receptor Signaling Pathway (h_tcrPathway) SPIB,SHC1 2,879 6,63E-03 4,01E-02 
39 
Chaperones modulate interferon Signaling Pathway 
(h_tidPathway) SPIB,TNF 4,301 5,43E-04 2,11E-02 
40 TNFR1 Signaling Pathway (h_tnfr1Pathway) SPIB,TNF 3,251 3,37E-03 2,57E-02 
41 TPO Signaling Pathway (h_TPOPathway) SPIB,SHC1 3,357 2,79E-03 2,57E-02 
42 Trka Receptor Signaling Pathway (h_trkaPathway) SPIB,SHC1 3,849 1,17E-03 2,11E-02 
43 VEGF, Hypoxia, and Angiogenesis (h_vegfPathway) SPIB,SHC1 3,202 3,68E-03 2,57E-02 
44 Wnt/LRP6 Signalling (h_wnt-lrp6Pathway) SPIB,KREMEN2 5,149 1,53E-04 1,04E-02 
45 
IL-2 Receptor Beta Chain in T cell Activation 
(h_il2rbPathway) IL2RB,SHC1 2,879 6,63E-03 4,01E-02 
46 Erk1/Erk2 Mapk Signaling pathway (h_erkPathway) PDGFRA,SHC1 3,251 3,37E-03 2,57E-02 
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Supplementary annex Table 7. MAGIA analysis: Predicted mRNA-miRNA interactions from 
comparisons MTC634 vs MTCM918T and MTCM918T vs MTCWT. 
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Abstract  
Medullary thyroid carcinoma accounts for 2-5% of thyroid malignancies. Around 75% of 
them are sporadic, and the remaining 25% are hereditary and related to Multiple Endocrine 
Neoplasia type 2 syndrome. Although it is well established a genotype-phenotype 
correlation related to specific germline RET mutations, the knowledge of pathways 
specifically associated with each mutation, as well as to non-RET mutated sporadic MTC 
still remain largely unknown. Gene expression patterns have provided a tool to identify 
molecular events related to specific tumor types and to different clinical features that could 
help to identify novel targets for therapy. Using an outstanding series of 68 frozen MTC 
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classified accordingly to RET mutation, we identified PROM1, LOXL2, GFRA1, DKK4 as 
related to RET
M918T
, while GAL was associated with RET
634 
mutation respectively. 
According to pathway enrichment analysis and GO biological processes, genes associated 
with MTC
M918T
 group were mainly involved in proliferative, cell adhesion and general 
malignant metastatic effects and Wnt, Notch, NFκB, JAK/Stat and MAPkinase signaling 
pathways.  Assays based on silencing PROM1 by siRNAs performed in MZ-CRC-1 cell 
line, harboring RET
M918T
, caused an increase in apoptotic nuclei, suggesting that PROM1 is 
necessary for the survival of these cells. To our knowledge this is the first time that 
PROM1 overexpression is reported among primary tumors. This finding could lead to the 
identification of novel therapeutic targets.   
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Introduction 
Medullary Thyroid Carcinoma (MTC) is a rare malignancy derived from calcitonin-producing 
parafollicular thyroid cells or thyroid C-cells; it constitutes 5% to 10% of all thyroid neoplasias 
(Ball 2000). Approximately 25% of all MTCs are hereditary as part of multiple endocrine neoplasia 
type 2 (MEN2; MIM#17140014), a rare cancer syndrome (1:30,000) that follows an autosomal 
dominant inheritance pattern and shows a variable clinical expression. 
MEN2 is subdivided into MEN2A, MEN2B and FMTC (familial medullary thyroid carcinoma), 
according to the clinical features exhibited by the patients. Specific activating point mutations in the 
RET proto-oncogene are responsible for the three forms of MEN2. RET encodes a tyrosine kinase 
receptor (RTK) implicated in neural crest tissue development and differentiation (Pachnis 1993), 
that activates a variety of signaling pathways. Ret signaling mainly takes place through 
autophosphorylation of Ret tyrosine residues which, once phosphorylated, trigger the recruitment of 
several intercellular adapters, leading to the activation of several cascades.  
MEN2A patients commonly carry  RET mutations in codon 634 encoding cysteine (Eng 1996) , and 
less frequently in the cysteine-encoding codons 609, 611, 618, 620, and 630 (Mulligan 1994; 
Mulligan, et al. 1993a). Patients with a mutated codon 634 have a high risk of lymph node 
metastasis and a more than 40% increased risk of developing the disease by age 20 (Machens et al. 
2003). FMTC cases mainly carry RET mutations affecting highly conserved cysteine regions, such 
as codons 609, 611, 618 and 620, as well as other infrequent mutations in residues of the 
intracellular domain in e.g. exons 13 (Dabir, et al. 2006) and 15 (Hofstra 1997). RET mutation 
M918T in exon 16 correlates with an aggressive disease(Drosten and Putzer 2006; Kodama 2005; 
Marx 2005), and is found as a germline mutation in the majority of MEN2B patients (94%) and as a 
somatic mutation in 30-50% of sporadic MTC cases (Marx 2005). This mutation lead to constitutive 
activation of RET and transforming potential in a lignad independent manner (Arighi, et al. 2005b). 
MTC progresses slowly and metastasizes to cervical and mediastinal nodal groups in up to 50% of 
cases. It also metastasizes to distant organs such as lungs, liver and bones in 20% of patients. Total 
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thyroidectomy remains the only effective treatment, but once metastatic disease has spread there is 
no effective therapy available (Weber 2006).   
Although there is a well-established genotype-phenotype correlation for MEN2 patients, the 
mechanisms by which RET-mutations cause tumors, the development of sporadic MTC in the 
absence of RET mutations, and the specific oncogenic pathways involved require further study. Our 
main aim was to identify signaling pathways specifically related to familial and sporadic MTC 
using transcriptional profiling to gain new information about specific markers that could be used as 
potential therapeutic targets. 
  
Material and Methods 
Human MTC Tissue samples and cell lines 
Sixty-eight tumors from unrelated patients diagnosed with MTC were collected at the time of 
surgery from Spanish hospitals through the Spanish National Tumor Bank Network and from the 
Surgical Pathology Department of Medical and Surgical Sciences, Padova, Italy. Tissue samples 
were embedded in Tissue-Tek® OCT compound (Sakura, Torrance, CA, USA), frozen in liquid 
nitrogen, and stored at -80ºC until they were used for RNA extraction and hybridization onto arrays, 
or for RET mutational screening (in case previous genetic information on the patient was absent). 
All tissues were evaluated by pathologists by hematoxylin and eosin staining; only samples with a 
high percentage (> 80%) of tumor cells were included in the study.  
After obtaining consent of each patient, clinical information was collected by questionnaire. The 
genetic and general characteristics of the cases are detailed in Supplementary Table 1.  
Two Tissue Microarrays (TMAs) were available for further analysis. The first TMA (TMA-1) 
contained 54 independent molecularly characterized formalin-fixed, paraffin-embedded (FFPE) 
MTC tissues; of these, 12 carried a germline RET mutation in codon 634, 9 had a somatic M918T 
mutation, and 22 were classified as WT if no mutations were found. This TMA also contained 4 
other thyroid cancer types and 2 normal tissues used as controls, as well as normal thyroid tissue of 
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13 MTC cases included in the TMA (Supplementary Table 2A). TMA-2 (Supplementary Table 2B) 
was constructed with cores from the corresponding paraffin-embedded material from 13 frozen 
samples used for profiling purposes as well as 2 MTCs which were not hybridized and 2 thyroid 
cancer of different subtype and 12 normal thyroid tissues from the corresponding MTCs. This TMA 
contained MTCs from patients carrying a germline RET mutation in codon 634 and somatic RET 
mutations affecting codon 918, as well as MTCs from patients classified as WT. 
Twenty-three additional independent FFPE MTCs were available to validate expression profiling 
through RT-qPCR (Supplementary Table 3).   
MZ-CRC-1 cells are derived from a metastatic MTC and harbor the M918T RET mutation (Cooley 
1995; Santoro et al. 1995).  
Molecular characterization of tumors 
Screening of RET was performed by direct sequencing of exons 10, 11, and 13-16 in DNA extracted 
from peripherial blood samples (when available), and if negative, from tumor specimens. Genomic 
tumor DNA was obtained following the manufacturer’s instructions using the DNeasy kit (Qiagen 
Inc., Valencia, CA, USA).  
RNA isolation 
Total RNA from 68 frozen MTC tissues was obtained following the manufacturer’s instructions 
using the TriReagent kit (MRC, Cincinnati, OH, USA). RNA purity and integrity was assessed 
using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). RNA of nineteen 
cases was degraded (RNA Integrity Number below 7) and discarded for hybridization assays, but 
considered in the RT-qPCR validation step. Total RNA from 23 independent FFPE MTCs was 
isolated following the manufacturer’s instructions using the RNeasy FFPE kit (Qiagen, Valencia, 
CA, USA). Concentration was determined using a Nanodrop ND-1000 spectrophotometer. These 
FFPE tumors were used for validation by RT-qPCR. After this first quality filter, 49 MTCs were 
used for hybridization assays, and 42 (19 frozen and 23 FFPE) samples for validation purposes.  
Total RNA from MZ-CRC-1 cells was extracted using the RNAeasy kit (QIAGEN, Alameda, CA).  
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cDNA synthesis, labeling, hybridization, and detection 
For each of the 49 MTC tumors used for profiling, 500 ng of total RNA was amplified according to 
the manufacturer’s instructions by double strand cDNA synthesis, followed by T7-based in vitro 
transcription. Universal Human Reference RNA (Stratagene, La Jolla, CA, USA) was used as a 
control for all samples. Amplified complementary RNA (cRNA) was labeled with cyanine 5 (Cy5)-
conjugated dUTP, whereas cRNA from Universal Human Reference RNA was labeled with cyanine 
3 (Cy3)-conjugated dUTP. The Agilent Whole Human Genome Array (4x44K) was used for 
competitive hybridization and the slides were washed, dried, and scanned in an Agilent microarray 
scanner (Agilent Technologies, Palo Alto, CA, USA).  
Normalization and preprocessing  
Two-channel arrays were hybridized and quantified using Feature Extraction v9.5 software. 
Microarray background substraction was done using the normexp method  (Ritchie 2007). The data 
set was normalized using loess within-array normalization and quantile between-array 
normalization. Differentially expressed genes were identified by applying linear models using the 
Bioconductor limma R package (Smyth 2005) (http://www.bioconductor.org). Normalized data 
were preprocessed using GEPAS server (Montaner 2006). Inconsistent replicates (SD>1) were 
discarded, and consistent replicates were averaged. Finally, genes that exhibited flat patterns 
(SD>0.8) across the set of samples were filtered and omitted in further comparisons. 
Unsupervised and supervised analysis 
Tumor samples were grouped according to their expression profiles by means of unsupervised 
clustering using GeneCluster 2.0 (Reich 2004). Unsupervised clustering was implemented by a 
SOM algorithm. Only tumors exhibiting the 634 or the M918T mutation, and tumors classified as 
WT were used in further analysis.  
Gene expression profiling and gene ontology analysis 
T-test was carried out using POMELOII (Morrissey 2009), and T-Rex from the GEPAS package 
was used for differential expression analysis  (Montaner 2006). To account for multiple hypothesis 
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testing, the estimated significance level (p-value) was adjusted using Benjamini’s False Discovery 
Rate (FDR) correction (Benjamini et al. 2001). Genes with an FDR<0.05 and with a fold-change > 
2 were selected for the validation step.  
Functional enrichment of gene ontologies (GOs) for differentially expressed genes (DEGs) was 
performed using the FatiGO tool (Al-Shahrour et al. 2004) implemented in Babelomics software. 
Fisher’s exact test was performed to obtain significant over-representation of GO terms in the DEGs 
list versus the rest of the genome. GO terms showing an FDR<0.05 were considered significant. 
Gene Set Enrichment Analysis (GSEA) (Subramanian 2005) using Biocarta and KEGG annotations 
was applied. Gene expression values were ranked based on the t statistic. Gene sets showing an 
FDR<0.25 were considered enriched between classes under comparison. 
Validation by quantitative RT-qPCR  
For validation of microarray data, five genes significantly differentially expressed among profiling 
results were selected to be assesed by RT qPCR. Thirty-two MTCs out of 49 previously hybridized 
samples, and 42 available MTCs from an independent series (19 frozen MTC tissues not used in 
profiling and  23 FFPE  tumors), were used for validation. As endogenous references we tested β-
glucoronidase (GUS), 60S acidic ribosomal protein P0 (RPLP0) and peptidylprolyl isomerase A 
(PPIA); GUS was used to normalize the quantification of mRNA expression.  
Reverse transcription was performed using 1 μg total RNA and random hexamers (FFPE samples), 
or 0.5 μg total RNA and oligodT (frozen specimens), and M-MLV Reverse Transcriptase (Promega 
Corporation, Madison, WI, USA).  
PCRs were done on an ABI Prism 7900 sequence detection system (Applied Biosystems, Foster 
City, CA, USA) using the Universal Probe Library set (https://www.roche-applied-science.com) as 
described  by the manufacturer. PCR reactions were performed in triplicates. The Kruskal-Wallis 
test (nonparametric ANOVA) for multiple class comparisons and the nonparametric Mann-Whitney 
test  for two class comparisons were used to compare the genetic classes. 
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For MZ-CRC-1 cells, total RNA was reverse transcribed using the TaqMan® Reverse Transcription 
kit from Applied Biosystems (Foster City, CA). The relative mRNA level of PROM1 was measured 
by RT-qPCR using TaqMan® probes from Applied Biosystems (Hs01009250_m1; PROM1). Probe 
Hs99999905_m1 (GAPDH) was used for data normalization. Quantification data were calculated 
by the 2
-ΔΔCT
 method.  
Cell culture and nucleofection 
MZ-CRC-1 cells were maintained in DMEM supplemented with 10% heat-inactivated fetal bovine 
serum, 1% pyruvate, 1% non-essential amino acids, 100U/ml penicillin and streptomycin at 37ºC in 
5% CO2 in air. For nucleofection, 2x10
6
 cells per condition were incubated with 2μM synthetic 
siRNAs (Sigma) directed against human PROM1 in a solution containing 100mM phosphate buffer, 
100mM KCl and 10mM MgCl2. Cells were nucleofected using the A30 program of an Amaxa 
Nucleofector II device (Lonza). Immediately after nucleofection, cells were resuspended in medium 
and seeded onto 6-well plates. 
Apoptosis assay 
Three days after transfection, the number of apoptotic nuclei was analyzed. Cell-permeant Hoechst 
dye 33342 was directly added to cells at a final concentration of 0.5mg/ml and incubation was 
continued for 15 minutes at 37ºC. Cells were then photographed under a fluorescence microscope 
(Olympus IX70). The percentage of apoptotic nuclei was scored in triplicate.  Five hundred to one 
thousand cells per condition were counted.   
Immunohistochemistry 
Immunohistochemical staining was performed on both MTC tissue microarrays available. TMA 
blocks were sectioned at a thickness of 3 μm and dried for 1 h at 60ºC.  Deparaffinization, 
rehydration and epitope retrieval were achieved by heat treatment in a PT Link (Dako, Glostrup, 
Denmark) at pH 9. Before staining the sections, endogenous peroxidase was blocked. Primary 
antibodies used were anti-PROM1 (1:500, ab19898 Abcam, Cambridge, MA, USA) and anti-
GFRA1 (1:500, C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA); incubations with primary 
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antibodies were according to the manufacturers' instructions. After incubation with anti-PROM1, 
the reaction was visualized with EnVision™ FLEX (Dako, Glostrup, Denmark) using 
diaminobenzidine chromogen as a substrate; anti-GFRA1 binding was visualized with the LSAB+ 
Kit (Dako, Glostrup, Denmark) using diaminobenzidine chromogen as a substrate. Sections were 
counterstained with hematoxylin. Appropriate positive and negative controls were also tested. 
Immunoexpression was graded semi-quantitatively by considering the percentage and intensity of 
the staining. A histological score was obtained for each sample, which ranged from 0 (no 
immunoreaction) to 300 (maximum immunoreactivity). Interpretation was done as previously 
described (Gallel 2008). Since each TMA included two cores from each case, immunohistochemical 
evaluation was done after examining all samples.  
Statistical analysis  
Immunoexpression was analyzed in two different ways, as a continuous variable,  and as a binary 
variable using  the median as the cut-off. For the  first analysis , Mann-Whitney U test was used, 
and for the second one, difference in expression was tested with a Chi-squared or Fisher's exact test 
when appropriated. Statistical analyses were carried out using SPSS software package version 17.0 
(SPSS, Inc., Chicago, IL). Nominal two-sided P-values less than 0.05 were considered statistically 
significant.   
 
Results  
Molecular genetic characteristics of the MTC tumors 
Tumors were classified according to their specific RET mutation. Among the 49 tumors available 
for profiling, 7 carried a germline RET mutation in codon 634, 14 carried the M918T RET mutation 
(1 germline and 13 somatic mutations), and 20 were classified as WT. The remaining eight MTCs 
had 6 different germline mutations and 2 different somatic mutations in RET (Supplementary Table 
1). These last 8 tumors were not considered in clustering analysis.  
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Data reveal differential expression profiles in inherited and sporadic MTC  
Unsupervised hierarchical clustering, performed using standard correlation as a measure of 
similarity across all hybridized samples, showed a relatively low heterogeneity distributed over two 
principal branches (Figure 1). An enrichment of familial MTC cases with various germline RET 
mutations was observed in the second branch of the cluster, whereas the first branch was enriched 
for sporadic MTC with somatic M918T RET mutations and WT cases. This observation led to us to 
do a supervised analysis based on the known mutations of each available tumor. Differential 
expression analysis was performed comparing MTCs
M918T
 vs MTCs
WT
, and MTCs
M918T
 vs MTCs
634
 
(Figures 2A and 2B), obtaining a  list of 360, and 18 significant genes  (GEO accession number 
GSE32662) respectively.  
Based on threshold-free methodology using GSEA, signaling pathways were identified as 
significantly differently expressed (FDR<25%) when comparing MTCs
M918T
 vs MTCs
634
 and 
MTCs
M918T
 vs MTCs
WT
 (Supplementary Tables 4A and 4B, respectively). The M918T cluster was 
correlated with several pathways related to malignant tumor behavior, such as the p53, caspase, 
cytokine, Wnt, NFκB, MAPK, IL1R, JAK/Stat, and Notch pathways. 
Analyses of Gene Ontologies (GO) revealed significant biological processes in the M918T group 
associated as well with malignant behavior  (shown in bold in Supplementary Table 5). Hierarchical 
clustering analysis of the most relevant FatiGO outputs for biological processes pointed to the 
importance of cell adhesion, migration and proliferation ontologies (data not shown). 
FatiGO analysis (Supplementary Table 6) and GSEA analysis (Supplementary Tables 4A and 4B) 
revealed similar significant pathways associated with the M918T group.  
 
Biomarkers of specific genetic condition.  
After applying the filtering criteria, five genes (PROM1, GFRA1, LOXL2, GAL, and DKK4) 
appeared to be biomarkers of different genetic conditions and were selected for further validation at 
the mRNA level.  
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GAL was the only gene statistically significant found to be a specific marker for the germline RET 
mutation in codon 634. The expression of the other four genes was validated by quantitative RT-
PCR as up-regulated markers among MTCs
M918T
. Due to limited availability of RNA, it was only 
possible to validate PROM1 and LOXL2 in FFPE MTC samples. Supplementary Figures 1A and 1B 
summarize these results in the independent frozen and FFPE series, respectively. 
Although not selected for further validation, other genes differentially expressed among the three 
different genetic conditions considered here have been reported to be involved in cancer of tissues 
derived from the same neural crest origin as MTC, and also in the RTK signaling pathway. 
Therefore, these previous findings were considered as a cross-validation of our results. Among 
these markers, the up-regulated genes associated with the M918T group were ESM1, NPR1, PITX2, 
RTN1, and SHC1. ESM1 (endothelial cell-specific molecule 1) is associated with cell migration and 
proliferation, and its over-expression has been previously described in sporadic RET
M918T
 MTC 
cases (Ameur et al. 2009). NPR1 (natriuretic peptide receptor A/guanylate cyclase A) regulates the 
activation of ERK1/2 (Deng 2010), as well as Ras/Raf/ERK and Wnt/β-cathenin pathways. PITX2 
(paired-like homeodomain 2) is involved in tumorigenesis and Wnt/β-cathenin signaling, and is 
expressed in neural crest cells (Zacharias 2010). RTN1 (reticulon 1), overexpression of which leads 
to apoptosis of neuroblastoma cell lines, is involved in secretion or membrane trafficking in 
neuroendocrine cells as well as in tumorigenesis, and is expressed in neurons and neuroendocrine 
cells (Steiner 2004). Fibroblasts transformed by RET
C634R
 display constitutive RET-mediated 
phosphorylation of SHC which activates the RAS/MAPK signaling pathway  (Ohiwa et al. 1997).  
 
Immunohistochemistry 
We performed immunohistochemistry for GFRA1 and PROM1. Results were evaluated following 
uniform pre-established criteria.  
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Differences  at the mRNA level were not observed at the protein level. GFRA1 protein levels were 
not significantly different among the groups. PROM1 showed higher staining in MTCs
M918T
 than in 
MTCs
634
 (P=0.059), in agreement with mRNA detection.  
 
Silencing PROM1 by siRNA induces apoptosis  
We used the MZ-CRC-1 cell line nucleofected with two different synthetic siRNAs against human 
PROM1 for in vitro validation. Knockdown efficiency was assessed in parallel dishes by RT-qPCR, 
and the number of apoptotic nuclei was scored as percentage of total nuclei. As shown in Figure 3 
both siRNAs caused an increase in the number of apoptotic nuclei, suggesting that PROM1 is 
necessary for the survival of these cells.  
 
Discussion 
MTC patients show relatively low survival if their carcinomas metastasize (Schlumberger 2008). 
Surgery is the primary treatment for MTC and there is a lack of alternatives for tumors with poor 
response to either conventional chemotherapy or radiotherapy (Schlumberger 2008). Thus, there is a 
pressing need to identify potential therapeutic targets. Although a genotype-phenotype correlation 
has been established for MEN2 cases and it is known that clinical behavior differs according to 
specific germline and somatic RET mutations, the signaling pathways involved in the clinical 
behavior are largely unknown. Therefore, it is important to identify pathways related to non-RET-
dependent sporadic MTC and to the most frequent pathogenic RET mutations, in order to reveal 
prognostic markers. Although this need is well recognized, there are several difficulties which have 
contributed to the lack of studies on MTC tumors. Firstly, comparisons of primary tumors versus 
normal C-cells are not possible due to the very low parafollicular cell representation (about 1%) in 
the thyroid cell mass(Khurana et al. 2004b). Besides these difficulties, it is a challenge to obtain a 
sufficiently large series of frozen MTC tissues for genomic study due to the rarity of MTC. This 
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explains why only few studies on MTC profiling were reported(Ameur et al. 2009; Jain et al. 
2004b; Lacroix et al. 2005; Musholt et al. 2005a; Watanabe et al. 2002a). Our study, based on one 
of the largest series of primary MTCs described so far, was focussed on finding differences among 
expression profiles according to the genetic condition of the MTC samples.   
 
Biomarkers and pathways specific to each genetic class   
In agreement with our finding in MTCs
634
, GAL over-expression was previously observed in PC12 
rat pheocromocytoma cell lines (Tofighi et al. 2008). GAL is involved in neuropeptide signaling, 
tumorigenesis, nervous system development and the regulation of cell proliferation; it is expressed 
in neuroblastoma and pheochromocytoma cancer cell lines, and it activates MAPK and ERK 
signaling (Berger et al. 2005; Hawes 2006; Sugimoto et al. 2009; Tofighi et al. 2008). The findings 
of the present study suggest that GAL over-expression may be involved in the development of the 
phenotype exhibited by MEN2A patients carrying a 634 germline RET mutation, who develop 
pheochromocytoma in at least 50% of cases (Eng 1996; Machens et al. 2005).  
GFRA1 (GDNF family receptor alpha 1), associated with MTCs
M918T
, is a known co-receptor of 
RET which mediates its activation through the binding of RET ligands. These  include ligands that 
are widely expressed and promote the survival of neurons during development. GFRA1 has been 
previously reported as a genetic risk factor associated with susceptibility to developing sporadic 
MTC in a case-control study (Gimm 2001), and  our results support its role in MTC development.  
DKK4 (Dickkopf-4), another gene overexpressed in MTCs
M918T
, was demonstrated to be 
significantly upregulated in colorectal cancer, and this upregulation reflected activation of the Wnt 
canonical pathway (Matsui 2009). Furthermore, KREMEN2 (kringle containing transmembrane 
protein 2) co-operates with DKK4 to regulate Wnt signaling (Mao and Niehrs 2003). KREMEN2 
was upregulated similar to DKK4 in M918T tumors included in our study. Deregulation of the Wnt 
pathway results in the development of cancer and other diseases, and Wnt/β-catenin signaling and 
JNK noncanonical pathways are implicated in RET signaling, which is activated in MTC. 
   Appendix II. Publications derived from the thesis 
 
 
  193 | P a g e  
Deregulation of the Wnt pathway specifically associated with RET
M918T
 MTC could open new 
perspectives for treatment.   
The most interesting results among the M918T group were the over-expression of LOXL2 (GEO 
accession number GSE32662) and PROM1. LOXL2 (lysyl oxidase-like 2) activates Snail/E-
cadherin and Src kinase/Focal adhesion kinase (Src/FAK) pathways, and is associated with tumor 
cell invasion. LOXL2 is linked to epithelial-mesenchymal transition (EMT), which leads to 
metastasis and lower survival rates in epithelial and neuroendocrine tumors (Peinado 2005, 2008; 
Peng et al. 2009; Ruckert et al. 2010). Increased expression of genes associated with EMT has been 
previously observed in MEN2B MTCs (Jain et al. 2004b). 
PROM1 was the gene most significantly over-expressed among the MTCs
M918T
 included in our 
series of primary tumors. PROM1 was recently reported by Zhu et al. (Zhu 2010) to be a cancer 
stem cell marker in MZ-CRC-1 cell lines harboring a M918T RET mutation. Since MTCs bearing 
the M918T RET mutation are resistant to treatment, a high PROM1 expression might be related to 
resistance to therapy. In this regard, high expression of PROM1 is associated with neural crest-
derived stem cells, and slowly differentiating cancer stem cells have been proven to be resistant to 
irradiation and cytotoxic drugs (Zhu 2010). To our knowledge, ours is the first study based on 
primary tumors pointing to a PROM1 over-expression associated with the M918T mutation. 
Another study recently showed an association of poor prognosis with a high expression of PROM1 
in medulloblastoma tumors, suggesting that it might be a potential prognostic marker  (Raso et al. 
2011). 
Immunohistochemical assessment of GFRA1 and PROM1 in the 71 FFPE MTCs revealed a 
tendency towards association of the M918T group with PROM1 over-expression.  Furthermore, 
after silencing PROM1 with two different siRNAs, we observed decreased levels of PROM1 mRNA  
which led to an increased number of apoptotic nuclei. This significant correlation between silencing 
of PROM1 and apoptosis, together with our profiling data led us to conclude that PROM1 is a 
specific biomarker for the M918T RET mutation, and its targeting seems feasible and might lead to 
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apoptotic cell death. In this regards, GO biological function analyses using FatiGO/Babelomics 
revealed that important processes such as anti-apoptotic functions, proliferation, migration, cell 
cycle and adhesion were highly associated with the M918T group. Pathway enrichment analysis of 
the M918T group using GSEA software pointed to signaling cascades mainly involved in tumor 
invasion and metastasis (NFκB, interleukin, cytokine, p38MAPK, Wnt, JAK/Stat, Notch, MAPK or 
cell adhesion), which agrees with what would be expected on the grounds of the clinical behaviour 
of M918T-related MTCs. Among these pathways, the Notch pathway is known to play an important 
role in the normal development of neuroendocrine cells, including the calcitonin producing C-cells 
of the thyroid (Cook 2010).  
 
In summary, we identified specific biomarkers related to different genetic conditions by means of 
expression analysis. The over-expression of LOXL2 and DKK4, involved in cell adhesion pathway 
and the EMT process, or the Wnt pathway respectively, as well the fact of a decrease in PROM1 
expression was associated with an increased number of apoptotic nuclei, open new therapeutic 
possibilities to improve MTC management.  
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Figure Legends:  
Figure 1. Unsupervised clustering of hybridized frozen MTC series. Partial heat map showing two 
principal branches after applying unsupervised clustering to the 49 MTCs. The first branch was 
enriched with MTC
M918T
 cases and the second with familial MTC cases, mostly with  RET
634 
mutation. Color bar, green and red, represents relative under- and over expression levels 
respectively. MTC cases were named using ID case and extensions as: S_918 (sporadic MTC with 
somatic M918T RET mutation), F_634 (familial MTC with 634 RET mutation) and S_WT (sporadic 
MTC with no RET mutation). 
Figure 2A. Differential expression analysis of MTCs
M918T
 vs MTCs
WT
 using the GEPAS package. 
The first 100 genes with a false discovery rate (FDR) <0.05 are shown, including information about 
t statistic.   
Figure 2B. Differential expression analysis of MTCs
M918T
 vs MTCs
634 
using the GEPAS package. 
The first 100 genes with a false discovery rate (FDR) <0.05 are shown, including information about 
t statistic.   
Figure 3. Top panel: Knockdown efficacy of two different siRNAs against human PROM1. MZ-
CRC-1 cells were nucleofected with either buffer or the indicated siRNAs against PROM1 
(PROM1.1 and PROM1.2). Three days later PROM1 expression was assessed by real time RT-
PCR. Bottom panel: Silencing of PROM1 causes apoptotic death of MZ-CRC-1 cells. Cells were 
nucleofected as above and three days later the number of nuclei showing apoptotic morphology was 
scored.   
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Figure 1. 
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Figure 2A. 
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Figure 2B. 
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Figure 3. 
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Supplementary Information legends: 
Supplemantary  Figure  1A.  RT-qPCR with Taqman probes of GFRA1, LOXL2, GAL, PROM1 
and DKK4 expression in an independent frozen MTC validation series.  
Supplementary Figure 1B.  RT-qPCR with Taqman probes of LOXL2 and PROM1 expression in 
an independent FFPE MTC validation series.  
Supplementary Table 1. Clinical and genetic information of the frozen MTC series.  
Supplementary table 2A. Genetic information of the TMA-1.  
Supplementary Table 2B.  General and genetic information of the tissues included in TMA-2 . 
Supplementary Table 3.  FFPE MTC series for independent validation through RT-qPCR using 
TaqMan probes. 
Supplementary Table 4A. Gene Set Enrichment Analysis (GSEA) of MTC
M918T
 vs MTC
634
. 
Enriched pathways in the M918T group. 
Supplementary Table 4B. Gene Set Enrichment Analysis (GSEA) of MTC
M918T
 vs MTC
WT
. 
Enriched pathways in the M918T group. 
Supplementary Table 5.  FatiGO/Babelomics analysis of GO biological processes. Statistically 
significant results for genes of the M918T group included in the Agilent Whole Human Genome 
Microarray 4x44K. Biological processes associated with malignant behavior are shown in bold. 
Supplementary Table 6.  Biocarta pathways in the M918T group of genes included in the Agilent 
Whole Human Genome Microarray 4x44K. Significant Biocarta terms (pvalue<0.05) from FatiGO 
analysis are shown. 
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Supplemantary  Figure  1A. 
 
Supplemantary  Figure  1B. 
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Supplementary table 1.  
 
Nº ID  Array
*
 MTC
†
  Gender 
Year 
of 
birth 
Antec. 
Germline 
mutation 
Somatic 
mutation 
Classification 
1 08T32 yes FAM F 1936 no C634R - ¨634¨ 
2 08T35 yes FAM F 1986 yes C634R - ¨634¨ 
3 08T38 yes FAM M 1966 yes C634R - ¨634¨ 
4 08T40 yes FAM M 1957 yes C634R - ¨634¨ 
5 11T258 yes FAM F 1988 yes C634S - ¨634¨ 
6 11T259 yes FAM M 1943 yes C634S - ¨634¨ 
7 08T34 yes FAM M 1973 yes C634Y - ¨634¨ 
8 09T185 yes FAM F 1955 yes C620G - - 
9 09T190 yes FAM F 1965 yes C620G - - 
10 08T41 yes FAM M 1968 yes C618S - - 
11 08T33 yes FAM F 1936 yes E 11, 10 Neg - - 
12 08T39 yes FAM M 1944 yes NA NA - 
13 09T176 yes FAM M 1967 yes NA - - 
14 08T51 yes FAM F 1976 no M918T - ¨918¨ 
15 04T238 yes S M 1944 no Neg M918T ¨918¨ 
16 04T240 yes S M 1924 no Neg M918T ¨918¨ 
17 04T241 yes S F 1979 no Neg M918T ¨918¨ 
18 04T96 yes S M 1949 no Neg M918T ¨918¨ 
19 08T31 yes S M 1949 no Neg M918T ¨918¨ 
20 08T47-1 yes S F 1948 no Neg M918T ¨918¨ 
21 08T47-2 yes S F 1948 no Neg M918T ¨918¨ 
22 08T49 yes S M 1968 no Neg M918T ¨918¨ 
23 09T87 yes S F 1949 no Neg M918T ¨918¨ 
24 09T168 yes S M 1961 no Neg M918T ¨918¨ 
25 09T171 yes S M 1938 no Neg M918T ¨918¨ 
26 09T182 yes S M 1979 no Neg M918T ¨918¨ 
27 11T260 yes S F 1929 no Neg M918T ¨918¨ 
28 08T50 yes S F 1944 no Neg Neg ¨WT¨ 
29 04T245 yes S M 1926 no Neg Neg ¨WT¨ 
30 09T28 yes S M 1968 no Neg Neg ¨WT¨ 
31 09T36 yes S M 1958 no Neg Neg ¨WT¨ 
32 09T133 yes S M 1939 no Neg Neg ¨WT¨ 
33 11T261 yes S F 1953 no Neg Neg ¨WT¨ 
34 11T266 yes S M 1955 no Neg Neg ¨WT¨ 
35 09T184 yes S F 2001 no Neg E-16 Neg ¨WT¨ 
36 09T186 yes S F 1946 no Neg E-16 Neg ¨WT¨ 
37 09T187 yes S M 1920 no Neg E-16 Neg ¨WT¨ 
38 09T188 yes S M 1941 no Neg E-16 Neg ¨WT¨ 
39 09T191 yes S M 1937 no Neg E-16 Neg ¨WT¨ 
40 09T192 yes S F 1959 no Neg E-16 Neg ¨WT¨ 
41 08T48 yes S F 1951 unknown E 11, 10 Neg E 11, 10 Neg ¨WT¨ 
42 08T42 yes S F 1963 no E 11, 10 Neg E 11, 10 Neg ¨WT¨ 
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43 04T243 yes S F 1922 no Neg unkown ¨WT¨ 
44 04T244 yes S F 1942 no Neg unkown ¨WT¨ 
45 04T247 yes S M 1937 no Neg unkown ¨WT¨ 
46 08T52 yes S F 1936 no Neg unkown ¨WT¨ 
47 04T248 yes S M 1954 unknown unkown unkown ¨WT¨ 
48 09T104 yes S M 1944 no Neg C634R - 
49 09T27 yes S M 1963 no Neg C630G - 
50 09T266 no FAM F 1979 yes C634Y - ¨634¨ 
51 11T262 no FAM F 1970 yes C634Y - ¨634¨ 
52 11T263 no FAM M 1963 yes C634Y - ¨634¨ 
53 11T265 no FAM M 1972 yes C634Y - ¨634¨ 
54 09T264 no FAM F 1947 unknown C634Y - ¨634¨ 
55 09T265 no FAM F 1966 yes C634Y - ¨634¨ 
56 11T50 no FAM F 1970 yes C634S - ¨634¨ 
57 11T65 no FAM F 1969 yes C634R - ¨634¨ 
58 11T66 no FAM F 1993 yes C634R - ¨634¨ 
59 09T170 no S M 1958 no Neg M918T ¨918¨ 
60 09T178 no S M 1947 no Neg M918T ¨918¨ 
61 11T264 no S M 1962 no Neg M918T ¨918¨ 
62 04T235 no S F 1938 no E 11, 10 Neg Neg ¨WT¨ 
63 04T242 no S M 1933 no Neg Neg ¨WT¨ 
64 04T246 no S M 1933 no Neg - ¨WT¨ 
65 09T180 no S F 1971 no Neg E-16 Neg ¨WT¨ 
66 09T181 no S M 1942 no Neg E-16 Neg ¨WT¨ 
67 09T195 no S F 1958 unknown E 11, 10 Neg Neg ¨WT¨ 
68 09T213 no S F 1944 no E 11, 10 Neg Neg ¨WT¨ 
 
* Indicate if the sample was or not hybridized onto Agilent Whole Genome 4X44K Array. Those not used 
for hybridization purposes, were used for independent validation through RT-qPCR using TaqMan probes. 
† Indicate the familial or the sporadic nature of the tumor, according to germline or somatic RET mutation 
status, as well as the existence of personal or familiar antecedents.  
Abbreviations. Gender: F, female; M, male; Antec- antecedents (personal or familiar); NA- not available; Neg 
– negative; E-10, E-11, E-16 : exon 10, exon 16 and exon 11, respectively. FAM- Familial, S-Sporadic 
 
 
Supplementary table 2A. 
  
Nº ID Tumor/tissue Somatic mutation 
Germinal 
mutation 
Normal 
thyroid 
Classification 
1 02T184 MTC - C618F   not used 
2 03T123 MTC - C618F   not used 
3 03T146 MTC - C618F   not used 
4 03T113 MTC - C634R   ¨634¨ 
5 03T114.3 MTC - C634R yes ¨634¨ 
6 03T222.2 MTC - C634R   ¨634¨ 
7 03T92 MTC - C634R   ¨634¨ 
8 01T233 MTC - C634W yes ¨634¨ 
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9 03T124.3 MTC - C634W yes ¨634¨ 
10 03T125 MTC - C634W   ¨634¨ 
11 03T116 MTC - C634Y   ¨634¨ 
12 03T127.2 MTC - C634Y   ¨634¨ 
13 03T128.2 MTC - C634Y   ¨634¨ 
14 03T81 MTC - C634Y   ¨634¨ 
15 03T82 MTC - C634Y yes ¨634¨ 
16 03T83 MTC - S891A yes not used 
17 01T180 MTC M918T Neg yes ¨918¨ 
18 02T367 MTC M918T Neg   ¨918¨ 
19 03T104 MTC M918T Neg   ¨918¨ 
20 03T120 MTC M918T Neg   ¨918¨ 
21 03T22.B MTC M918T Neg   ¨918¨ 
22 03T272 MTC M918T Neg   ¨918¨ 
23 03T85 MTC M918T Neg   ¨918¨ 
24 03T89 MTC M918T Neg   ¨918¨ 
25 03T91 MTC M918T Neg yes ¨918¨ 
26 02T326 MTC C618R Neg   not used 
27 03T247 MTC C620F Neg   not used 
28 03T122 MTC C634R Neg   not used 
29 03T147 MTC C634S Neg   not used 
30 04T288 MTC A883F Neg   not used 
31 03T121 MTC  E 10, 11, 15, 16 neg Neg   ¨WT¨ 
32 02T402 MTC  E 10, 11, 15, 16 neg Neg   ¨WT¨ 
33 03T138.1 MTC  E 10, 11, 15, 16 neg Neg yes ¨WT¨ 
34 01T189 MTC  E 10, 16 neg Neg   ¨WT¨ 
35 03T144 MTC  E 15, 16 neg Neg   ¨WT¨ 
36 03T117 MTC  E 11, 16 neg Neg   ¨WT¨ 
37 03T118 MTC  E 11, 16 neg Neg   ¨WT¨ 
38 03T119 MTC  E 11, 16 neg Neg   ¨WT¨ 
39 03T95 MTC  E 11, 16 neg Neg   ¨WT¨ 
40 03T90 MTC  E 11, 16 neg Neg yes ¨WT¨ 
41 03T84 MTC  E 16 neg Neg   ¨WT¨ 
42 03T88 MTC  E 16 neg Neg   ¨WT¨ 
43 03T94.2 MTC  E 16 neg Neg yes ¨WT¨ 
44 01T93.1 MTC  E 16 neg Neg yes ¨WT¨ 
45 03T93.1 MTC  E 16 neg Neg yes ¨WT¨ 
46 03T96 MTC  E 16 neg Neg   ¨WT¨ 
47 01T203 MTC  E 16 neg NA yes ¨WT¨ 
48 02T315 MTC Neg Neg   ¨WT¨ 
50 03T271.2 MTC Neg Neg   ¨WT¨ 
51 03T87 MTC Neg Neg   ¨WT¨ 
52 01T64 MTC Neg Neg   ¨WT¨ 
53 01T65 MTC Neg Neg   ¨WT¨ 
54 03T145 MTC NA Neg   not used 
55 03T273 MTC NA Neg   not used 
57 07T42 PDTC       control 
58 07T43.1 PTC       control 
59 07T45.1 PTC       control 
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60 07T49.1 PTC       control 
61 MC 
medulla 
cortex       
control 
62 Pl placenta       control 
Abbreviations. NA- not available; Neg – negative; E-10, E-11, E-15, E-16 : exon 10, exon 11, exon 15 and exon 
16, respectively. 
 
Supplementary Table 2B. 
 
Nº ID case Tumor 
Somatic 
mutation 
Germline 
mutation 
Normal 
thyroid 
Classification 
1 08T32 MTC - C634R yes ¨634¨ 
2 08T35 MTC - C634R yes ¨634¨ 
3 08T40 MTC - C634R yes ¨634¨ 
4 08T34 MTC - C634Y yes ¨634¨ 
5 08T36* MTC - C634Y yes ¨634¨ 
6 08T37* MTC - C634R yes ¨634¨ 
7 08T49 MTC M918T Neg yes ¨918¨ 
8 08T31 MTC M918T Neg no ¨918¨ 
9 04T96 MTC M918T Neg no ¨918¨ 
10 08T47-2 MTC M918T Neg no ¨918¨ 
11 08T48 MTC WT E 10, 11 Neg yes ¨WT¨ 
12 08T41 MTC WT E 10, 11 Neg yes ¨WT¨ 
13 08T50 MTC WT E 10, 11 Neg yes ¨WT¨ 
14 08T33 MTC Unkown E 10, 11 Neg yes ¨WT¨ 
15 08T39 MTC Unkown Unkown yes not used 
16 4020462 Hürthle cell neoplasm       control 
17 06B873  FTC       control  
*tumors not hybridized due to lack of RNA. 
Abbreviations. FTC- Follicular Thyroid Carcinoma; Neg – negative.  
 
 
Supplementary Table  3.   
 
Nº ID case Gender 
Year of 
birth 
MTC
*
 RET mutation Classification  
1 03T124.3 M 1978 Familial C634W ¨634¨ 
2 03T128.2 F 1944 Familial C634Y ¨634¨ 
3 03T116 F 1973 Familial C634Y ¨634¨ 
4 01T233 M 1982 Familial C634Y ¨634¨ 
5 03T125 F 1952 Familial C634W ¨634¨ 
6 03T127.1 M 1948 Familial C634Y ¨634¨ 
7 03T092 F 1917 Familial C634R ¨634¨ 
8 03T114.3 M 1958 Familial C634Y ¨634¨ 
9 03T113 M 1948 Familial C634R ¨634¨ 
10 03T081 M 1960 Familial C634Y ¨634¨ 
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11 03T082 F 1965 Familial C634Y ¨634¨ 
12 03T222.2 F 1959 Familial C634R ¨634¨ 
13 03T104 F 1962 Sporadic M918T ¨918¨ 
14 03T091 F 1954 Sporadic M918T ¨918¨ 
15 03T085 F 1937 Sporadic M918T ¨918¨ 
16 01T180 F 1949 Sporadic M918T ¨918¨ 
17 02T367 M 1928 Sporadic M918T ¨918¨ 
18 03T120 F 1931 Sporadic M918T ¨918¨ 
19 03T272 M 1948 Sporadic M918T ¨918¨ 
20 03T089 M 1949 Sporadic M918T ¨918¨ 
21 06T001 F 1961 Sporadic M918T ¨918¨ 
22 02T402 M 1951 Sporadic Negative WT 
23 03T121 M 1952 Sporadic Negative WT 
* Indicate the familial or the sporadic nature of the tumor, according to germline 
or somatic RET mutation status, as well as the existence of personal or familiar 
antecedents.  
Abbreviations. Gender: F, female; M, male; 
 
Supplementary Table 4A.   
 
BIOCARTA PATHWAY NAME NES NOM p-val* FDR q-val† 
TCRPATHWAY 1,766 0,002 0,053 
NKTPATHWAY 1,830 0,000 0,055 
HIVNEFPATHWAY 1,784 0,002 0,056 
INFLAMPATHWAY 1,768 0,005 0,058 
ATRBRCAPATHWAY 1,788 0,005 0,060 
STEMPATHWAY 1,833 0,004 0,066 
DEATHPATHWAY 1,732 0,005 0,066 
NO2IL12PATHWAY 1,793 0,006 0,068 
NTHIPATHWAY 1,709 0,011 0,077 
NFKBPATHWAY 1,845 0,000 0,079 
BCRPATHWAY 1,678 0,011 0,086 
IL1RPATHWAY 1,688 0,009 0,086 
RELAPATHWAY 1,667 0,017 0,087 
LAIRPATHWAY 1,640 0,013 0,103 
CASPASEPATHWAY 1,849 0,004 0,110 
DCPATHWAY 1,906 0,000 0,115 
TH1TH2PATHWAY 1,605 0,024 0,127 
TNFR1PATHWAY 1,576 0,030 0,151 
CTLA4PATHWAY 1,556 0,041 0,155 
IL12PATHWAY 1,562 0,038 0,155 
NKCELLSPATHWAY 1,531 0,032 0,175 
FMLPPATHWAY 1,513 0,033 0,189 
AMIPATHWAY 1,484 0,057 0,212 
TNFR2PATHWAY 1,476 0,063 0,212 
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ERYTHPATHWAY 1,489 0,054 0,215 
ETSPATHWAY 1,443 0,070 0,234 
P38MAPKPATHWAY 1,414 0,052 0,237 
CSKPATHWAY 1,446 0,071 0,239 
WNTPATHWAY 1,422 0,069 0,240 
CCR5PATHWAY 1,415 0,068 0,243 
IL2PATHWAY 1,405 0,078 0,243 
CYTOKINEPATHWAY 1,425 0,068 0,244 
MAPKPATHWAY 1,447 0,021 0,246 
KEGG PATHWAY NAME NES NOM p-val* FDR q-val† 
NATURAL KILLER CELL MEDIATED CYTOTOXICITY 2,276 0,000 0,001 
P53 SIGNALING PATHWAY 2,142 0,000 0,002 
TYPE I DIABETES MELLITUS 2,067 0,000 0,002 
ASTHMA 1,917 0,000 0,010 
CYTOKINE-CYTOKINE RECEPTOR INTERACTION 1,880 0,000 0,012 
APOPTOSIS 1,837 0,000 0,016 
NATURAL KILLER CELL MEDIATED CYTOTOXICITY 1,802 0,000 0,022 
HEMATOPOIETIC CELL LINEAGE 1,801 0,000 0,019 
CELL CYCLE 1,794 0,000 0,018 
ONE CARBON POOL BY FOLATE 1,777 0,004 0,019 
DNA REPLICATION 1,765 0,005 0,020 
TOLL-LIKE RECEPTOR SIGNALING PATHWAY 1,732 0,005 0,027 
T CELL RECEPTOR SIGNALING PATHWAY 1,629 0,009 0,063 
JAK-STAT SIGNALING PATHWAY 1,520 0,042 0,105 
B CELL RECEPTOR SIGNALING PATHWAY 1,519 0,021 0,140 
LEUKOCYTE TRANSENDOTHELIAL MIGRATION 1,506 0,014 0,145 
NOTCH SIGNALING PATHWAY 1,505 0,030 0,135 
PATHOGENIC ESCHERICHIA COLI INFECTION-EHEC 1,485 0,021 0,148 
PYRIMIDINE METABOLISM 1,461 0,009 0,166 
COMPLEMENT AND COAGULATION CASCADES 1,458 0,029 0,159 
* NOM p-value is the significance of the normalized enrichment score (NES); †FDR q-val is the false discovery rate (FDR), the estimated 
probability that a gene set with a given NES represents a false positive finding; The GSEA analysis report highlights enriched gene sets 
with an FDR of less than 25%. 
 
Supplementary Table 4B. 
 
BIOCARTA PATHWAY NAME NES NOM p-val* FDR q-val† 
CYTOKINEPATHWAY 2,153 0,000 0,000 
COMPPATHWAY 2,139 0,000 0,001 
DCPATHWAY 2,090 0,000 0,005 
LAIRPATHWAY 2,020 0,000 0,008 
INFLAMPATHWAY 1,998 0,000 0,007 
NKTPATHWAY 1,990 0,000 0,006 
ERYTHPATHWAY 1,931 0,002 0,014 
STEMPATHWAY 1,797 0,004 0,053 
NKCELLSPATHWAY 1,715 0,015 0,100 
GCRPATHWAY 1,697 0,013 0,105 
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FMLPPATHWAY 1,651 0,008 0,132 
RAC1PATHWAY 1,611 0,025 0,164 
CXCR4PATHWAY 1,593 0,019 0,172 
TH1TH2PATHWAY 1,590 0,024 0,164 
IL1RPATHWAY 1,527 0,030 0,233 
SPPAPATHWAY 1,517 0,037 0,233 
KEGG PATHWAY NAME NES NOM p-val* FDR q-val† 
COMPLEMENT AND COAGULATION CASCADES 2,430 0,000 0,000 
ASTHMA 2,160 0,000 0,001 
TYPE I DIABETES MELLITUS 2,118 0,000 0,001 
PROTEASOME 1,923 0,000 0,013 
HEMATOPOIETIC CELL LINEAGE 1,772 0,000 0,045 
PORPHYRIN AND CHLOROPHYLL METABOLISM 1,771 0,002 0,037 
CYTOKINE-CYTOKINE RECEPTOR INTERACTION 1,732 0,000 0,047 
PATHOGENIC ESCHERICHIA COLI INFECTION 1,728 0,000 0,042 
PYRIMIDINE METABOLISM 1,698 0,000 0,047 
P53 SIGNALING PATHWAY 1,680 0,002 0,049 
ANDROGEN AND ESTROGEN METABOLISM 1,673 0,002 0,047 
PENTOSE AND GLUCURONATE INTERCONVERSIONS 1,664 0,013 0,047 
NICOTINATE AND NICOTINAMIDE METABOLISM 1,607 0,018 0,071 
CELL CYCLE 1,603 0,004 0,068 
MAPK SIGNALING PATHWAY 1,614 0,012 0,092 
TOLL-LIKE RECEPTOR SIGNALING PATHWAY 1,550 0,004 0,098 
APOPTOSIS 1,500 0,007 0,132 
DNA REPLICATION 1,498 0,030 0,126 
ARGININE AND PROLINE METABOLISM 1,493 0,039 0,124 
CELL ADHESION MOLECULES (CAMS) 1,445 0,041 0,153 
RENIN-ANGIOTENSIN SYSTEM 1,433 0,074 0,174 
PARKINSON'S DISEASE 1,398 0,080 0,210 
GAP JUNCTION 1,389 0,031 0,212 
LONG-TERM DEPRESSION  1,360 0,031 0,244 
CITRATE CYCLE (TCA CYCLE) 1,355 0,095 0,242 
 
*
NOM p-value is the significance of the normalized enrichment score (NES); 
†
FDR q-val is the false discovery 
rate (FDR), the estimated probability that a gene set with a given NES represents a false positive finding. The 
GSEA analysis report highlights enriched gene sets with an FDR of less than 25%. Pathways are ranked by the 
FRD q-value. 
 
   Supplementary Table 5. 
 
Nº Term (GO) M918T gene list 
odds_ratio 
_log 
pvalue adj_pvalue 
1 
muscle organ 
development 
(GO:0007517) 
FAM65B,TNNI3,SPIB,MEOX2,EZH2,PAX7 1,92 3,85E-04 2,88E-02 
2 
organ morphogenesis 
(GO:0009887) 
TNNI3,SPIB,CDH13,HOXC8,TNF,PDGFRA,CHST11, 
MEOX2,ONECUT2,RUNX2,PITX2,SHC1 
1,78 3,23E-06 1,50E-03 
3 
tissue development 
(GO:0009888) 
TNNI3,SPIB,IKZF1,TNF,CHST11,NRTN,MEOX2, 
ONECUT2,RUNX2,EZH2,PAX7 
1,67 2,08E-05 4,36E-03 
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4 
negative regulation of 
cytokine production 
(GO:0001818) 
SPIB,TNF,CIDEA 3,08 4,68E-04 3,26E-02 
5 
chondrocyte 
differentiation 
(GO:0002062) 
SPIB,CHST11,RUNX2 3,04 5,24E-04 3,33E-02 
6 
myeloid leukocyte 
differentiation 
(GO:0002573) 
SPIB,IKZF1,TNF,RELB,IFI16 3,01 8,59E-06 2,10E-03 
7 
DNA metabolic process 
(GO:0006259) 
SPIB,FANCI,PDGFRA,ESCO2,CIDEA,TYMS,SHC1,TERT 1,55 5,13E-04 3,33E-02 
8 
DNA replication 
(GO:0006260) 
SPIB,PDGFRA,TYMS,SHC1,TERT 1,95 1,01E-03 4,83E-02 
9 
protein amino acid 
phosphorylation 
(GO:0006468) 
SPIB,NEK2,GSG2,TNF,PIM2,TRIB2,ADRA2A,STK17B, 
PDGFRA,SHC1 
1,43 3,05E-04 2,70E-02 
10 
anti-apoptosis 
(GO:0006916) 
SPIB,CDH13,TNF,IL2RB,PIM2,PAX7,TERT 2,31 1,24E-05 2,79E-03 
11 
induction of apoptosis 
(GO:0006917) 
SPIB,TNF,CASP4,STK17B,BID,CIDEA,IFI16 2,15 3,18E-05 5,82E-03 
12 
cellular component 
movement 
(GO:0006928) 
SPIB,CDH13,TNF,ADRA2A,PDGFRA,NRTN,ONECUT2 
,MTSS1 
1,44 1,07E-03 4,94E-02 
13 
cytoskeleton 
organization 
(GO:0007010) 
SPIB,NEK2,CXCL1,ADRA2A,ARHGAP4,MTSS1,SHC1 1,61 8,24E-04 4,26E-02 
14 cell cycle (GO:0007049) 
SPIB,NEK2,GSG2,TNF,PIM2,FANCI,GAS2L1,ESCO2, 
HMGA2 
1,34 1,04E-03 4,92E-02 
15 
cell adhesion 
(GO:0007155) 
SPIB,SIRPG,CDH13,SDK1,TNF,ONECUT2,CLEC4M, 
MTSS1,SHC1,LOXL2 
1,41 3,68E-04 2,83E-02 
16 
leukocyte adhesion 
(GO:0007159) 
SPIB,TNF,CLEC4M 3,14 3,93E-04 2,88E-02 
17 
enzyme linked receptor 
protein signaling 
pathway (GO:0007167) 
SPIB,CDH13,STAP1,PDGFRA,CHST11,CIDEA,NRTN 
,ONECUT2,RUNX2,MTSS1,SHC1 
2,19 1,64E-07 1,60E-04 
18 
transmembrane 
receptor protein 
tyrosine kinase signaling 
pathway (GO:0007169) 
SPIB,CDH13,STAP1,PDGFRA,NRTN,RUNX2,MTSS1, 
SHC1 
2,25 4,62E-06 1,50E-03 
19 
transforming growth 
factor beta receptor 
signaling pathway 
(GO:0007179) 
SPIB,CHST11,CIDEA,ONECUT2 2,56 3,56E-04 2,83E-02 
20 
protein kinase cascade 
(GO:0007243) 
SPIB,GSG2,TNF,ADRA2A,STK17B,NRTN,HMGA2,SHC
1 
1,67 2,41E-04 2,28E-02 
21 
Rho protein signal 
transduction 
(GO:0007266) 
SPIB,CDH13,ADRA2A,ARHGAP4 2,24 1,12E-03 4,95E-02 
22 
pattern specification 
process (GO:0007389) 
SPIB,MFNG,RAX,HOXC8,MEOX2,PAX7,PITX2 2,16 2,99E-05 5,82E-03 
23 aging (GO:0007568) SPIB,SHC1,TERT,LOXL2 2,33 8,30E-04 4,26E-02 
24 
positive regulation of cell 
proliferation 
(GO:0008284) 
SPIB,SIRPG,CDH13,TNF,ADRA2A,PDGFRA,RUNX2,SH
C1 
1,91 5,07E-05 7,81E-03 
25 
negative regulation of 
cell proliferation 
(GO:0008285) 
SPIB,SIRPG,CDH13,CXCL1,TNF,RERG 1,73 1,00E-03 4,83E-02 
26 
apoptotic mitochondrial 
changes (GO:0008637) 
SPIB,PIM2,BID 3,21 3,26E-04 2,73E-02 
27 
negative regulation of 
metabolic process 
(GO:0009892) 
SPIB,IKZF1,HOXC8,TNF,IGF2BP2,CIDEA,RUNX2,HMG
A2 
1,43 1,09E-03 4,94E-02 
28 
positive regulation of 
metabolic process 
(GO:0009893) 
SPIB,IKZF1,CDH13,TNF,IL2RB,PDGFRA,ONECUT2,RU
NX2,SHC1 
1,38 7,97E-04 4,24E-02 
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29 
regulation of signal 
transduction 
(GO:0009966) 
SPIB,CDH13,TNF,DKK4,TRIB2,ADRA2A,CHST11,CIDEA
,ONECUT2, 
RUNX2,HMGA2,SHC1 
1,68 8,33E-06 2,10E-03 
30 
negative regulation of 
signal transduction 
(GO:0009968) 
SPIB,DKK4,CHST11,CIDEA,ONECUT2,RUNX2,HMGA2 2,42 6,16E-06 1,80E-03 
31 
positive regulation of cell 
death (GO:0010942) 
SPIB,TNF,CASP4,STK17B,BID,CIDEA,IFI16 1,83 2,27E-04 2,28E-02 
32 
peptide transport 
(GO:0015833) 
SPIB,CPLX3,TNF,TAP1,CLEC4M 2,67 4,07E-05 6,61E-03 
33 
cell-cell adhesion 
(GO:0016337) 
SPIB,SIRPG,CDH13,TNF,CLEC4M,SHC1 1,93 3,66E-04 2,83E-02 
34 
regulation of cell-cell 
adhesion (GO:0022407) 
SPIB,SIRPG,TNF 3,26 2,85E-04 2,61E-02 
35 
positive regulation of 
cell-cell adhesion 
(GO:0022409) 
SPIB,SIRPG,TNF 3,75 7,30E-05 1,02E-02 
36 
cell projection assembly 
(GO:0030031) 
SPIB,CDH13,ONECUT2,MTSS1 2,39 6,52E-04 3,74E-02 
37 
myeloid cell 
differentiation 
(GO:0030099) 
SPIB,IKZF1,TNF,RELB,IFI16 2,28 2,40E-04 2,28E-02 
38 
regulation of cell 
adhesion (GO:0030155) 
SPIB,SIRPG,CDH13,TNF,ONECUT2 2,45 1,08E-04 1,27E-02 
39 
positive regulation of 
cell migration 
(GO:0030335) 
SPIB,CDH13,PDGFRA,ONECUT2 2,51 4,32E-04 3,08E-02 
40 
cellular response to DNA 
damage stimulus 
(GO:0034984) 
SPIB,FANCI,ESCO2,CIDEA,IFI16,TYMS 1,73 9,90E-04 4,83E-02 
41 
regulation of growth 
(GO:0040008) 
SPIB,IKZF1,CDH13,ESM1,HMGA2,RERG,SHC1 1,99 8,81E-05 1,17E-02 
42 
regulation of cell 
proliferation 
(GO:0042127) 
SPIB,SIRPG,CDH13,CXCL1,TNF,ADRA2A,PDGFRA,CH
ST11,RUNX2,RERG,PTGER2,SHC1 
1,76 3,91E-06 1,50E-03 
43 
vitamin D biosynthetic 
process (GO:0042368) 
SPIB,TNF 4,07 7,38E-04 4,06E-02 
44 
odontogenesis of 
dentine-containing tooth 
(GO:0042475) 
SPIB,PDGFRA,RUNX2 2,83 9,42E-04 4,75E-02 
45 
regulation of apoptosis 
(GO:0042981) 
SPIB,CDH13,TNF,IL2RB,PIM2,CASP5,CASP4,STK17B,C
HST11,BID,CIDEA,PAX7,IFI16,TERT 
1,94 8,91E-08 1,45E-04 
46 
positive regulation of 
apoptosis (GO:0043065) 
SPIB,TNF,CASP4,STK17B,BID,CIDEA,IFI16 1,84 2,08E-04 2,25E-02 
47 
negative regulation of 
apoptosis (GO:0043066) 
SPIB,CDH13,TNF,IL2RB,PIM2,CHST11,CIDEA,PAX7,T
ERT 
2,13 3,18E-06 1,50E-03 
48 
regulation of 
programmed cell death 
(GO:0043067) 
SPIB,CDH13,TNF,IL2RB,PIM2,CASP5,CASP4,STK17B,C
HST11,BID,CIDEA,PAX7,IFI16,TERT 
1,93 9,90E-08 1,45E-04 
49 
positive regulation of 
programmed cell death 
(GO:0043068) 
SPIB,TNF,CASP4,STK17B,BID,CIDEA,IFI16 1,84 2,17E-04 2,27E-02 
50 
negative regulation of 
programmed cell death 
(GO:0043069) 
SPIB,CDH13,TNF,IL2RB,PIM2,CHST11,CIDEA,PAX7,TE
RT 
2,12 3,44E-06 1,50E-03 
51 
positive regulation of 
DNA replication 
(GO:0045740) 
SPIB,PDGFRA,SHC1 3,06 4,96E-04 3,30E-02 
52 
positive regulation of cell 
adhesion (GO:0045785) 
SPIB,SIRPG,CDH13,TNF 2,84 1,27E-04 1,43E-02 
53 
smooth muscle cell 
proliferation 
(GO:0048659) 
SPIB,CDH13,TNF,SHC1 2,89 1,06E-04 1,27E-02 
54 
regulation of smooth 
muscle cell proliferation 
SPIB,CDH13,TNF,SHC1 2,93 9,23E-05 1,17E-02 
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(GO:0048660) 
55 
positive regulation of 
smooth muscle cell 
proliferation 
(GO:0048661) 
SPIB,CDH13,TNF,SHC1 3,19 3,44E-05 5,92E-03 
56 
skeletal system 
morphogenesis 
(GO:0048705) 
SPIB,HOXC8,PDGFRA,CHST11,RUNX2 2,58 5,97E-05 8,74E-03 
57 
cytokine secretion 
(GO:0050663) 
SPIB,TNF,CIDEA 3,02 5,53E-04 3,37E-02 
58 
regulation of 
developmental process 
(GO:0050793) 
SPIB,IKZF1,CDC42SE1,CDH13,TNF,IL2RB,PIM2,CHST1
1,CIDEA,RUNX2,EZH2,PAX7,TERT 
1,67 4,49E-06 1,50E-03 
59 
cartilage development 
(GO:0051216) 
SPIB,CHST11,RUNX2,PAX7 2,59 3,22E-04 2,73E-02 
60 
negative regulation of 
protein transport 
(GO:0051224) 
SPIB,TNF,CIDEA 2,91 7,49E-04 4,06E-02 
61 
positive regulation of 
cellular component 
movement 
(GO:0051272) 
SPIB,CDH13,PDGFRA,ONECUT2 2,44 5,50E-04 3,37E-02 
62 
centrosome separation 
(GO:0051299) 
SPIB,NEK2 4,16 6,34E-04 3,71E-02 
63 
negative regulation of 
amino acid transport 
(GO:0051956) 
SPIB,TNF 3,85 1,10E-03 4,94E-02 
64 
palate development 
(GO:0060021) 
SPIB,PDGFRA,MEOX2 3,06 4,96E-04 3,30E-02 
65 
limb development 
(GO:0060173) 
SPIB,RAX,CHST11,MEOX2 2,39 6,70E-04 3,77E-02 
66 
positive regulation of 
calcidiol 1- (GO:0060559) 
SPIB,TNF 4,16 6,34E-04 3,71E-02 
 
Supplementary Table 6. 
Nº Term (Biocarta Pathway) M918T gene list odds_ratio_log pvalue adj_pvalue 
1 
Angiotensin II mediated activation of JNK Pathway via Pyk2 
dependent signaling (h_At1rPathway) SPIB,SHC1 3,302 3,07E-03 2,57E-02 
2 BCR Signaling Pathway (h_bcrPathway) SPIB,SHC1 3,028 5,06E-03 3,28E-02 
3 
Bioactive Peptide Induced Signaling Pathway 
(h_biopeptidesPathway) SPIB,SHC1 3,202 3,68E-03 2,57E-02 
4 
CBL mediated ligand-induced downregulation of EGF receptors 
(h_cblPathway) SPIB,PDGFRA 4,168 6,78E-04 2,11E-02 
5 
Cadmium induces DNA synthesis and proliferation in 
macrophages (h_cdMacPathway) SPIB,TNF 3,945 9,89E-04 2,11E-02 
6 
Apoptotic Signaling in Response to DNA Damage 
(h_chemicalPathway) SPIB,BID 3,682 1,56E-03 2,12E-02 
7 Cytokine Network (h_cytokinePathway) SPIB,TNF 3,762 1,36E-03 2,12E-02 
8 
Induction of apoptosis through DR3 and DR4/5 Death Receptors 
(h_deathPathway) SPIB,BID 3,156 4,01E-03 2,66E-02 
9 Phospholipids as signalling intermediaries (h_edg1Pathway) SPIB,PDGFRA 3,302 3,07E-03 2,57E-02 
10 EGF Signaling Pathway (h_egfPathway) SPIB,SHC1 3,414 2,52E-03 2,57E-02 
11 EPO Signaling Pathway (h_epoPathway) SPIB,SHC1 3,682 1,56E-03 2,12E-02 
12 Role of Erk5 in Neuronal Survival (h_erk5Pathway) SPIB,SHC1 3,849 1,17E-03 2,11E-02 
13 Fc Epsilon Receptor I Signaling in Mast Cells (h_fcer1Pathway) SPIB,SHC1 2,845 7,06E-03 4,17E-02 
14 Growth Hormone Signaling Pathway (h_ghPathway) SPIB,SHC1 3,202 3,68E-03 2,57E-02 
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15 
Adhesion and Diapedesis of Granulocytes 
(h_granulocytesPathway) SPIB,TNF 3,945 9,89E-04 2,11E-02 
16 Calcium Signaling by HBx of Hepatitis B virus (h_HBxPathway) SPIB,SHC1 5,149 1,53E-04 1,04E-02 
17 
Role of ERBB2 in Signal Transduction and Oncology 
(h_her2Pathway) SPIB,SHC1 3,251 3,37E-03 2,57E-02 
18 HIV-I Nef (h_HivnefPathway) SPIB,TNF,BID 2,949 6,98E-04 2,11E-02 
19 Stress Induction of HSP Regulation (h_hsp27Pathway) SPIB,TNF 3,945 9,89E-04 2,11E-02 
20 IGF-1 Signaling Pathway (h_igf1Pathway) SPIB,SHC1 3,539 2,01E-03 2,38E-02 
21 
Multiple antiapoptotic pathways from IGF-1R signaling lead to 
BAD phosphorylation (h_igf1rPathway) SPIB,SHC1 3,302 3,07E-03 2,57E-02 
22 Signal transduction through IL1R (h_il1rPathway) SPIB,TNF 3,202 3,68E-03 2,57E-02 
23 IL 2 signaling pathway (h_il2Pathway) SPIB,IL2RB,SHC1 4,025 3,87E-05 1,02E-02 
24 Cytokines and Inflammatory Response (h_inflamPathway) SPIB,TNF 3,302 3,07E-03 2,57E-02 
25 Insulin Signaling Pathway (h_insulinPathway) SPIB,SHC1 3,539 2,01E-03 2,38E-02 
26 Integrin Signaling Pathway (h_integrinPathway) SPIB,SHC1 3,156 4,01E-03 2,66E-02 
27 Keratinocyte Differentiation (h_keratinocytePathway) SPIB,TNF 2,879 6,63E-03 4,01E-02 
28 NF-kB Signaling Pathway (h_nfkbPathway) SPIB,TNF 3,682 1,56E-03 2,12E-02 
29 Nerve growth factor pathway (NGF) (h_ngfPathway) SPIB,SHC1 3,357 2,79E-03 2,57E-02 
30 p38 MAPK Signaling Pathway (h_p38mapkPathway) SPIB,SHC1 3,202 3,68E-03 2,57E-02 
31 PDGF Signaling Pathway (h_pdgfPathway) SPIB,PDGFRA,SHC1 3,773 7,48E-05 1,02E-02 
32 Regulation of transcriptional activity by PML (h_pmlPathway) SPIB,TNF 3,849 1,17E-03 2,11E-02 
33 Links between Pyk2 and Map Kinases (h_pyk2Pathway) SPIB,SHC1 3,302 3,07E-03 2,57E-02 
34 
Acetylation and Deacetylation of RelA in The Nucleus 
(h_RELAPathway) SPIB,TNF 4,168 6,78E-04 2,11E-02 
35 SODD/TNFR1 Signaling Pathway (h_soddPathway) SPIB,TNF 4,301 5,43E-04 2,11E-02 
36 Sprouty regulation of tyrosine kinase signals (h_spryPathway) SPIB,SHC1 3,762 1,36E-03 2,12E-02 
37 TNF/Stress Related Signaling (h_stressPathway) SPIB,TNF 3,608 1,78E-03 2,30E-02 
38 T Cell Receptor Signaling Pathway (h_tcrPathway) SPIB,SHC1 2,879 6,63E-03 4,01E-02 
39 
Chaperones modulate interferon Signaling Pathway 
(h_tidPathway) SPIB,TNF 4,301 5,43E-04 2,11E-02 
40 TNFR1 Signaling Pathway (h_tnfr1Pathway) SPIB,TNF 3,251 3,37E-03 2,57E-02 
41 TPO Signaling Pathway (h_TPOPathway) SPIB,SHC1 3,357 2,79E-03 2,57E-02 
42 Trka Receptor Signaling Pathway (h_trkaPathway) SPIB,SHC1 3,849 1,17E-03 2,11E-02 
43 VEGF, Hypoxia, and Angiogenesis (h_vegfPathway) SPIB,SHC1 3,202 3,68E-03 2,57E-02 
44 Wnt/LRP6 Signalling (h_wnt-lrp6Pathway) SPIB,KREMEN2 5,149 1,53E-04 1,04E-02 
45 IL-2 Receptor Beta Chain in T cell Activation (h_il2rbPathway) IL2RB,SHC1 2,879 6,63E-03 4,01E-02 
46 Erk1/Erk2 Mapk Signaling pathway (h_erkPathway) PDGFRA,SHC1 3,251 3,37E-03 2,57E-02 
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1. Cancer Res. 2012 Jul 17. [Epub ahead of print] 
 
The hematologic-specific β-tubulin VI exhibits genetic variability influencing paclitaxel 
toxicity. 
Leandro-García LJ, Leskelä S, Inglada-Perez L, Landa I, de Cubas AA, Maliszewska A, Comino-
Méndez I, Letón R, Gómez-Graña A, Torres R, Ramírez JC, Alvarez S, Rivera J, Martinez C, Lozano 
ML, Cascon A, Robledo M and Rodríguez-Antona C.  
 
Cellular microtubules composed of α-β-tubulin heterodimers that are essential for cell 
shape, division and intracellular transport are valid targets for anticancer therapy. 
However, not all the conserved but differentially expressed members of the β-tubulin 
gene superfamily have been investigated for their role in these settings. In this study, we 
examined roles for the hematologic isoform β-tubulin VI and functional genetic variants in 
the gene. β-tubulin VI was highly expressed in blood cells with a substantial interindividual 
variability (7-fold variation in mRNA). We characterized DNA missense variations leading 
to Q43P, T274M and R307H, and a rare nonsense variant, Y55X. Since variations in the 
hematologic target of microtubule binding drugs might alter their myelosuppressive 
action, we tested their effect in cell lines stably expressing the different β-tubulin VI full 
length variants, finding that the T274M change significantly decreased sensitivity to 
paclitaxel-induced tubulin polymerization. Furthermore, patients treated with paclitaxel 
and carrying β-tubulin VI T274M exhibited a significant reduction in thrombocytopenia 
than wild-type homozygous patients (P=0.031). Together, our findings define β-tubulin VI 
as a hematologic isotype with significant genetic variation in humans that may affect the 
myelosuppresive action of microtubule-binding drugs. 
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2. Clin Cancer Res. 2012 Jul 13. [Epub ahead of print] 
 
Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced 
Peripheral Neuropathy. 
Leandro-García LJ, Leskelä S, Jara C, Gréen H, Avall-Lundqvist E, Wheeler HE, Dolan ME, Inglada-
Perez L, Maliszewska A, de Cubas AA, Comino-Méndez I, Mancikova V, Cascón A, Robledo M, 
Rodríguez-Antona C. 
 
PURPOSE: Peripheral neuropathy is the dose-limiting toxicity of paclitaxel, a 
chemotherapeutic drug widely used to treat several solid tumors such as breast, lung, and 
ovary. The cytotoxic effect of paclitaxel is mediated through β-tubulin binding in the 
cellular microtubules. In this study, we investigated the association between paclitaxel 
neurotoxicity risk and regulatory genetic variants in β-tubulin genes. 
EXPERIMENTAL DESIGN: We measured variation in gene expression of three β-tubulin 
isotypes (I, IVb, and IIa) in lymphocytes from 100 healthy volunteers, sequenced the 
promoter region to identify polymorphisms putatively influencing gene expression and 
assessed the transcription rate of the identified variants using luciferase assays. To 
determine whether the identified regulatory polymorphisms were associated with 
paclitaxel neurotoxicity, we genotyped them in 214 patients treated with paclitaxel. In 
addition, paclitaxel-induced cytotoxicity in lymphoblastoid cell lines was compared with β-
tubulin expression as measured by Affymetrix exon array. 
RESULTS: We found a 63-fold variation in β-tubulin IIa gene (TUBB2A) mRNA content and 
three polymorphisms located at -101, -112, and -157 in TUBB2A promoter correlated with 
increased mRNA levels. The -101 and -112 variants, in total linkage disequilibrium, 
conferred TUBB2A increased transcription rate. Furthermore, these variants protected 
from paclitaxel-induced peripheral neuropathy [HR, 0.62; 95% confidence interval (CI), 
0.42-0.93; P = 0.021, multivariable analysis]. In addition, an inverse correlation between 
TUBB2A and paclitaxel-induced apoptosis (P = 0.001) in lymphoblastoid cell lines further 
supported that higher TUBB2A gene expression conferred lower paclitaxel sensitivity. 
CONCLUSIONS: This is the first study showing that paclitaxel neuropathy risk is influenced 
by polymorphisms regulating the expression of a β-tubulin gene. 
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3. Hum Pathol. 2012 Jul;43(7):1103-12. Epub 2011 Dec 29. 
 
Thyroid paraganglioma. Report of 3 cases and description of an immunohistochemical 
profile useful in the differential diagnosis with medullary thyroid carcinoma, based on 
complementary DNA array results. 
Castelblanco E, Gallel P, Ros S, Gatius S, Valls J, De-Cubas AA, Maliszewska A, Yebra-Pimentel MT, 
Menarguez J, Gamallo C, Opocher G, Robledo M, Matias-Guiu X. 
 
Thyroid paraganglioma is a rare disorder that sometimes poses problems in differential 
diagnosis with medullary thyroid carcinoma. So far, differential diagnosis is solved with 
the help of some markers that are frequently expressed in medullary thyroid carcinoma 
(thyroid transcription factor 1, calcitonin, and carcinoembryonic antigen). However, some 
of these markers are not absolutely specific of medullary thyroid carcinoma and may be 
expressed in other tumors. Here we report 3 new cases of thyroid paraganglioma and 
describe our strategy to design a diagnostic immunohistochemical battery. First, we 
performed a comparative analysis of the expression profile of head and neck 
paragangliomas and medullary thyroid carcinoma, obtained after complementary DNA 
array analysis of 2 series of fresh-frozen samples of paragangliomas and medullary thyroid 
carcinoma, respectively. Seven biomarkers showing differential expression were selected 
(nicotinamide adenine dinucleotide dehydrogenase 1 alpha subcomplex, 4-like 2, 
NDUFA4L2; cytochrome c oxidase subunit IV isoform 2; vesicular monoamine transporter 
2; calcitonin gene-related protein/calcitonin; carcinoembryonic antigen; and thyroid 
transcription factor 1) for immunohistochemical analysis. Two tissue microarrays were 
constructed from 2 different series of paraffin-embedded samples of paragangliomas and 
medullary thyroid carcinoma. We provide a classifying rule for differential diagnosis that 
combines negativity or low staining for calcitonin gene-related protein (histologic score, 
<10) or calcitonin (histologic score, <50) together with positivity of any of NADH 
dehydrogenase 1 alpha subcomplex, 4-like 2; cytochrome c oxidase subunit IV isoform 2; 
or vesicular monoamine transporter 2 to predict paragangliomas, showing a prediction 
error of 0%. Finally, the immunohistochemical battery was checked in paraffin-embedded 
blocks from 4 examples of thyroid paraganglioma (1 previously reported case and 3 new 
cases), showing also a prediction error of 0%. Our results suggest that the comparative 
expression profile, obtained by complementary DNA arrays, seems to be a good tool to 
design immunohistochemical batteries used in differential diagnosis. 
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4. Oncogene. 2011 Dec 12. doi: 10.1038/onc.2011.556. [Epub ahead of print] 
 
Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma. 
 
Macià A, Gallel P, Vaquero M, Gou-Fabregas M, Santacana M, Maliszewska A, Robledo M, Gardiner 
JR, Basson MA, Matias-Guiu X, Encinas M. 
Medullary thyroid carcinoma (MTC) is a malignancy derived from the calcitonin-producing 
C-cells of the thyroid gland. Oncogenic mutations of the Ret proto-oncogene are found in 
all heritable forms of MTC and roughly one half of the sporadic cases. However, several 
lines of evidence argue for the existence of additional genetic lesions necessary for the 
development of MTC. Sprouty (Spry) family of genes is composed of four members in 
mammals (Spry1-4). Some Spry family members have been proposed as candidate tumor-
suppressor genes in a variety of cancerous pathologies. In this work, we show that 
targeted deletion of Spry1 causes C-cell hyperplasia, a precancerous lesion preceding 
MTC, in young adult mice. Expression of Spry1 restrains proliferation of the MTC-derived 
cell line, TT. Finally, we found that the Spry1 promoter is frequently methylated in MTC 
and that Spry1 expression is consequently decreased. These findings identify Spry1 as a 
candidate tumor-suppressor gene in MTC. 
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5. Nat Genet. 2011 Jun 19;43(7):663-7. doi: 10.1038/ng.861. 
Exome sequencing identifies MAX mutations as a cause of hereditary 
pheochromocytoma. 
 
Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, Landa I, Leandro-García LJ, Letón R, Honrado E, 
Ramos-Medina R, Caronia D, Pita G, Gómez-Graña A, de Cubas AA, Inglada-Pérez L, Maliszewska A, 
Taschin E, Bobisse S, Pica G, Loli P, Hernández-Lavado R, Díaz JA, Gómez-Morales M, González-
Neira A, Roncador G, Rodríguez-Antona C, Benítez J, Mannelli M, Opocher G, Robledo M, Cascón A. 
 
Hereditary pheochromocytoma (PCC) is often caused by germline mutations in one of nine 
susceptibility genes described to date, but there are familial cases without mutations in 
these known genes. We sequenced the exomes of three unrelated individuals with 
hereditary PCC (cases) and identified mutations in MAX, the MYC associated factor X gene. 
Absence of MAX protein in the tumors and loss of heterozygosity caused by uniparental 
disomy supported the involvement of MAX alterations in the disease. A follow-up study of 
a selected series of 59 cases with PCC identified five additional MAX mutations and 
suggested an association with malignant outcome and preferential paternal transmission 
of MAX mutations. The involvement of the MYC-MAX-MXD1 network in the development 
and progression of neural crest cell tumors is further supported by the lack of functional 
MAX in rat PCC (PC12) cells and by the amplification of MYCN in neuroblastoma and 
suggests that loss of MAX function is correlated with metastatic potential. 
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6. Mol Endocrinol. 2010 Dec;24(12):2382-91. Epub 2010 Oct 27. 
Research resource: Transcriptional profiling reveals different pseudohypoxic signatures 
in SDHB and VHL-related pheochromocytomas. 
 
López-Jiménez E, Gómez-López G, Leandro-García LJ, Muñoz I, Schiavi F, Montero-Conde C, de 
Cubas AA, Ramires R, Landa I, Leskelä S, Maliszewska A, Inglada-Pérez L, de la Vega L, Rodríguez-
Antona C, Letón R, Bernal C, de Campos JM, Diez-Tascón C, Fraga MF, Boullosa C, Pisano DG, 
Opocher G, Robledo M, Cascón A. 
The six major genes involved in hereditary susceptibility for pheochromocytoma 
(PCC)/paraganglioma (PGL) (RET, VHL, NF1, SDHB, SDHC, and SDHD) have been recently 
integrated into the same neuronal apoptotic pathway where mutations in any of these 
genes lead to cell death. In this model, prolyl hydroxylase 3 (EglN3) abrogation plays a 
pivotal role, but the molecular mechanisms underlying its inactivation are currently 
unknown. The aim of the study was to decipher specific alterations associated with the 
different genetic classes of PCCs/PGLs. With this purpose, 84 genetically characterized 
tumors were analyzed by means of transcriptional profiling. The analysis revealed a 
hypoxia-inducible factor (HIF)-related signature common to succinate dehydrogenase 
(SDH) and von Hippel-Lindau (VHL) tumors, that differentiated them from RET and 
neurofibromatosis type 1 cases. Both canonical HIF-1α and HIF-2α target genes were 
overexpressed in the SDH/VHL cluster, suggesting that a global HIF deregulation accounts 
for this common profile. Nevertheless, when we compared VHL tumors with SDHB cases, 
which often exhibit a malignant behavior, we found that HIF-1α target genes showed a 
predominant activation in the VHL PCCs. Expression data from 67 HIF target genes was 
sufficient to cluster SDHB and VHL tumors into two different groups, demonstrating 
different pseudo-hypoxic signatures. In addition, VHL-mutated tumors showed an 
unexpected overexpression of EglN3 mRNA that did not lead to significantly different 
EglN3 protein levels. These findings pave the way for more specific therapeutic 
approaches for malignant PCCs/PGLs management based on the patient's genetic 
alteration. 
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7. Horm Metab Res. 2009 Sep;41(9):672-5. Epub 2009 Apr 2. 
Rationalization of genetic testing in patients with apparently sporadic 
pheochromocytoma/paraganglioma. 
 
Cascón A, López-Jiménez E, Landa I, Leskelä S, Leandro-García LJ, Maliszewska A, Letón R, de la 
Vega L, García-Barcina MJ, Sanabria C, Alvarez-Escolá C, Rodríguez-Antona C, Robledo M. 
 
Hereditary susceptibility to pheochromocytoma (PCC) and paraganglioma (PGL) 
represents a very complex genetic scenario. It has been reported that the absence of 
familial antecedents of the disease does not preclude the existence of a mutation 
affecting any of the five major susceptibility genes. In fact, 11-24% of apparently sporadic 
cases (without familial or syndromic antecedents) harbor an unexpected germline 
mutation, but we do not know what is happening in "truly apparently" sporadic patients 
(i.e., apparently sporadic cases diagnosed with only one tumor). In the present study, we 
have analyzed 135 apparently sporadic patients developing a single tumor for the five 
major susceptibility genes: VHL, RET, SDHB, SDHC, and SDHD. Fourteen percent of cases 
were found to harbor a germline mutation, and only 2.2% of patients were older than 45 
years at onset. By taking into account the tumor location and a threshold age at onset of 
45 years, we propose a rational scheme for genetic testing. Analyzing VHL and RET genes 
would be recommended only in young patients developing a single PCC. On the other 
hand, genetic testing of SDHD should be done in all patients developing an extra-adrenal 
tumor before the age of 45, and SDHC could be the responsible gene in cases developing a 
single head and neck tumor, independently of age. Finally, the analysis of SDHB should 
always be performed because of its association to malignancy and the low penetrance of 
mutations affecting this gene. 
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8. Electrochemistry Communications 11 (2009) 664–667. 
DNA surface nanopatterning by selective reductive desorption from polycrystalline gold 
electrode. 
Henry OYF, Maliszewska A, O’Sullivan CK. 
 
Selective electrochemical desorption was employed to pattern polycrystalline gold 
electrodes with thiolated DNA. The sacrificial thiol 3-mercaptopropionic acid (3-MPA) was 
selectively desorbed from the crystallographic plane Au(111) to revealed bare gold 
domains, surrounded by SAMs of 3-MPA present on the adjacent low index planes 
Au(110) and Au(100). Thiolated DNA sequences were further immobilized on the revealed 
Au(111) and the hybridisation efficiency towards complementary and non-complementary 
sequences evaluated. All derivatisation steps were followed by cyclic voltammetry and 
faradaic electrochemical impedance spectroscopy. Successful hybridisation resulted in 
large drops in resistance to charge transfer, attributed to the extension of the DNA surface 
duplex into solution resulting in an increased diffusion of electrochemical probes to the 
electrode surface. The results demonstrated the feasibility of the method to generate a 
DNA sensor able to efficiently discriminate between complementary and non-
complementary sequences with good reproducibility. 
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9. J Org Chem. 2007 Mar 30;72(7):2682-5. Epub 2007 Mar 1. 
Synthesis of alpha-phosphorylated alpha,beta-unsaturated imines and their selective 
reduction to vinylogous and saturated alpha-aminophosphonates. 
 
Palacios F, Vicario J, Maliszewska A, Aparicio D. 
 
An efficient synthesis of α,β-unsaturated imines derived from α-aminophosphonates is 
achieved through aza-Wittig reaction of P-trimethyl phosphazenes with β,γ-unsaturated 
α-ketophosphonates. Selective 1,2-reduction of such 1-azadienes affords β,γ-unsaturated 
α-aminophosphonates, phosphorylated analogs of vinylglycines, which are hydrogenated 
to yield saturated α-aminophosphonate derivatives. 
 
 
 
